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Abstract 
Defective in cullin neddylation-like (DCNL) proteins are known to coordinate the 
addition of NEDD8 to the cullin subunit of the largest family of ubiquitin E3 ligases, 
the Cullin-RING ligases (CRLs), in a process known as neddylation. The human 
genome encodes five DCNL proteins which are thought to exhibit a large degree 
of overlap in function, with only a few neddylation processes having been 
definitively ascribed to a single DCNL homologue. It currently remains unclear 
whether these DCNL proteins have functions that extend beyond their roles in 
cullin neddylation. In the present study we now describe a novel role for one of 
the family members, DCNL5, in the programmed cell death response known as 
apoptosis. We have shown that cells lacking DCNL5 function fail to promote  
caspase 8 cleavage – an important early activation step -  in response to various 
inducers of the extrinsic apoptosis pathway.  
Caspase 8 cleavage and activation requires polyubiquitination which is known to 
be mediated by cullin 3 in coordination with the dual ubiquitin and NEDD8 ligase 
RBX1. This process is thought to occur in lipid rafts at the plasma membrane and 
in the cytosol. In the present work, we provide the first indication that DCNL5 is 
able to translocate out of the nucleus where it was previously thought to be 
exclusively located, and this occurs in response to TNFα-related apoptosis-
inducing ligand (TRAIL) stimulation. In addition, we present evidence for the first 
known interaction between DCNL5 and cullin 3 in U2OS cells under endogenous 
conditions. The DCNL5 KO cells demonstrated a lack of a polyubiquitination event 
that occurs in WT cells; unmodified caspase 8 was shown to associate with a 
polyubiquitinated protein (the identity of which we were unable to determine) in 
response to TRAIL and this interaction was absent in KO cells, perhaps 
representing the key mechanism underlying DCNL5 involvement.  
This emerging function for DCNL5 in promoting caspase 8 cleavage was confirmed 
in multiple cancer cell lines including U2OS, H460 and HeLa cells. Importantly, we 
demonstrated that siRNA-mediated silencing of DCNL5 prevented CASP8 cleavage. 
A lot of our work suggested that DCNL5’s role in CASP8 activation is mediated by 
the cullin CUL3. However, treatment with the neddylation inhibitor MLN4924 
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caused a reduction, but not a total loss of caspase 8 cleavage, suggesting that if 
cullin 3 is involved, it may be independent of its neddylation status. This hints at 
the surprising possibility that a CRL complex exists that that does not require 
neddylation for some of its function. Furthermore, while our data suggests that 
DCNL5 may regulate apoptosis via cullin 3, we were unable to exclude a cullin 
neddylation-independent role for DCNL5 in this process. Future work will need to 
answer this question by identifying and characterising the molecular target of 
DCNL5 in apoptosis signalling to ascertain the precise mechanism underlying 
DCNL5 regulation of this clinically important signalling event.  
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1 Introduction  
1.1 Ubiquitin  
Ubiquitin is a small signalling protein that was first discovered in 1975  and consists 
of 76 amino acids (Schlesinger, Goldstein and Niall, 1975) and is pivotal in a variety 
of cellular processes including the universal degradation pathway of living 
organisms which is its best studied role. Ubiquitin was initially described as a 
modifier of proteins which targeted them for degradation by the 26S proteasome 
(Hershko and Ciechanover, 1998) but has since been shown to have a role in a 
wide array of processes. Ubiquitin is highly conserved and expressed in most 
tissues in eukaryotes and acts predominantly through its association with other 
proteins via specific isopeptide linkages on lysine residues. The small protein 
possesses a C-terminal di-glycine motif which is exposed prior to conjugation by 
processing enzymes: these enzymes modify inactive ubiquitin precursors which is 
required for subsequent addition of ubiquitin to target proteins (Amerik and 
Hochstrasser, 2004). Ubiquitin is added to target lysine (K) residues in substrates 
or to one of 7 lysine’s present internally within ubiquitin molecules (Peng et al., 
2003; Haglund and Dikic, 2005) to form polyubiquitin chains and these chains are 
summarised in Figure 1-1 (Rudolph et al., 2001; Pickart and Fushman, 2004).  
The lysine residue and the number of ubiquitin molecules added to each residue 
on a target protein determines its fate, which can vary from degradation by the 
26S proteasome via polyubiquitin chains on K48 (Chau et al., 1989; Thrower, 2000) 
and K11 (Meyer and Rape, 2014) to endocytosis-mediating sorting through the use 
of multi mono-ubiquitination on various lysines (Nakatsu et al., 2000; Raiborg et 
al., 2002). Another more recently discovered type of ubiquitin chain is the 
branched polyubiquitin modification. These chains were discovered by proteomic 
analyses which found that ubiquitin molecules within a polyubiquitin chain were 
capable of being modified at two or more lysine residues (Hyoung et al., 2007). 
Physiologically, these branched chains have been shown to play roles in enhancing 
protein degradation by K11 branched chains (Meyer and Rape, 2014) and K48/K63 
branched chains (Liang et al., 2018) as well as roles in regulating NF-κB signalling 
(Ohtake et al., 2016). Some of these types of ubiquitin modifications are shown 
below in Figure 1-1.  
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An additional level of regulation in ubiquitin biology includes the post-
translational modifications of ubiquitin molecules themselves. Ubiquitin has been 
shown to undergo acetylation at lysine residues K6 and K48  which inhibited K11, 
K48 and K63-mediated polyubiquitination while separately stabilising the 
monoubiquitination of the histone H2B which was identified as an endogenous 
substrate for acetylated ubiquitin  (Ohtake et al., 2015). Ubiquitin and the 
ubiquitination process  is also regulated phosphorylation. Phosphorylation at 
serine 65 arises due to oxidative stress and this modification of ubiquitin causes 
an accumulation of polyubiquitinated proteins and a global reduction in protein 
turnover rates in Saccharomyces cerevisiae (Swaney, Rodríguez-Mias and Villén, 
2015). The mitochondrial serine/threonine kinase PINK1 also mediates the 
phosphorylation of ubiquitin at the same serine residue mentioned above, as well 
as the ubiquitin-like domain of the E3 ubiquitin ligase parkin, which serves to 
relieve its autoinhibition via an allosteric mechanism which allows parkin to 
promote degradation of depolarized mitochondria (Okatsu et al., 2018). Overall, 
there exists significant complexity in ubiquitin biology and thus many layers of 
regulation for the process of ubiquitination. 
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Figure 1-1 Types of Ubiquitination.  
(A) Mono-ubiquitination involves the covalent linkage of a single ubiquitin molecule to a target lysine 
residue of a substrate via an iso-peptide bond. (B) Polyubiquitination involves the addition of multiple 
ubiquitin molecules which are linked internally via their N-terminal lysine residues. The length of the 
chain can vary from 2 molecules to more than 10, and these residues can be homogenous in the 
lysine linkage or heterogenous. (C) Multi mono-ubiquitination involves the addition of individual 
ubiquitin molecules at 2 or more different residues on a target protein. (D) Branched 
polyubiquitination involves the formation of chains stemming from multiple lysine residues within a 
ubiquitin molecule and can be homogenous or heterogenous in the lysine linkages. 
1.1.1 The Ubiquitin Proteome System (UPS) 
As already mentioned, one of the key roles of ubiquitination is to target proteins 
for degradation via the 26S proteasome. The ubiquitin proteasome system (UPS) 
is vital in maintaining the correct balance of proteins within a cell which in turn 
controls signalling pathways, feedback loops and other regulatory mechanisms. 
The UPS begins with the addition of ubiquitin to target proteins using the E1/E2/E3 
enzymes described in section 1.1.2, and in cases where proteins have been 
targeted for degradation, this culminates in recognition of the ubiquitin signals 
which has shown to require at least 4 ubiquitin molecules in a chain (Thrower, 
2000) and the subsequent degradation by a large intra-cellular protease called 26S 
A B C 
D 
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proteasome. Proteins are broken down into peptides in the proteasome before 
these are then degraded down further into the constituent amino acids by 
peptidases in the cytosol. Addition of ubiquitin is an ATP dependent process as is 
the breakdown of proteins within the 26S proteasome. An overview of the UPS is 
shown in Figure 1-2. 
The 26S proteasome consists of a central 20S complex which is flanked on either 
end by two 19S caps which recognize ubiquitinated proteins and process them for 
degradation by the 20S core complex (Baumeister et al., 1998). The core of the 
complex is a cylindrically shaped structure possessing caspase, trypsin and 
chymotrypsin-like proteolytic activity (Bedford et al., 2010) and consists of two 
outer α rings and two inner β rings, with each one containing three individual 
proteolytic subunits (β5, β2 and β1) (Ciechanover, 2005). The 19S regulatory 
particle can be divided into two further sub-complexes consisting of the lid and 
the base which cap the ends of the 20S core particle. The lid contains 9 proteins 
including the de-ubiquitinating enzyme Rpn11 (Lander et al., 2012) while the base 
consists of a ring of AAA-ATPase family members (Baumeister et al., 1998). These 
ATPases generate mechanical force through cycles of ATP binding and hydrolysis 
to unfold proteins, open the gated chamber of the 20S core and translocate the 
polypeptides to the catalytic core for further degradation (Bar-nun and Glickman, 
2012). 
Proteasome inhibitors (PIs) have become an effective therapeutic strategy for 
treatment of diseases, most notably multiple myeloma (MM) and other 
lymphomas, as well as being predicted to be useful in treating conditions such as 
atherosclerosis and diabetes given their reliance on finely-tuned proteasome 
function (Thibaudeau and Smith, 2019). PIs represent a key axiom of MM treatment 
in all phases (Moreau et al., 2012) and there are a few key drugs that are used 
routinely, including the reversibly binding peptide-like molecule bortezimib, the 
second generation irreversible binding peptide-like molecule carfilzomib and  the 
orally available ixazomib (Merin and Kelly, 2014; Besse et al., 2019).  
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Figure 1-2 The Ubiquitin Proteasome System Overview.  
Proteins are targeted for degradation in an ATP-dependent manner using the sequential actions of 
E1, E2 and E3 enzymes. Proteins that are targeted for degradation, typically via polyubiquitin chains 
on lysines 11 or 48, are then transported to the 26S proteasome by chaperone proteins and degraded 
in a multistep and ATP-dependent process in the caps and core cylinder of the proteasome. Proteins 
are broken down into peptides in the proteasome and are then further degraded in the cytosol to 
individual amino acids. 
1.1.2 Ubiquitination Machinery 
The process of ubiquitination is mediated by 3 classes of proteins which act 
sequentially and cooperatively following initial priming by processing enzymes 
(Larsen, Krantz and Wilkinson, 1998): E1 (ubiquitin activating), E2 (ubiquitin 
conjugating) and E3 (ubiquitin ligase) enzymes. The E3 enzymes are the most 
numerous (600 proteins) and thus convey a higher degree of specificity and 
accuracy for a target than E2 or E1 enzymes. There are approximately 40 E2  
enzymes while there are only two E1 enzymes in cells called UBA1 and UBA6 
(Hershko and Ciechanover, 1998; Pelzer et al., 2007; Jin et al., 2007; Schulman 
and Wade Harper, 2009). The E1 enzyme uses ATP to adenylate ubiquitin rendering 
it highly reactive (Haas and Rose, 1982), before transferring ubiquitin to the 
sulfhydryl group of an E2 enzyme (Stewart et al., 2016) in a transthiolation 
reaction. An E3 ligase enzyme then mediates the binding of the C-terminal amide 
moiety of ubiquitin to the ε-amino group of the target protein’s lysine residue(s) 
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via an isopeptide bond (Hershko and Ciechanover, 1998; Soucy et al., 2010). 
Repeated rounds of this process can occur in order to form polyubiquitin chains 
via one of the 7 lysine residues contained within the ubiquitin amino acid sequence 
or via the N-terminus (Ciechanover and Ben-Saadon, 2004).  
 
Figure 1-3 The Ubiquitination Process.  
This diagram outlines the core components and steps required in the ubiquitination of a target 
substrate. Briefly, ubiquitin is activated in an ATP dependent fashion by the ubiquitin activating 
enzyme (E1) before being transferred to the sulfhydryl group of an E2 enzyme by a thioester linkage. 
The mechanism of transfer of ubiquitin to a target substrate with the assistance of an E3 enzyme 
depends on the family of E3 enzyme in question. In all cases, the E3 enzyme, which is highly specific, 
binds to the E2 enzyme laden with ubiquitin and mediates the transfer of the molecule to the target 
protein in either a scaffold capacity (RING E3s) or as an active enzyme catalysing the process (HECT 
E3s). 
1.1.3 Ubiquitin E3 Enzymes 
Ubiquitin E3 enzymes are the most abundant of the enzymes responsible for the 
ubiquitination process; they can interact with both the target protein and the 
ubiquitin-charged E2 enzyme. E3 enzymes are critical in the targeting of specific 
proteins for ubiquitination and the assembly of structures which allow this 
process. There are 2 major and well characterized categories of E3 enzymes, along 
with a third, more recently discovered variant. The 2 more prominent categories 
are characterized by their core protein domains: Homologous to the E6-AP 
Carboxyl Terminus (HECT) (Rotin and Kumar, 2009) and Really Interesting New 
Gene (RING)-based E3 ligases (Petroski and Deshaies, 2005). While their 
differences are numerous, the fundamental mechanistic contrast between the two 
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families is the HECT domain has catalytic activity and forms a thioester bond with 
ubiquitin before transferring it to the target substrate (Scheffner et al., 1993), 
while the RING domain proteins act as a platform and recruit the E2 enzyme to a 
target substrate to directly mediate the transfer of ubiquitin from the E2 (Jackson 
et al., 2000).  
The third category is known as RING between RING fingers (RBRs), and these 
complexes have both RING domains as well as an active site-containing cysteine, 
and includes the E3 ligase Parkin (Eisenhaber et al., 2007; Riley et al., 2013). 
Briefly, RBR E3s were initially defined based on a predicted tripartite motif of 
three zinc-binding domains consisting of two RING domains linked via an in-
between RING (IBR) domain (Morett and Bork, 1999; Van Der Reijden et al., 1999). 
RBRs were later shown to feature an active site cysteine within the second RING 
domain which differentiated them from RING E3 ligases (Wenzel et al., 2011). The 
first RING domain mediates the interaction with the ubiquitin-charged E2 enzyme, 
which then transfers the ubiquitin molecule to the catalytic cysteine of the second 
RING domain and from there ubiquitin is added to a target substrate (Walden and 
Rittinger, 2018).  
1.1.4 Cullin RING Ligases 
The most abundant variant of the ubiquitin E3 enzymes is a family of proteins 
known as cullin-RING ligases (CRLs). CRLs are a protein complex constructed 
around a small RING-finger protein (RBX1/2) and a cullin protein (of which there 
are 8 in mammalian cells). Cullin proteins are described in more detail in section 
1.2.3. An example of a CRLs is the SCF complex (Skp1–Cullin–F-box) which is 
involved in ubiquitination of proteins involved in the regulation of the cell cycle 
while the anaphase promoting complex (APC) is a cullin-like RING-ligase complex 
which also regulates the cell cycle in a collaborative manner with the SCF complex 
(Peters, 1998). The core components of the SCF complex include the RING protein 
Rbx1, Cullin 1, Skp1 and an F-box protein, the latter being involved in recruiting 
and mediating substrate specificity (Zheng et al., 2002). The structural 
arrangement of these components to form the SCF complex is shown below in 
Figure 1-4. The cullin protein and RING protein form the cores of CRLs, while the 
substrate receptor is formed of the protein known as F-BOX and this interacts with 
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SKP1 which is an adaptor protein. Substrate receptors vary for different cullin 
proteins and therefore for different CRL complexes (Lydeard, Schulman and 
Harper, 2013). CRL complexes thus are structurally similar but have different 
functions which is dictated by the substrate adaptors that in turn impart the ability 
of these complexes to regulate numerous intracellular targets. 
CRL complexes require modification by the ubiquitin-like protein NEDD8 (neural 
precursor cell expressed, developmentally downregulated 8), which is added in a 
reversible reaction to a highly conserved lysine residue in all cullin proteins (Hori 
et al., 1999). While the APC mentioned above is technically a CRL, it is unique in 
not being regulated by neddylation since the core of the APC, the APC2 subunit is 
homologous to cullin 1 (Zheng et al., 2002)  but is not neddylated (Pan et al., 
2004). Neddylation allows a structural rearrangement of the RING protein which 
favours the addition of ubiquitin to target substrates, while inhibiting the 
interaction with CAND1, an exchange factor required for recruitment of new 
substrate adaptors to the CRL core (Duda et al., 2008; Baek et al., 2020). This 
modification of the cullin core of CRLs is essential for their activity and ability to 
mediate ubiquitination. Further details about the neddylation process and 
pathway are described in section 1.2. 
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Figure 1-4 Components of the SCF Complex.  
The SCF complex is an example of a cullin-RING ligase which is the largest family of ubiquitin E3 
ligases. Shown in this schematic diagram is the arrangement of the core components. Cullin 1 is 
bound at its C-terminus to the RING protein RBX 1, which interacts with a ubiquitin-laden E2 enzyme 
via its C terminal domain. The N-terminal domain of cullin 1 interacts with the substrate receptor 
SKP1 which in turn is bound to the substrate receptor-binding protein F-BOX. Cullin 1 is neddylated 
which is required for its catalytic activity as cores of CRL complexes. 
  
1.2 NEDD8  
1.2.1 Structure and Function 
There are other proteins which are structurally related to ubiquitin and have 
similar functions and are known as ubiquitin-like proteins. These include SUMO 
(small ubiquitin-like modifier), NEDD8 (neural precursor cell expressed, 
developmentally downregulated 8) interferon-stimulated gene 15 (ISG15), FAT10 
and autophagy-related protein 8 (ATG8) (van der Veen and Ploegh, 2012) and many 
more; there are roughly 20 ubiquitin-like proteins. The focus of this thesis however 
is on NEDD8. NEDD8 was discovered in the early 1990’s and was later characterized 
and shown to be 60% identical and 80% homologous to ubiquitin (Kamitani et al., 
1997). Both Ubiquitin and NEDD8 require processing to expose a di-glycine motif 
which ultimately becomes covalently linked to the specific lysine(s) in a target 
protein (Gong and Yeh, 1999a; Walden, Podgorski and Schulman, 2003; Shen et 
al., 2005; Reverter et al., 2005). The process of addition of NEDD8 to target 
proteins is known as neddylation and bears significant similarity to the process of 
ubiquitination. NEDD8 is added to lysine residues in target proteins via an iso-
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peptide bond (Enchev, Schulman and Peter, 2015), like with ubiquitin, only the 
addition of NEDD8 does not target proteins for degradation. Another difference is 
that neddylation typically occurs as monomers rather than as chains like with 
ubiquitin, however recent data has shown that there may be a role for NEDD8 
outside of its monomeric addition to lysines. Unanchored trimeric, acetylated 
NEDD8 has been recently shown to attenuate PARP1 activation following the 
initiation of oxidative stress, which likely delays the initiation of PARP1-dependent 
cell death (Keuss et al., 2019).  
The key and best characterised role of neddylation is to induce a structural 
rearrangement of cullin proteins (Duda et al., 2008; Baek et al., 2020), which as 
previously described, form the cores of the ubiquitin E3 ligases family of CRLs. 
Thus, NEDD8 is a key regulator of the processes including cell cycle progression 
through the activation of complexes such as the SCF. Cullins and their role as 
NEDD8 targets are described in 1.2.3. NEDD8 is thought to predominantly act 
through mono-neddylation (for reasons presently not fully understood) of one or 
multiple lysine residues in a target protein (which are predominantly cullin 
proteins), however there are in vitro instances of hyper-neddylation (which 
includes formation of NEDD8 chains) of cullins (Ohki et al., 2009) in addition to 
the aforementioned role of free, trimeric NEDD8. Neddylation has been implicated 
in diseases such as Alzheimer’s for its role in regulating CRL activity (Chen, Neve 
and Liu, 2012) and cardiac biology (Kandala, Kim and Su, 2014) and more recently 
has been identified as a potential therapy target in small intestinal 
neuroendocrine tumours (Fotouhi et al., 2019) highlighting the physiological 
importance of this process and the overall impact understanding the role of NEDD8 
is in therapy. Currently, the physiological role of NEDD8 in disease is its regulation 
of the largest family of ubiquitin E3 ligases and this underlines the importance of 
studying the neddylation process. 
1.2.2 NEDD8 Machinery 
Like ubiquitin, NEDD8 is added to its target via 3 proteins, known as NEDD8 E1, E2 
and E3 enzymes (Gong and Yeh, 1999a; Kurz et al., 2005b). While this subset of 
enzymes is specific for NEDD8, the E3 enzymes also catalyse the ligation of 
ubiquitin and are thus also ubiquitin E3 ligases (Enchev, Schulman and Peter, 
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2015). The process of neddylation (outlined in Figure 1-5) involves NEDD8 
activating enzyme (NAE), one of two E2 enzymes (UBC12/UBE2M and UBE2F), one 
of either RING-box proteins 1 or 2 (RBX1/2) which are NEDD8 E3s as well as 
ubiquitin E3s. This process is aided by proteins known as defective in cullin 
neddylation 1 domain containing protein (DCUN1D1-5 but also known as DCNL 
proteins 1-5, which they will be referred to henceforward) (Enchev, Schulman and 
Peter, 2015; Gong and Yeh, 1999b; Soucy et al., 2009; Walden, Podgorski and 
Schulman, 2003; Gong and Yeh, 1999a).  
NEDD8 requires processing by de-neddylase enzymes including de-neddylase 1 
(DEN1 but also referred to as NEDP1) which is a NEDD8-specific cysteine protease 
that cleaves 5 amino acid residues from its C-terminal end to form what is known 
as mature NEDD8 (Wu et al., 2003) and ubiquitin C-terminal hydrolase isozyme 3 
(UCHL3) which is a dual ubiquitin and NEDD8 protease (Wada et al., 1998). NEDP1 
was initially described as de-neddylating SCF complexes (Mendoza et al., 2003) 
but has since been shown to be responsible for the de-neddylation of non-cullin 
proteins in cells but capable of cullin de-neddylation in vitro (Chan et al., 2008). 
UCHL3 and NEDP1 have been shown to demonstrate overlap in function in vivo 
since lack of either protein does not result in neddylation defects (Kurihara et al., 
2000; Chan et al., 2008). The COP9 signalosome complex subunit 5 (CSN5) is the 
major enzyme responsible for cullin de-neddylation in cells (Cope et al., 2002) 
and is discussed in more detail later in this report. 
The E1 enzyme NAE consists of two proteins which form a hetero-dimer, APPBP1, 
the regulatory subunit and UBA3, the catalytic subunit (Osaka et al., 1998; Gong 
and Yeh, 1999a; Walden, Podgorski and Schulman, 2003) and NAE is structurally 
and functionally related to the ubiquitin E1 UAE (Soucy et al., 2010) and the fact 
that NAE consist of two proteins while UAE exists as a single protein may indicate 
that the NEDD8 E1 may precede the ubiquitin E1 in evolutionary terms. NAE 
adenylates NEDD8 and then forms a thioester bond with adenylated NEDD8 before 
the ubiquitin-like protein is transferred to an active site cysteine of one of the 
two E2 enzymes (Gong and Yeh, 1999a; Walden, Podgorski and Schulman, 2003). 
Specificity in the NEDD8 conjugation pathway is achieved by the unique 
interaction between the E2 enzymes and a UBA3-specific groove formed by loops 
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which are unique to the NAE complex and not present in any other UBL E1 enzymes 
(Huang et al., 2004). The dual NEDD8 and ubiquitin E3 enzymes RBX1 and RBX2 
mediate the addition of NEDD8 to cullin proteins (Scott et al., 2014). RBX1 forms 
an integral part of CRL1, CRL2, CRL3 and CRL4 while RBX2 forms a part of CRL5 
(Enchev, Schulman and Peter, 2015). RBX proteins thus promote the ubiquitination 
of substrates as ubiquitin E3s while also serving to promote the neddylation of the 
cullin proteins to which they are bound. It has been shown by crystal structure 
that NEDD8 itself guides the multifunctional RING E3  via a linker region which 
acts as a lever to position the E2 active site close to a specific acceptor  lysine 
target in the cullin protein with the assistance and coordination from accessory 
proteins including the DCNL proteins (Scott et al., 2010; Scott et al., 2014) which 
are discussed in detail in section 1.2.4. It is worth noting that RBX1 is able to 
interact with both UBC12 (UBE2M) and UBE2F, while RBX2 is specific for UBE2F 
(Huang et al., 2009).  
NEDD8 is cleaved from CRLs by the COP9 signalosome (CSN) (not shown in the 
diagram) which is thus a key regulator of E3 ligase activity (Wolf, Zhou and Wee, 
2003). The CSN is a highly conserved multi-protein complex which a major 
regulator of de-neddylation and is the cullin de-neddylase enzyme in cells. It is 
incredibly selective for  neddylated CRL complexes and posses no de-
ubiquitination or de-neddylation activity (Fischer et al., 2011; Lingaraju et al., 
2014). The CSN is required for the efficient assembly and maintenance of active 
CRL complexes through its ability to remove NEDD8 from cullin proteins to 
promote CRL disassembly (Cope et al., 2002), which in turn is required for the 
formation of new CRL complexes with different substrate adaptors (Wolf, Zhou 
and Wee, 2003). More recently, the CSN has been shown to associate tightly with 
around 10-20% of CRL complexes (Lydeard, Schulman and Harper, 2013) and this 
association often occurs at the substrate receptor region of CRLs which is 
intriguing given the diversity in structure of these modules. Furthermore, this 
interaction occurs independently of cullin neddylation since MLN4924 treatment 
has little effect on global organisation of the CRL network (Bennett et al., 2010). 
The  variable SR module-CSN interaction likely explains the differing association 
of the CSN with different cullins, for example association with cullin 4B is close to 
40% whereas association with cullin 3 is less than 5%  (Bennett et al., 2010). It is 
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thought that the balance between substrate availability and CSN abundance in 
vivo dictates the CRL landscape and provides significant and precise control over 
cellular processes (Emberley, Mosadeghi and Deshaies, 2012; Enchev et al., 2012). 
The CSN subunit 5 (CSN5) possesses a JAMM Zn2+-metalloprotease motif which 
forms the catalytic core of the CSN complex and is critical to its de-neddylase 
activity (Cope et al., 2002; Ambroggio, Rees and Deshaies, 2004). CSN5 requires 
assembly with the other subunits of the CSN for it catalytic activity in vivo (Sharon 
et al., 2009; Birol et al., 2014). 
 
Figure 1-5 The Neddylation Process.  
This schematic diagram provides a simplistic overview of the process of NEDD8 conjugation to a 
target substrate (which in most known cases is a cullin protein). Following the processing of NEDD8 
by NEDP1 (not shown), it is conjugated to the E1 NAE in an ATP dependent process and forms a 
thioester bond with a cysteine residue. Next, NEDD8 is transferred to one of the two E2 enzymes to 
an active site cysteine residue, before the E3 enzymes RBX1 or RBX2 mediate the conjugation of 
NEDD8 to the cullin protein to which the E3 is already bound as the core of a CRL complex. DCNL 
family members facilitate the addition of NEDD8 to cullin proteins and can bind both the E2 enzyme 
and the cullin protein. 
1.2.3 Cullin Proteins 
Cullin proteins were briefly mentioned in section 1.1.4 for their role in forming 
the cores of the ubiquitin E3 ligase family known as cullin-RING ligases. Cullin 
proteins are molecular scaffold proteins which were originally discovered in 
nematodes (Kipreos et al., 1996) for their role in cell cycle regulation, while also 
independently being discovered in budding yeast (Mathias et al., 1996) for their 
role in ubiquitin-dependent proteolysis of cell cycle regulators (which gave rise to 
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their name in yeast as Cdc or cell division control proteins). In humans there exist 
7 homologues: cullins 1 through 3, cullin 4A and cullin 4B, and cullins 5 and 7 
(Sarikas, Hartmann and Pan, 2011). There also exist other cullin-related proteins 
such as PARC (also known as cullin 9) which was found to play a role in p53 
regulation but not through ubiquitination activity (Nikolaev et al., 2003) and has 
been shown not to form CRL complexes unlike all other cullin proteins (Cardozo 
and Pagano, 2004). Another protein called APC2 which is a subunit of the highly 
complex APC has been shown to show some cullin-homology (Yu et al., 1998; 
Zachariae et al., 1998; Tang et al., 2001). Cullin protein structure has largely been 
elucidated in the context of its role in forming CRL complexes and significant 
biochemical data exists confirming the high degree of conservation between 
different organisms from yeast to humans in the functionality of the protein family 
as a scaffold protein (Liu and Nussinov, 2011; Lydeard, Schulman and Harper, 
2013; Baek et al., 2020). 
Most cullin protein family members share core structural similarity; cullins 1 to 5 
have 3 cullin repeats in their N-terminal domain which is structured like a stalk. 
Their globular C-terminal domain consists of a cullin homology domain (CHD) as 
well as neddylation site in a subdomain known as the WHB (winged helix-B) 
domain, which is conserved across all cullins. Cullin 7 is not only larger in size 
than cullins 1-5 but is also thought to be structurally different (Sarikas, Hartmann 
and Pan, 2011; Lydeard, Schulman and Harper, 2013). Little structural data is 
available for cullin 7, but it is known to contain a domain known as the CPH domain 
that is conserved between cullin 7, PARC (also known as cullin 9) and HERC2 (a 
ubiquitin E3 ligase). This domain has been shown to be responsible for protein-
protein interactions with p53 (Kaustov et al., 2007). The cullin repeat number 1 
(CR1) is responsible for the recognition of adaptor proteins and substrate binding 
proteins to mediate binding of different substrates in cullins 1-5. The C-terminal 
domain of cullin proteins, specifically the α/β subdomain, is responsible for 
binding to RBX proteins which in turn bind to the E2 enzyme laden with ubiquitin 
(Sarikas, Hartmann and Pan, 2011; Liu and Nussinov, 2011). The WHB subdomain 
of the C-terminal region of cullins interacts with RBX RING domain in unmodified 
CRLs (Zheng et al., 2002).  The basic structure and organization of cullin protein 
domains is shown below in Figure 1-6. 
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Figure 1-6 Cullin Proteins Domains.  
Shown in this diagram is the domain and general structure of cullins 1,3 4A and 7. The first 3 are 
similar in size (around 750 amino acids) and consist of a stalk-like N-terminal domain which consists 
of 3 cullin repeat regions (CR1-3). CR1 is responsible for the recognition of adaptor proteins. The C-
terminal domains of cullins 1-5 is globular and contains a cullin homology domain (CHD) and a 
neddylation site (shown by the green line), both of which are present in cullin 7. Cullin 7 is larger than 
the other cullin proteins and contains a domain (CPH) which is conserved between cullin 7 and the 
protein known as PARC (cullin 9) as well as a DOC1-like domain which is also seen in complexes 
such as the anaphase promoting complex. Cullin 7 structure is largely unknown beyond this. 
Cullin proteins bind to their RING domain-containing partners RBX1 or RBX2 via a 
conserved intermolecular β sheet interface (Zheng et al., 2002). Cullin proteins 
have long been known to require neddylation to promote CRL-catalysed 
ubiquitination of target substrates. NEDD8 is conjugated to the cullin C-terminal  
WHB domain (Zheng et al., 2002) which contributes to the relative repositioning 
of the cullin C and N-terminal regions which is thought to promote ubiquitination 
activity of the CRL complex (Duda et al., 2008). It is only recently that the full 
role of neddylation has been uncovered as a result of the determination of the 
crystal structure of neddylated CRL1β-TRCP in complex with the E2 UBE2D and its 
substrate phospho-IκBα (Baek et al., 2020). NEDD8 functions as a catalyst for a 
series of dynamic structural rearrangements that promote cullin WHB domain and 
RING rearrangement which in turn allows for the positioning of the Ub-laden E2 
enzyme close to the substrate to promote ubiquitination (Baek et al., 2020). In 
essence, NEDD8 brings into proximity the normally distal elements of a CRL-E2 
complex to facilitate the transfer of ubiquitin from the E2 active site to the target 
substrate. 
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Figure 1-7 Structure of CRL1β-TRCP Complex 
A 
B 
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(A) provides an overview of all the proteins involved in the CRL1β-TRCP complex assembly. Cullin 1 
(green) binds to SKP1 (grey) via its N terminal domain while SKP1 in turn binds to the F-Box protein 
β-TRCP (purple). The substrate IκBα is shown in pink, while the E2 enzyme UBE2D is shown in 
cyan. Cullin 1 interacts with the RING protein RBX1 via a conserved β-sheet. Ubiquitin is shown in 
orange and NEDD8 is shown in yellow. (B) shows the structure from an opposite angle and provides 
a clearer picture of the cullin WHB subdomain interacting with NEDD8. This Cryo-EM structure was 
accessed from the protein data bank (accession code 6TTU) and EMDataResource database 
(accession code EMD-10585)  (Baek et al., 2020) and processed using Pymol 2.4 software. 
 
Non-neddylated cullin can interact with a protein called CAND1. CAND1 blocks the 
C-terminal cullin neddylation site  and the CAND1 C-terminus inhibits cullin-
adaptor interaction mediated by the cullin N-terminus (Helmstaedt et al., 2011).   
CAND1 protein serves to sequester inactive cullin proteins in complexes with DCNL 
proteins (Keuss et al., 2016; Liu et al., 2018) and acts as an regulator of CRL 
formation (Liu et al., 2002). CAND1 functions as a substrate receptor exchange 
factor, it facilitates the assembly of new CRL complexes through recruitment and 
exchange of F-BOX proteins (Pierce et al., 2013). It is likely that substrate adaptor 
availability drives the displacement of CAND1 – then the cullin gets neddylated. A 
simplified outline of the neddylation of a cullin protein and assembly of a ubiquitin 
E3 ligases is shown in Figure 1-8. 
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Figure 1-8 Regulation of Cullin RING Ligases Assembly by CAND1 and NEDD8. 
This simplified diagram shows the basic stages involved in activation of CRL complexes. The DCNL 
family of proteins aid in releasing CAND1 binding from inactive cullin proteins and are responsible 
for coordinating the binding of the RING protein to the cullin in order to mediate neddylation.The 
DCNL proteins bind to cullin proteins via an interaction surface that includes 3 highly conserved and 
essential amino acids known as the ‘DAD’ patch. Neddylation is required for conformational changes 
needed to facilitate the transfer of ubiqutin to a target substrate.  
1.2.4 Defective in Cullin Neddylation-Like (DCNL) Protein Family 
DCNL proteins were initially discovered and studied in budding yeast where the 
single homologue is known as Dcn1p (defective in cullin neddylation 1) and in C. 
elegans where it is known as Dcn1. This protein was found to greatly increase the 
rate of the neddylation reaction in both organisms (Kurz et al., 2005a). It was 
later demonstrated that the human variant of the protein, DCNL1, functions to 
recruit NEDD8-laden E2 (Kim et al., 2008) and is also pivotal in the release of the 
effects of CAND1 on CRL complexes. Un-neddylated cullins exist in complex with 
CAND1 and DCNL proteins (Keuss et al., 2016; Liu et al., 2018) while neddylated 
complexes exist in active ubiquitination E3 complexes (Kim et al., 2008).  
Human cells express 5 DCNL proteins (Sarkaria et al., 2006; Kim et al., 2008; 
Meyer-Schaller et al., 2009; Bommeljé et al., 2014; Huang et al., 2014; Keuss et 
al., 2016) which each have distinct N-terminal domains which are thought to 
dictate their subcellular localisation (Keuss et al., 2016). DCNL3 is unique in 
having a myristoylation site and in localising to the plasma membrane (Meyer-
Schaller et al., 2009), DCNL1 and 2 contain N-terminal UBA domains and localise 
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to the nucleus and cytoplasm (Wu et al., 2011) while DCNL4 and 5 posses nuclear 
localisation sequences and thus localise almost exclusively to the nucleus (Huang 
et al., 2011; Keuss et al., 2016). The basic domain structure of the DCNL family 
of proteins are shown in Figure 1-9. DCNL1 is the most ubiquitously expressed of 
the DCNL family of proteins and is also the best studied homologue. Further 
evidence for the role of the N-terminal domain of these proteins in their 
localisation includes the fact that mutations in the nuclear localization sequence 
of DCNL5 resulted in its diffusion into the cytoplasm (Keuss et al., 2016).  
A key region in the DCNL proteins is the ‘DAD’ patch, which is part of the conserved 
C-terminal region called the potentiating neddylation domain (PONY) (Kurz et al., 
2008). The DAD patch is so-named due to consisting of D226, A253, and D259 
residues in yeast Dcn1 (Kurz et al., 2008). Mutations in these key residues of the 
cullin-interaction subsurface lead to a loss of neddylation and were shown to be 
sufficient and essential for the binding to cullins (Kurz et al., 2008). The 
subcellular localisation of DCNL family members has been shown to occur 
independently of their ability to bind cullin proteins (Keuss et al., 2016). Whether 
the DAD-patch region is responsible for binding to other proteins remains 
unknown.  
DCNL proteins are all expressed in tissue culture cells and differ in their 
subcellular localisation as mentioned previously. Expression of these proteins is 
more varied in animal tissues: DCNL1 is widely expressed in cancer cell lines as 
well as most types of animal tissue (specifically mouse tissue) including testis, 
brain, lung and spleen. DCNL2 expression in tissues is limited to brain, liver and 
kidney tissues and expression is good in cancer cell lines in tissue culture. DCNL3 
expression is strong in only testis and brain and its expression in cancer cell lines 
is less pronounced. DCNL4 is expressed in most tissues and expression in cancer 
cell lines is similar. DCNL5 is expressed the strongest in cancer cell lines compared 
to all the other DCNL proteins, while its expression is limited to the testis and 
thymus in mouse tissue (Keuss et al., 2016). DCNL proteins have been shown to 
show no preference for any particular cullin in vitro (Keuss et al., 2016) and their 
function and role in vivo is thought to be regulated by the subcellular localisation 
of both DCNL proteins and cullin proteins (Keuss et al., 2016). Below, we will 
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discuss the roles of DCNL1, DCNL3 and DCNL5 in vivo.  DCNL2 and DCNL4 lack 
experimental characterisation and their physiological roles are largely 
undetermined, however structurally DCNL2 is most related to DCNL1 while DCNL4 
is most related to DCNL5 so it is possible that there is overlap of function in cells. 
 
 
Figure 1-9 Key Domains of DCNL Proteins.  
Shown in this figure are shematic diagrmas representing the 5 DCNL protein family members in 
humans. The proteins are structurally very similar and are known to overlap significantly in function 
in vitro, however their key differences lie in the N-terminal domains. DCNL1 and DCNL2 contain a 
UBA domain and DCNL1 is the most ubiquitously expressed of these proteins, localising to the 
cytosol and to the nucleus. DCNL3 contains a myristoylation site in its N-terminal region which allows 
it to localise to the plasma membrane, as well as to the cytosol and the nucleus. DCNL4 and DCNL5 
contain a nuclear localization sequence in their N-terminal regions (RKRR and KKKRK respectively) 
which allow them to localise predominantly to the nucleus. The C-terminal region of all DCNL proteins 
consists of a potentiating neddylation domain (PONY) which is responsible for binding to cullin 
proteins via the highly conserved amino acid residue motif known as the ‘DAD’ patch. 
1.2.4.1 Mechanism of DCNL Proteins 
The structure of yeast Dcn1 was solved in 2008 which revealed the existence of 
an N-terminal UBA domain and a C-terminal domain which was termed the 
potentiating of neddylation  (PONY) domain (shown in Figure 1-10) and contained 
within this domain were three key residues responsible for mediating the 
40 
 
 
 
interaction of Dcn1 with cullin proteins as mentioned previously. These residues 
are located in close proximity to the neddylated lysine in yeast cullin homologue 
Cdc53 (Kurz et al., 2008).  Dcn1 was shown to interact directly with the NEDD8 E2 
UBC12, similar to RBX proteins which are NEDD8 E3s, while not participating 
directly in the catalytic transfer of NEDD8 to the cullin protein. In order to 
determine whether Dcn1 plays a catalytic role in the transfer of NEDD8 via 
transthiolation reaction using cysteine residues, the five cysteine residues in Dcn1 
were mutated individually. None of the resulting mutants lacked the ability to 
promote neddylation of Cdc53 in vivo and thus it was concluded that Dcn1 
functions as a scaffold-like protein that lacks a catalytic role in the transfer of 
NEDD8 but plays an essential role in promoting neddylation (Kurz et al., 2008).  
 
Figure 1-10 Structure of S. cerevisiae DCN1 
This ribbon representation of budding yeast DCN1 shows the N-terminal UBA domain (residues 12-
56) in light purple and the C-terminal PONY domain (residues 70-269) in yellow.  This structure was 
accessed from the protein data bank (accession code 3BQ3) (Kurz et al, 2008) and processed using 
Pymol 2.4 software. 
The DCNL protein family have been described both as  scaffold-type E3 ligases and 
as co-E3 ligases which play an auxiliary role in neddylation. Given that they have 
been characterised as playing an essential role in promoting neddylation 
(discussed more below) and the yeast DCNL homologue Dcn1 has been shown to 
be sufficient to promote neddylation in a purified reconstituted system while also 
interacting directly with the E2 enzymes, (Kurz et al., 2008), they are considered 
to be true NEDD8 E3s rather than auxiliary factors in this thesis. Mechanistically, 
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the role of yeast Dcn1 was suggested to restrict the normally flexible E3 RING 
domain-bound - NEDD8-laden UBC12 complex to promote a catalytically 
favourable arrangement to allow the transfer of Rub1 (yeast homologue of NEDD8) 
to Cdc53 (Scott et al., 2010). Thus, in yeast, the two E3 enzymes Dcn1 and the 
RBX1 homologue Hrt1 function cooperatively to promote the transfer of NEDD8 to 
a target cullin protein; both are required in the process and loss of either one 
significantly impairs neddylation.  
More recently, human DCNL proteins have been shown to interact with the NEDD8 
E2 enzymes UBC12 and UBE2F via N-terminal acetylated regions of the E2s and 
this interaction was shown to vary between DCNL proteins, representing potential 
therapeutic targets (Monda et al., 2013). It has been shown that yeast Dcn1 
recognised the acetylated N-termini of UBC12 (Scott et al., 2011) and this was 
later expanded to show in humans that all DCNL proteins interact with UBC12 or 
UBE2F – and this acetylation was shown to neutralize a positive charge at the N-
terminus of NEDD8 E2 enzymes (which would normally obstruct the interaction), 
as well as making positive interactions upon burial in a deep pocket within the 
DCNL PONY domain (Scott et al., 2011; Monda et al., 2013). A visual summary of 
the role of DCNL proteins can be seen in Figure 1-11. The critical acetylated 
residue was a methionine therefore this represents a key acetylation-specific 
interaction of the PONY domain. The researchers elucidated specificity for UBC12 
and UBE2F peptides to inhibit different DCNL proteins which suggested that it may 
be possible to develop small molecules to specifically target N-acetyl-methionine-
dependent protein interactions between different DCNL proteins (Monda et al., 
2013).  
Inhibitors have been developed which target this DCNL-acetylated-E2 interaction 
and are described in more detail below, but briefly, these compounds elucidate 
new non-redundant roles for the DCNL proteins since one of these compounds 
called DI-591 specifically reduces cullin 3 neddylation in vivo by targeting DCNL1-
UBC12 interaction preferentially (Zhou et al., 2017). In addition, the affinity of 
this compound for DCNL1 and DCNL2 over the other DCNL proteins suggests that 
there are structural differences within the PONY domains of the DCNL proteins 
which may provide insight into their potential roles in cell, which is perhaps 
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unsurprising since the sequences of DCNL1 and DCNL2 are 82% identical, while 
DCNL1 and DCNL3 are only 40% identical (Monda et al., 2013). 
 
Figure 1-11 DCNL Mechanism Outline 
This simplified diagram illustrates the role DCNL proteins play in promoting neddylation. DCNL 
proteins bind to the E2 enzyme via the E2 acetylated N-terminus which buries into a deep pocket 
within the DCNL PONY domain, and bind to cullin proteins via their DAD-patch. DCNLs stabilise the 
flexible linker of the E2 to promote the favourable catalytic transfer of NEDD8 to the cullin protein. 
1.2.4.2 DCNL1 
As previously mentioned, DCNL1 is the most studied of the DCNL family members, 
and part of this stems from the fact that it is the oldest of the DCNL proteins from 
an evolutionary standpoint and is the most closely related DCNL protein to the 
single homologs found in lower organisms (Kurz et al., 2008). DCNL1 is not solely 
responsible for cullin neddylation in mammalian cells (in contrast to in lower 
organisms) because KO mice are viable which would likely not be the case if all 
cullins were affected by the absence of DCNL1; all cullins are still mostly 
neddylated (Huang et al., 2011). DCNL1 has been shown to play an essential role 
in cullin 1 neddylation via its ability to promote nuclear localisation of neddylation 
components and recruitment of the E2 enzyme UBC12 (Huang et al., 2011). The 
UBA domain in the N-terminus of DCNL1 has not been shown to be required for its 
neddylation activity in vitro or in vivo and its precise role has until recently 
remained elusive (Kurz et al., 2008; Wu et al., 2011). Research has now shown 
that  the UBA domain undergoes monoubiquitination by the Ariadne RBR ligases 
TRIAD1 and HHARI and this depends on CRL association (Kelsall et al., 2019) of all 
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the proteins. This monoubiquitination was shown to be required for CRL activity 
and was suggested to promote structural remodelling and substrate switching 
(Kelsall et al., 2019). It has also been shown that polyubiquitin chain binding to 
the DCNL1 UBA domain inhibits its ability to promote neddylation, therefore the 
UBA domain may function as a sensor to regulate DCNL1 activity (Huang et al., 
2015). It was suggested that the binding of polyubiquitinated proteins to the UBA 
domain regulated the subcellular localisation of DCNL1. Binding of 
polyubiquitinated proteins to the UBA domain was shown to promote 
monoubiquitination and nuclear export of the protein. This finding was consistent 
with previous research which showed that monoubiquitination of DCNL1 drives its 
nuclear export (Wu et al., 2011). Thus, there exist multiple roles for the UBA 
domain of DCNL1 however further work is required to better elucidate these. 
DCNL1 is also known as squamous cell carcinoma-related oncogene (SCCRO1) and 
has been shown to be overexpressed in squamous cell carcinomas which correlates 
with poor clinical outcome (Sarkaria et al., 2006). DCNL1 has also been 
demonstrated to function as an oncogene through its ability to facilitate malignant 
transformation of cells in culture and xenograft formation in nude mice and has 
been implicated in the pathogenic progression of platelet-derived growth factor 
(PDGF)-dependent gliomas (Broderick et al., 2010). The UBA domain in DCNL1 has 
been shown to contain mutations in human cancers and this is thought to reduce 
the ability to regulate DCNL1 activity in cells and increase its transforming activity 
(Huang et al., 2015). 
1.2.4.3 DCNL3 
As stated above, DCNL3 contains a myristoylation site in its N-terminus which 
accounts for its localisation at the plasma membrane (Meyer-Schaller et al., 2009; 
Huang et al., 2011; Keuss et al., 2016). DCNL3 has been shown to act in a non-
redundant manner to mediate the neddylation of cullin 3 specifically at the plasma 
membrane of mammalian cells (Meyer-Schaller et al., 2009). This was an 
interesting finding since it represented the first piece of evidence for a unique 
role of DCNL protein in cells, which is at least in part dictated by their subcellular 
localisation. DCNL3 has more recently been suggested to lack E3 ligase activity 
and actually function as a tumour suppressor by sequestering cullin proteins at the 
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plasma membrane, preventing them from translocating to the nucleus and 
inhibiting their DCNL1-mediated neddylation (Huang et al., 2014). This finding was 
supported by the discovery that DCNL3 knockdown in cells increased the 
neddylation of cullins 1, 3, 4A and 4B (Keuss et al., 2016), suggesting that DCNL3 
may actually inhibit cullin neddylation. This is however in contradiction with the 
compelling previous finding that ectopically expressed human DCNL3 is able to 
promote cullin (Cdc53) neddylation in yeast DCNL1 KO cells in a heterologous 
assay, which supports the assertion that DCNL3 possesses E3 ligase activity (Meyer-
Schaller et al., 2009). To date, the precise role of DCNL3 is ambiguous and requires 
further investigation, but if its inhibitory role is real, it may stem from its ability 
to sequester cullins away from neddylation machinery (Keuss et al., 2016; Huang 
et al., 2014). This data suggests that the E3 ligase activity of DCNL proteins may 
not be the same in vivo and raises the possibility that this protein family have 
roles outside of promoting cullin neddylation. 
1.2.4.4 DCNL5 
DCNL5 has been implicated as an oncogene and is found to be overexpressed in 
oral and lung squamous cell carcinomas (Bommeljé et al., 2014). Researchers 
showed that its neddylation ability in vitro relied only on its PONY domain through 
the use of various mutants including whole N-terminal deletion constructs, while 
in vivo its neddylation activity required both its PONY domain and its N-terminal 
nuclear localisation sequence (Bommeljé et al., 2014; Keuss et al., 2016). siRNA-
mediated knockdown of DCNL5 in cancer cell lines resulted in a decrease in 
viability of cancer cells with high endogenous DCNL5 expression (Bommeljé et al., 
2014). DCNL5 has also been implicated in immune signalling because in addition 
to high expression in immune tissues, DCNL5 undergoes phosphorylation at a 
specific N-terminal serine reside in response to toll-like receptor signalling by IKKα 
(Thomas et al., 2018). This phosphorylation was found not to affect the kinetics 
of cullin neddylation reactions mediated by DCNL5, and IKK-mediated signalling 
events such as NF-κB signalling were unaffected in the absence of DCNL5 (Thomas 
et al., 2018). This finding provides some insight into the potential post-
translational regulation of DCNL proteins but the specific role of phosphorylation 
of the N-terminus of DCNL5 was not able to be determined. In the present 
research, we describe a role for DCNL5 in the apoptosis response and there may 
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therefore exist a level of crosstalk between immune signalling described above 
and apoptosis at the level of DCNL5 – possibly involving phosphorylation of the 
protein. 
It has also been shown that DCNL5 and DCNL1 independently contribute to cullin 
4A neddylation in cells (Keuss et al., 2016) indicating a novel function for DCNL5. 
Keuss and colleagues then went on to show that DCNL5 is involved in the DNA 
damage response (while DCNL1 is not) by demonstrating that DCNL5 co-localises 
with cullin 4A at sites of DNA damage (Keuss et al., 2016).The localisation of cullin 
4A to sites of DNA damage was in keeping with previous research (Meir et al., 
2015). What was even more interesting was that this response was the same in a 
DAD-patch mutant of DCNL5 which is unable to bind cullins. It was shown that the 
cell death following irradiation (sensitivity) in the DCNL5 KO cells can be rescued 
by expression of WT DCNL5 as well as the DAD-patch mutant DCNL5, suggesting 
that this role of DCNL5 is cullin-independent (Keuss et al., 2016). This data 
supported a role for DCNL5 in the DNA damage response in vivo but more 
intriguingly this finding appears to be one of the first likely non-cullin roles for 
any DCNL member described.  
1.2.5 Non-Cullin Roles for NEDD8 
There are several other non-cullin targets that have been described in the 
literature, however to date, cullin proteins are the only fully verified substrates 
for NEDD8. Under normal conditions, the roles of ubiquitin and NEDD8 are well 
defined and well separated and this is in part due to a single amino acid difference 
in the C-termini of the proteins (alanine in NEDD8 and arginine in ubiquitin) which 
prevents ubiquitin being selected by neddylation machinery (Whitby et al., 1998). 
When neddylation is studied in vivo, cancer cells or cancer-derived cell lines often 
exhibit un-physiologically high NEDD8 expression while overexpression of NEDD8 
specifically is often used to discover and analyse potential novel targets for the 
ubiquitin-like protein. This perturbs the ratio of ubiquitin to NEDD8 and results in 
artificial neddylation of targets through the use of ubiquitin machinery (Hjerpe et 
al., 2012). The ubiquitin E1 UBE1 was shown to be able to promote neddylation 
under conditions in which the normally equal ratio of NEDD8:ubiquitin is 
artificially perturbed by NEDD8 overexpression, however how UBE1 engages with 
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NEDD8 machinery to actually promote aberrant neddylation was not evaluated 
(Hjerpe et al., 2012). In spite of this important discovery, some non-cullin targets 
have been described for NEDD8 and these can be (if they haven’t been already) 
validated along the lines of the criteria laid out by Enchev and colleagues to 
determine whether a candidate protein is a true physiological neddylation target. 
This criteria includes whether the modification occurs under physiological levels 
of NEDD8 and NEDD8 substrate expression levels and whether this neddylation can 
be inhibited by MLN4924 (Enchev, Schulman and Peter, 2015). The examples of 
non-cullin targets presented below require a careful degree of scrutiny as in 
almost all cases, full verification of the substrates under physiological conditions 
as well as inhibition with MLN4924 is often lacking. 
NEDD8 has been reported to be critical for the activation of the HECT-domain E3 
ligase (Scheffner and Kumar, 2014) SMAD ubiquitination regulatory factor 1 
(SMURF1); NEDD8 and the NEDD8 E2 enzyme UBC12 (UBE2M) were shown to 
interact directly with SMURF1 and SMURF1 was found to auto-neddylate itself on 
multiple lysine residues via an active site cysteine unrelated to the HECT active 
site (Xie et al., 2014). This finding was expanded upon more recently to show that 
both SMURF1 and SMURF2 contain non-covalent NEDD8 binding sites within their 
catalytic HECT domains in addition to covalent residues described previously. In 
SMURF proteins, mutations in the five residues in the conserved NEDD8-binding 
sequence resulted in reduced neddylation and reduced auto-ubiquitination 
(therefore increased stability) (He et al., 2017). Loss of non-covalent interactions 
with NEDD8 reduced ubiquitination of SMURF substrates which play roles in cell 
migration and TGFβ signalling pathways (He et al., 2017). Thus, NEDD8 seems to 
play covalent and non-covalent roles in the regulation of HECT-domain-containing 
E3 ligases in addition to its well studied role in regulating CRL activity. The fact 
that researchers used endogenous expression-level yeast constructs when 
analysing Rsp5 (yeast SMURF1 homologue) neddylation (Xie et al., 2014) lends 
some credence to the assertion that this non-cullin E3 ligase may be a true target 
for neddylation. 
Other reported non-cullin targets for NEDD8 are caspase proteins. These proteases 
are responsible for mediating the programmed cell death response known as 
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apoptosis. In D. melanogaster, drICE is an effector caspase (Hay and Guo, 2006), 
and a systematic in vivo RNAi analysis coupled with genetic validation identified 
drICE to be neddylated under endogenous conditions by the RING E3 ligase 
inhibitor of apoptosis 1 (IAP1) and de-neddylated by DEN1 (Broemer et al., 2010). 
Neddylation of drICE was shown to inhibit its ability to cleave a downstream target 
(PARP1) in vitro which was suggested to account for the anti-apoptotic effects of 
NEDD8 in vivo (Broemer et al., 2010). As well as identifying a role for NEDD8 in 
the apoptosis response, this work also revealed the role for IAP proteins as NEDD8 
E3 ligases. The human orthologue of IAP1, XIAP, was shown to posses NEDD8 E3 
ligases activity but it was not demonstrated to function as a ligase for the human 
orthologue of drICE, caspase 7, questioning the role for NEDD8 in human caspase 
regulation as well as the validity of caspases as NEDD8 targets (Nagano et al., 
2012).  
Other research has independently identified human caspase 1, which is involved 
in inflammatory signalling, as a target for neddylation. NEDD8 was shown to be 
required for the self-cleavage of the inactive pro-caspase 1 zymogen to generate 
its catalytically active subunits (Segovia et al., 2015). Inhibition of neddylation 
with the NAE inhibitor MLN4924 resulted in a reduction in caspase 1 processing 
(perhaps due to cullin involvement upstream), while increased auto-catalytic 
activity was seen with overexpression of NEDD8 (although this should be 
considered carefully given the previously described limitations of studying NEDD8 
overexpression) (Segovia et al., 2015). The role of caspases as potential targets 
for NEDD8 will be briefly explored in the present research, however cullin proteins 
remain the only true and fully verified substrates for NEDD8 and great caution 
needs to be advised when determining whether a substrate is a real target for 
NEDD8. 
1.2.6 Neddylation Inhibitors 
1.2.6.1 MLN4924 – NAE Inhibitor 
Given the importance of neddylation in the regulation of CRL activity, NEDD8 has 
relatively recently become a therapeutic target and an inhibitor of neddylation 
has been developed. This inhibitor, known as MLN4924, specifically targets the 
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NEDD8 E1 enzyme NAE to inhibit its ability to bind to NEDD8 and thus inhibit the 
neddylation process. MLN4924 creates a covalent NEDD8-MLN4924 adduct which 
structurally resembles the adenylated NEDD8 (NEDD8-AMP) but cannot be 
processed further to form the high energy NEDD8-NAE thioester. The adduct 
formed by MLN4924 which sits within the NAE active site is highly stable and blocks 
enzymatic activity and therefore results in potent ablation of neddylation 
(Brownell et al., 2010). MLN4924 has shown promise in treating various cancers in 
primary research settings. The drug has been shown to supress colon cancer cell 
growth specifically through the inhibition of cullin 1 neddylation which culminates 
in the activation of autophagy via suppression of the P13K/AKT/mTOR pathway 
(Lv et al., 2018). MLN4924 has also been shown to induce cell cycle arrest at G2 
phase as well as induce DNA damage and sensitise oesophageal squamous cell 
carcinoma cells to cisplatin by enhancing apoptosis (Lin et al., 2018).  
Mechanistically, the inhibitor has been shown to prevent the growth of human 
gastric cancer cells through stabilisation of CDT1 (a replication licensing factor) 
as well as other CRL substrates via inhibition of cullin 1 neddylation preferentially. 
Stabilization of CDT1 promotes DNA re-replication and G2-phase cell cycle arrest 
(Lan et al., 2016). MLN4924 has also shown promise in clinical trials for the 
treatment of acute myeloid leukaemia and myelodysplastic syndromes; the drug 
was successfully administered with minimal off-target effects and modest clinical 
activity was observed (Swords et al., 2015). The drug is also being used currently 
in other clinical trials targeting the same conditions as well as non-small cell lung 
cancer and the role of the drug in combination with chemotherapy for the 
treatment of bile duct cancer of the liver. 
1.2.6.2 COP9 Signalosome Inhibitor 
A potent, selective and orally bioavailable inhibitor of CSN5 has been developed, 
called CSN5i-3, which traps CRLs in the neddylated state, prompting subsequent 
inactivation of a small subset of CRLs by inducing degradation of their substrate 
recognition module  and stabilisation of the CRL substrates (Schlierf et al., 2016). 
The researchers showed that the results of treatment with this inhibitor resembled 
the effects of treatment with MLN4924, and they showed that the inhibitor 
differentially affected the viability of cancer cell lines. Overall, this inhibitor may 
show even more specificity towards certain CRLs than MLN4924 which is largely 
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general in its action, and CSN5i-3 has shown promise in pre-clinical studies. A key 
question that remains regarding the mechanism of this inhibitor is how does 
trapping CRLs in their neddylated (and thus active) state inhibit their 
ubiquitination activity? It is currently thought that trapping CRLs in their active 
state promotes substrate receptor molecule degradation by auto-ubiquitination of 
the CRL. This hypothesis was confirmed when CRL substrate receptor degradation 
was shown to be inhibited by pre-treatment with proteasome inhibitors prior to 
CSNi-3 treatment, indicating that CSNi-3 promotes proteasome-mediated 
degradation of substrate receptor molecules (Schlierf et al., 2016). It is currently 
unclear why CSN inhibitors appear to show more specificity for a subset of CRLs 
when compared to MLN4924. 
1.2.6.3 DCNL Inhibitors 
Since the advancement in the understanding of the interaction between DCNL 
proteins and their respective NEDD8 E2 enzymes, UBC12 and UBE2F, progress has 
been made in targeting this interaction. A few inhibitors targeting the interaction 
between DCNL proteins and the NEDD8 E2s (described in detail in section 1.2.4.1 
above) have been the developed, one of which was called DI-591. This cell-
permeable compound was shown to bind to DCNL1 and DCNL2 with KD values of 
21.9nM and 11.2nM respectively, however even at concentrations of up to 10μM 
there was no detectable binding to DCNL3, 4 or 5 (Zhou et al., 2017). What was 
also interesting is that the compound specifically reduced the neddylation of cullin 
3 only while having minimal effect on the neddylation of other cullin proteins. 
This specific reduction in cullin neddylation promoted accumulation of NRF2 
protein and its transcriptional activation (Zhou et al., 2017), which is the case 
because NRF2 is a cullin 3 CRL substrate, thus, inhibiting cullin 3 neddylation 
inhibits the degradation of NRF2 (Cullinan et al., 2004; Kobayashi et al., 2004). 
Interestingly, another research group developed a class of inhibitors that target 
this interaction interface between DCNL proteins and NEDD8 E2 enzymes and their 
inhibitors specifically targeted DCNL1 and DCNL2, in vitro, however in vivo they 
found that DCNL1-UBC12 interactions were inhibited preferentially and this also 
resulted in specific reduction in cullin 3 neddylation (Scott et al., 2017). This work 
highlights the potential therapeutic benefit of these types of inhibitors in the 
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targeting of DCNL1 as an oncogene in cancer therapy, as well as regulating specific 
cullin neddylation in cells. 
Another class of inhibitors have been discovered which contain a pyrazolo-pyridine 
core and target the N-terminal acetyl group-binding site within UBC12 through the 
optimisation of an initial lead compound through the addition of hydrophobic 
interactions to mimic the endogenous acetylated N-terminus of UBE2M (Kim et 
al., 2019). Interestingly, the researchers showed that these compounds engage 
DCNL1 in cells and selectively reduce the steady state levels of neddylated cullin 
1 and cullin 3 in two squamous carcinoma cell lines which harboured DCNL1 
amplification. They also showed that the compounds also target DCNL2-mediated 
neddylation in vitro (Kim et al., 2019). The emergence of new compounds that 
can specifically target individual DCNL proteins as well as specific cullins in cells 
represents a key therapeutic avenue given the higher degree of control over the 
target and given the role of DCNL1 as an oncogene these compounds may represent 
useful bases for drug development in cancer therapy. 
1.3 Apoptosis  
Cell death can occur by a variety of mechanisms, including programmed cell death 
by the apoptosis pathway. This tightly regulated process results in a range of 
hallmark events including DNA fragmentation, chromatin condensation and cell 
lysis and is mediated by a key family of enzymes known as caspases which are 
cysteine-aspartic proteases (casp-ase). The apoptosis pathway can be broken 
down into two key branches: the extrinsic pathway and the intrinsic pathway 
(Fulda and Debatin, 2006), these differ in their triggers and in some of the 
caspases involved and both are discussed in more depth in the subsequent 
sections. Apoptosis is a highly regulated and tightly controlled process, involving 
many steps, and is often altered in cancer cells. Diseased cells can have mutation 
in the p53 gene, resulting in a dysregulation of the cell cycle, an impairment in 
the apoptosis pathways and can often lead to the formation of tumours. Tumorous 
cells often have mechanisms in place to evade cell death and significant work has 
been undertaken to better understand the pathways involved in mediating cell 
death. As well as the two main branches of the pathway, there also exist other 
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mechanisms that can cause death, including necrosis as well as caspase-
independent apoptosis (Tait and Green, 2008).  
The focus of the present work, however, is on the extrinsic and intrinsic apoptosis 
pathways. We focus on the extrinsic branch of the pathway in particular and more 
specifically on the role of caspase 8 which is one of the key initiator caspases and 
a core component of signalling complexes required for propagating the apoptosis 
stimulus via this branch of the pathway. The apoptosis pathways, as well as the 
various proteins and complexes involved in this process are discussed in the next 
sections of this report. A general overview of the two branches of the apoptosis 
pathway are shown in Figure 1-12. The extrinsic pathway is activated by a variety 
of ligands acting at a variety of receptors but shown below is only the binding of 
TNFα to a trimeric TNF receptor 1 molecule. (TNF-related apoptosis inducing 
ligand, TRAIL, also acts through the same basic pathway). This causes recruitment 
of adaptor proteins and can ultimately result in the cleavage and activation of 
caspase 8. The intrinsic branch of the pathway involves the release of cytochrome 
c from the mitochondrion and activation of caspase 9 which mediates downstream 
cleavage of effector caspases, similar to the role of caspase 8. Both pathways 
converge on the activation of executioner caspases which mediate cleavage of 
downstream proteins including poly(ADP ribose) polymerase (PARP) which is a 
repair enzyme preferentially cleaved by caspases 3 and 7 (Lazebnik et al., 1994). 
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Figure 1-12 A General Overview of the Two Branches of the Apoptosis Pathway.  
This simplified diagram shows a broad overview of the extrinsic and the intrinsic branches of the 
apoptosis response. The extrinsic branch of the pathway is the receptor-mediated branch and can 
be triggered by TNFα or TNFα-related family of ligands. Binding of the ligand to TNFα-superfamily 
receptors results in trimerization of the receptor and formation of a receptor-bound complex of death-
domain containing proteins. This leads to the cleavage and activation of the key initiator caspase, 
caspase 8, which is then able to activate the effector caspases 3 and 7. The intrinsic branch is 
triggered by internal stimuli including DNA damage and ER stress, and results in the release of 
cytochrome c from the mitochondrion. Cytochrome c forms the apoptosome along with pro-caspase 
9 and APAF-1 which results in the cleavage and activation of caspase 9. Like caspase 8, caspase 9 
is an initiator caspase and can activate the downstream effector caspases. Caspase 8 can also 
activate the intrinsic branch of the pathway to amplify the apoptosis signal, via a protein called BID. 
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1.3.1 Caspase Proteins 
The caspase family of proteins are proteases which cleave target substrates at 
specific sites after an aspartic acid residue via an active cysteine residue in their 
active sites. Caspases are the key mediators of apoptosis and can be grouped by 
their function and role in apoptosis. In humans, caspases 2, 8, 9 and 10 are known 
as initiator caspases, caspases 3, 6 and 7 are known as executioner caspases and 
caspases 1, 4, 5 and 12(L) (long form) are inflammatory caspases. The short form 
of caspase 12(S) is truncated and functionally redundant while the long form is 
specific to individuals of African descent and plays a role in attenuating the 
inflammatory and innate immune responses to endotoxins (Saleh et al., 2004). 
Caspase 14 also exists but its function is less well characterised. We will focus on 
the initiator caspases and executioner caspases in this report. Caspases differ in 
their structure but also in the sequences within peptides or proteins that they 
recognise for cleavage (Julien and Wells, 2017). 
All caspases except for caspase 9 (Shi, 2002) exist as inactive pro-enzymes (pro-
caspase 9 possesses some activity) consisting in their simplest form of a pro-
domain and small and large subunits. Initiator caspases as well as inflammatory 
caspases contain domains known as death effector domains (DED) and caspase 
recruitment domains (CARD) within their pro-domains which serve to mediate 
homophilic interactions between pro-caspases and their adaptors (Chang and 
Yang, 2000). Executioner caspases contain much shorter pro-domains (~30 amino 
acids compared to over 100 amino acids for initiator caspases) which are thought 
to actually inhibit caspase activation. Active executioner caspases have been 
shown to consist of hetero-dimers of both subunits which are required for their 
proteolytic activity (Thornberry et al., 1992). An overview of the domains within 
the different caspase family members can be seen in Figure 1-13. 
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Figure 1-13 Caspase Family Domains.  
Caspases can be grouped into three families: initiator, executioner and inflammatory caspases. The 
fundamental make up of all caspases is similar, they consist of small and large subunits as well as a 
pro-domain region consisting of death effector domains (DED) in initiator caspases 8 and 10 or 
caspase recruitment domains in initiator caspases 2 and 9 as well as all inflammatory caspases. 
These regions mediate inter and intra-caspase molecule interactions as well as interactions with 
adaptor proteins. Executioner caspases contain very short pro-domains (not shown in the figure) 
which serve to inhibit their activation. 
1.3.2 Intrinsic Apoptosis 
The intrinsic apoptosis pathway is also known as the mitochondrial apoptosis 
pathway since it involves the release of factors from the mitochondria. This 
pathway is activated by internal stimuli including ER stress and DNA damage and 
the key caspase responsible for propagating the signal and mediating downstream 
events is caspase 9, one of the initiator caspases. Apoptotic stimuli cause the 
release of a protein called cytochrome c from the intermembrane space. This 
protein functions as an electron shuttle in the respiratory chain and is an essential 
protein for normal functioning of cells. Cytochrome c is released into the cytosol 
via a two-step process involving solubilization of the protein followed by the 
permeabilization of the outer mitochondrial membrane by a protein called Bax 
(Ott et al., 2002).  
Cytosolic cytochrome c is then able to mediate the allosteric activation and 
oligomerization (in the presence of deoxy ATP) of the adaptor molecule apoptosis-
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protease activating factor 1 (APAF-1) to form what is known as the apoptosome 
(Cain, Bratton and Cohen, 2002). This complex is able to recruit seven molecules 
of pro-caspase 9 via the caspase recruitment domains (CARD) of each APAF-1 
molecule which allows for the formation of dimers between the two proteins 
through binding by two highly charged and complementary surfaces (Qin et al., 
1999). Recruitment of pro-caspase 9 to the apoptosome complexes allows for 
activation and cleavage of the initiator via self-processing mechanisms. It was 
demonstrated that cleaved caspase 9 is not required to form an active cell death 
complex, only pro-caspase 9 is required (Acehan et al., 2002). Cleaved and 
activated caspase 9 is then able to mediate activation of executioner caspases 
resulting in the downstream consequences of apoptosis.  
When studying the intrinsic apoptosis, chemical agents can be used to specifically 
trigger this branch of the pathway. One such agent is staurosporine which is a 
potent inhibitor of protein kinase C (PKC) in addition to two thirds of all kinases 
making it very promiscuous, and it is derived from Streptomyces staurosporeus. 
Staurosporine has been used extensively as an inducer of apoptosis and it is 
understood to cause, amongst other events, cytochrome C release from 
mitochondria to activate downstream caspases and the characteristic events 
underlying apoptosis (Zhang et al., 2005; Manns et al., 2011; Yadav et al., 2015; 
Malsy et al., 2019). Staurosporine has been shown to require several hours to 
mediate cytochrome C release (Bossy-Wetzel, Newmeyer and Green, 1998) which 
is important when studying the timing of apoptosis events. Staurosporine has also 
been shown to induce necroptosis (a type of programmed necrosis, which itself is 
a form of premature cell death mediated by autolysis) in instances where caspase 
activity is compromised, including via the use of pan-caspase inhibitors (Dunai et 
al., 2012). 
1.3.3 Extrinsic Apoptosis  
The extrinsic branch of the apoptosis pathway differs from the intrinsic pathway 
both in terms of the mechanism of activating executioner caspases but also in the 
triggering of the pathway. Extrinsic apoptosis is mediated by death receptors 
which are members of the tumour necrosis factor receptor (TNFR) superfamily. 
Some of the key receptors involved in extrinsic apoptosis include Fas/Apo1, 
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TNFR1, death receptor 4 (DR4) and death receptor 5 (DR5) with the last two being 
involved in TNF-related apoptosis-inducing ligand (TRAIL) signalling. These 
receptors all contain intracellular death domains which recruit death domain-
containing adaptor proteins required to mediate downstream signalling events 
required for apoptosis. TNFR family members consist of type I transmembrane 
proteins possessing 2 to 4 cysteine-rich domains in the extracellular domain, and 
most receptors trimerize upon ligand binding. Ligand binding leads to the 
recruitment of the aforementioned death domain-containing proteins TNFR-
associated death domain protein (TRADD) or Fas-associated death domain protein 
(FADD) (Locksley, Killeen and Lenardo, 2001). TRADD is recruited to TNFR1 
following binding of the cytokine TNFα while FADD is recruited to the Fas receptor 
or DR4/DR5 following Fas or TNFα-related apoptosis inducing ligand (TRAIL) 
binding respectively (Walczak and Krammer, 2000). Extrinsic apoptosis involves 
the activation of the initiator caspase 8 or 10 to mediate the cleavage and 
activation of effector caspases which are common to both the extrinsic and 
intrinsic branches of the apoptosis pathway. It is important to note that there 
exists crosstalk between the two pathways which was initially discovered in Fas 
and TNFα signalling: caspase 8 can mediate the cleavage of a protein called BID 
to form truncated BID (tBID) which then translocates to the mitochondria and 
promotes cytochrome C release (Li et al., 1998).  
1.3.3.1 TNFα-Mediated Apoptosis 
TNFα is a cytokine which induces a variety of cellular processes including 
inflammatory cytokine production and cell survival as well as cell death. TNF is 
produced as a type II transmembrane protein and is cleaved by a metalloprotease 
called TNF alpha converting enzyme (TACE) (Black et al., 1997). TNF signals 
through two key receptors, TNFR1 and TNFR2 with soluble TNFα showing a 
preference for TNFR1 and membrane-bound TNFα showing a preference for TNFR2 
(Wajant, Pfizenmaier and Scheurich, 2003). Furthermore, TNFR1 expression is 
constitutive while TNFR2 expression is highly regulated and this receptor lacks an 
intracellular death domain. TNF receptors trigger multiple intracellular signalling 
pathways including I-κB kinase (IKK) and c-Jun N-terminal kinase (JNK) to mediate 
gene expression regulation via transcription factors including NF-κB and AP-1 
(Varfolomeev and Ashkenazi, 2004).  
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TNFα binds to pre-trimerized TNFR1 receptors (Chan et al., 2000) which promotes 
binding of the death domain-containing protein TRADD (Locksley, Killeen and 
Lenardo, 2001). Following binding of TRADD, additional adaptors are recruited to 
the receptor bound complex (known as complex I) including receptor-interacting 
protein (kinase) 1 (RIP1) and TNFR-associated factor 2 (TRAF2). These then 
activate the IKK complex which stimulates NF-κB activity by promoting the 
phosphorylation and subsequent ubiquitination and degradation of IκBα, which 
allows for the nuclear translocation of NF-κB and subsequent transcriptional 
activities which promote survival (Miyamoto et al., 1994) via mechanisms 
including increased expression of cellular inhibitors of apoptosis (cIAPs). cIAPs are 
also recruited to complex I by TRAF2 (Chen and Goeddel, 2002). 
It has long been known that association of FADD is required to mediate apoptosis 
as this adaptor is responsible for the recruitment of pro-caspase 8 to form what is 
known as the death-inducing signalling complex (DISC), which was initially 
discovered and detailed in Fas signalling (Peter and Krammer, 2003) and also plays 
an essential role in TRAIL-mediated apoptosis. In the case of TNFα signalling, it 
was discovered that a second complex (complex II) forms downstream of the 
receptor-bound complex which is responsible for pro-death signalling (Micheau 
and Tschopp, 2003). Complex II thus forms following dissociation of the core 
components of complex I into the cytosol and consists of FADD, pro-caspase 8 and 
RIP3. The transition between complex I and complex II hinges on the association 
between TRADD and FADD (Hsu et al., 1996).  
The precise components of complex II are thought to vary, but another key 
component of this complex is a protein called cellular FLICE-like inhibitory protein 
(cFLIP) of which there are two isoforms: short (cFLIPS) and long (cFLIPL). cFLIP is 
structurally related to caspase 8 but each isoform has a different mechanism for 
inhibiting caspase 8 activation. cFLIPL contains two DED domains and an inactive 
caspase-like domain while cFLIPS consists only of two DED domains (Krueger et al., 
2001). Both isoforms are recruited to the DISC via their DED domains while cFLIPS 
blocks caspase 8 cleavage by preventing the initial cleavage step of the pro-
enzyme while cFLIPL allows for this step to occur but prevents full maturation of 
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caspase 8 by forming a hetero-dimer with caspase 8 as an intermediary fragment 
(Krueger et al., 2001). 
For TNFα signalling to induce apoptosis, this requires the inhibition of NF-κB 
activation, the co-treatment with an inhibitor of protein translation such as 
cycloheximide, or the depletion of endogenous cellular inhibitors of apoptosis 
(cIAPs). In addition, down regulation of cFLIP is a key factor in promoting apoptosis 
following TNFα signalling and this can be achieved experimentally through the use 
of the protein synthesis inhibitor cycloheximide which specifically reduces levels 
of cFLIP but not of the other components of the DISC/complex II (Paja̧k, Gajkowska 
and Orzechowski, 2005). An outline of the two main physiological outcomes of 
TNFα signalling as well as the key components involved is shown below in Figure 
1-14. 
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Figure 1-14 An Overview of TNFα Signalling in Apoptosis.  
TNFα binds to trimerized TNFR1 which causes the recruitment of the death domain-containing 
protein TRADD. This in turn recruits the secondary adaptors TRAF2 and RIP1 to form the receptor-
bound complex I, which promotes the phosphorylation and degradation of the inhibitor of NF-κB 
known as IκBα which allows for nuclear translocation of NF-κB and upregulation of genes related to 
inflammation and survival. This pathway is the default pathway following TNFα binding to its receptor. 
In circumstances where NF-κB signalling is inhibited or the inhibitor of apoptosis cFLIP is 
downregulated, a second complex forms which is cytosolic (complex II) which involves the 
recruitment of FADD which in turn recruits the initiator caspase 8 (shown here) or caspase 10 as ell 
as RIP3. FADD and pro-caspase 8 form what is known as death-inducing signalling complex (DISC) 
which is common to various death-inducing pathways from, different TNFα-like ligands. The DISC 
promotes caspase 8 cleavage and activation which then activates downstream effector caspases to 
mediate the various processes involved in apoptosis and cell death. 
Further complicating our understanding of this signalling pathway, TNFα has been 
shown to induce two distinct pathways of caspase 8 activation and this has been 
shown to hinge on the role of the kinase RIP1. In the RIP1-independent pathway, 
caspase 8 cleavage is regulated by cFLIP and this can be overcome using 
cycloheximide as mentioned above to specifically reduce the levels of this 
endogenous inhibitor. In a RIP1 dependent manner, caspase 8 can also be 
activated using a Smac mimetic which targets inhibitor of apoptosis (IAP) proteins 
in the same way as the endogenous Smac protein. This promotes the release of 
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RIP1 from the activated complex I to form a complex consisting of RIP1, FADD and 
caspase 8 (Wang, Du and Wang, 2008). This complex was later named the 
Ripoptosome and shown to also consist of the other initiator caspase , caspase 10, 
as well as cFLIPL  (Feoktistova et al., 2011). The complexity of TNFα-mediated 
apoptosis makes studying the effect of the cytokine as an inducer of cell death 
challenging, and we therefore additionally employ the use of TRAIL in our 
experimental work, which has a better characterised and more streamlined 
mechanism.  
1.3.3.2 TRAIL-Mediated Apoptosis 
TNF-related apoptosis-inducing ligand (TRAIL) is a type II transmembrane protein 
that is related to both TNFα and Fas. TRAIL can be proteolytically cleaved from 
the cell surface to release its extracellular C-terminal portion while pre-formed 
TRAIL can also be stored in the cytoplasm and released during the activation-
induced cell death (AICD) process which serves as a negative regulator of T 
lymphocytes (Monleón et al., 2001). TRAIL binds to trimeric receptors in a similar 
fashion to TNFα as described in the previous section, and in the initial stages of 
research into TRAIL it was shown that TRAIL is selective in inducing apoptosis in 
tumour cells compared to normal cells (Ashkenazi et al., 1999; Walczak et al., 
1999), however, it quickly emerged that there were likely species specific 
differences in sensitivity to TRAIL (Jo et al., 2000) as well as organ and tissue 
specific differences (Seki et al., 2003). Another potential indication that TRAIL 
may represent a useful therapeutic agent was the high expression of its receptors 
DR4 and DR5 in various malignancies (Sträter et al., 2002; Kurbanov et al., 2005). 
This is also supported by the finding that TRAIL resistant MCF-7 cells undergo 
constitutive endocytosis of DR4 and DR5 which is thought to confer this resistance 
(Zhang and Zhang, 2008). 
TRAIL can bind to one of 4 homologous receptors in humans which include DR4 and 
DR5 as mentioned already, as well as decoy receptor 1 (DcR1) and decoy receptor 
2 (DcR2). DR4 and DR5 are involved in mediating apoptosis (thus their name ‘Death 
Receptor’) and have conserved intracellular death domain motifs that are involved 
in recruitment of the death domain containing protein FADD to mediate apoptosis 
(Pan et al., 1997a; Walczak et al., 1997; Pan et al., 1997b). DcR1 and DcR2 were 
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shown to be non-functional homologues of DR4 and DR5 that actually protected 
cells from apoptosis by different mechanisms (which are discussed in 1.3.3.3) (Pan 
et al., 1997a; Degli-Esposti et al., 1997b; Degli-Esposti et al., 1997a; Sheridan et 
al., 1997; Marsters et al., 1997).  
FADD interacts with the intracellular death domains of death receptors via 
homophilic interactions (Walczak and Krammer, 2000). In TRAIL signalling, FADD 
is the key adaptor molecule and as in TNFα signalling, FADD then recruits pro-
caspase 8 via DED domain interaction between the two proteins (see Figure 1-13 
for more information about caspase domain structure), this is an event which 
occurs at the receptor-bound complex in TRAIL signalling but not in TNFα 
signalling, where this occurs at the cytosolic complex II (Harper et al., 2003). 
FADD and pro-caspase 8 form the death-inducing signalling complex (DISC) which 
serves as a platform for caspase 8 cleavage and activation (Kischkel et al., 2000; 
Sprick et al., 2000). The mechanism underlying caspase 8 cleavage is discussed in 
depth in section 1.3.4, but very briefly it involves its ubiquitination and auto-
processing to produce catalytically active clusters of caspase 8 which are 
maintained in aggregates in the cytosol to mediate downstream cleavage events.  
There exist two mechanisms by which caspase 8 can activate downstream effector 
caspases and this is categorized into type I and type II cells (Scaffidi et al., 1998). 
In type I cells, caspase 8 cleavage at the DISC occurs in sufficient quantities to 
induce caspase 3 cleavage and activation within 30 minutes. In type II cells, little 
caspase 8 is produced at the DISC so mitochondrial outer membrane 
permeabilization is required to activate the apoptosome to assist in the activation 
of downstream effector caspase activation. It was shown that mitochondrial 
involvement is present in both cell types however it is only essential for type II 
cells, Furthermore it was shown that overexpression of the protein Bcl-2, which is 
an inhibitor of apoptosis, was able to inhibit TRAIL-induced apoptosis in only the 
type II cells (Scaffidi et al., 1998). This finding was taken further when it was 
discovered that caspase 8 cleavage can occur both upstream and downstream of 
mitochondria in a feedback loop which was shown by overexpressing Bcl-2 and 
finding that caspase 8 and BID cleavage were reduced resulting in resistance to 
TRAIL. This supported a finding whereby executioner caspases are able to promote 
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caspase 8 cleavage and thus serve as a feedback loop to amplify the apoptotic 
process (Fulda, Meyer and Debatin, 2002). 
DISC formation occurs at the receptor bound complex II in TRAIL signalling as 
opposed to the cytosolic complex II in TNFα signalling. While less common and less 
well understood, TRAIL signalling can also promote inflammatory signalling via a 
second complex that forms after the DISC which involves the recruitment of 
proteins including  TRAF2 and RIP1 (which are all involved in pro-survival signalling 
from complex I during TNFα signalling) as well as the regulatory subunit of the IKK 
kinase complex NEMO (Varfolomeev et al., 2005). This second complex has been 
shown to activate JNK, p38 and NF-κB signalling pathways, and activation of these 
pathways and the formation of this second complex was shown to be increased by 
caspase activation which was postulated to act regulatory mechanism 
(Varfolomeev et al., 2005). Consensus seems to be that activation of pro-
inflammatory responses occurs downstream of caspase 8 recruitment to the DISC 
and thus also requires FADD, however the involvement of RIP1 and FLIP may not 
be essential (Grunert et al., 2012). A summary of the TRAIL signalling pathways 
can be seen in Figure 1-14. It is interesting that TNFα and TRAIL can induce pro-
survival and pro-apoptosis signalling pathways but do so from different complexes 
with similar components. 
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Figure 1-15 An Overview of TRAIL Signalling in Apoptosis.  
TRAIL binding to its receptors DR4 or DR5 leads to the recruitment of FADD which interacts with the 
intracellular death domains of the trimerized receptors. FADD in turn recruits pro-caspase 8 via 
homophilic interactions between their DED domains, to form the DISC (complex I). At the DISC, 
caspase 8 is ubiquitinated and undergoes auto-catalytic processing to form active pools of caspase 
8 which are released from the DISC. In type I cells this is sufficient to induce downstream caspase 
activity, in type II cells amplification of the signal is required which is mediated by cleaved BID (tBID) 
which can promote cytochrome C release from mitochondria to ultimately activate caspase 9 via the 
apoptosome  and promote effector caspase activation. Under specific circumstances, and possibly 
in a feedback loop, a second complex can form (complex II) which consists of FADD and pro-caspase 
8 as well as RIP1, TRAF2 and NEMO. This complex can promote inflammatory signalling via 
pathways such as MAPK and NF-κB which can upregulate inhibitors such as cFLIP which shut off 
the apoptosis induction pathway. The inflammatory signalling is also thought to play a role in 
signalling for phagocytic engulfment of apoptotic cells. 
1.3.3.3 Regulation of TRAIL signalling 
TRAIL signalling is tightly regulated by various proteins including cFLIP which was 
mentioned previously for its role in TNFα signalling, as well as by proteins called 
inhibitors of apoptosis (IAPs) which were also mentioned briefly. cFLIP plays a key 
role in DISC-mediated apoptotic signalling in TRAIL signalling as well as in TNFα 
signalling – cFLIP is structurally similar to caspase 8 but is lacks catalytic activity 
The short form of cFLIP is truncated and contains DED domains only, while the 
long form closely resemble the full-length pro caspase 8 but lacks catalytic 
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activity. Expression of cFLIP was found to be up-regulated in gallbladder 
carcinoma and down-regulation of the protein sensitised the cells to TRAIL-
induced apoptosis (Zong et al., 2009). cFLIP has also been shown to become up-
regulated in response to TRAIL treatment in non-small-cell lung carcinoma cells 
that evaded TRAIL-mediated apoptosis indicating a mechanism by which cancer 
cells are able to evade cell death. This resistance was inhibited both by co-
stimulation with the protein synthesis inhibitor cycloheximide (which specifically 
interacts with cFLIP in an inhibitory fashion) as well as by inhibition of 
Ca2+/calmodulin signalling (Kaminskyy et al., 2013). cFLIP expression has also 
been shown to correlate with sensitivity to TRAIL in human melanoma cells, where 
TRAIL resistance was found to be conveyed as a result of high cFLIP expression in 
cells that were not sensitive to TRAIL stimulation, and resistance to TRAIL was 
able to be induced by ectopic expression of cFLIP in cells that were highly sensitive 
to the drug (Geserick et al., 2008). 
TRAIL signalling is also regulated by expression of its receptors, with decoy 
receptors acting as crucial negative regulators of TRAIL signalling. DcR1 lacks a 
cytoplasmic domain (Pan et al., 1997a) and transient overexpression of this 
receptor did not induce apoptosis which contrasts from overexpression of DR4 and 
DR5 which significantly increased apoptosis (Degli-Esposti et al., 1997b), while 
DcR1 also appears to inhibit TRAIL signalling due to sequestering of TRAIL ligand 
away from the functional receptors (Sheridan et al., 1997). It was suggested that 
the lower expression of DcR1 in cancer cells accounted for their increased 
sensitivity to TRAIL compared to normal cells. DcR2 contains a truncated 
intracellular death domain and is able to induce NF-κB activation (Degli-Esposti et 
al., 1997a) similarly to DR4/5 but is unable to induce apoptosis. Furthermore, it 
was shown by two groups independently that overexpression of DcR2 protected 
normally sensitive cells to TRAIL stimulation and confirmed the inability of the 
receptor to induce apoptosis (Degli-Esposti et al., 1997a; Marsters et al., 1997).  
TRAIL receptor variation and the existence of decoy receptors has made using 
TRAIL in therapy challenging. There is however a large body of data on the 
significance on the ratio of decoy receptors to functional death receptors in 
tumour cells, with one group reporting that high DcR1 expression on leukemic 
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blasts is associated with poor outcome and causes apoptosis resistance and 
another group reporting that reduction in levels of an additional decoy receptor 
more recently discovered called DcR3 enhances TRAIL-mediated apoptosis in 
pancreatic cancer (Wang et al., 2013). DcR2 has also been shown to be a p53 
target gene that regulates chemosensitivity (Liu et al., 2005), thus understanding 
the distribution and expression of TRAIL receptors is key in developing new cancer 
therapy strategies. 
1.3.4 Caspase 8 
Caspase 8 is the critical initiator caspase involved in the extrinsic branch of the 
apoptosis pathway. It is also involved in amplification of the apoptosis signal via 
cleavage of BID and activation of the intrinsic branch under certain circumstances, 
as mentioned previously. Caspase 8 is cleaved and activated following stimulation 
of TNFα, TRAIL and Fas and its recruitment to death signalling complexes as well 
as its activation and cleavage has been well studied and well characterised. 
1.3.4.1 Activation of Caspase 8 
Pro-caspase 8 consists of a pro-domain which contains two death effector domains 
(DEDs) as well as two enzymatic domains known as p18 and p10 sub-domains. The 
full-length monomeric caspase 8 molecule is recruited to the DISC (we will focus 
on DISC assembly following TRAIL stimulation) via its DED domains which interact 
with the DED domains of FADD via homophilic interactions. Recruitment to the 
DISC and DED interactions result in the dimerization of pro-caspase 8 which is a 
required step in promoting its activation (Muzio et al., 1998; Boatright et al., 
2003; Pop et al., 2007). Research has shown that dimerization-incompetent 
processed caspase 8 as well as monomeric-procaspase 8 exhibit a lack of catalytic 
activity (Keller et al., 2009) and that cleaved caspase 8 shows specificity towards 
pro-caspase 8 and dimerization enhances intramolecular cleavage due to 
structural rearrangements, suggesting a model whereby different types of 
cleavage within caspase 8 populations can occur (Keller, Grütter and Zerbe, 2010). 
There exist two pro-caspase 8 isoforms: 8a (p55) and 8b (p53) which are 
collectively known as p55/53 caspase 8. This full-length form of caspase 8 
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undergoes cleavage at aspartic acid residues contained within linkers either 
between the pro-domain and the catalytic domains, or between the two catalytic 
sub-domains, thus various intermediate cleaved forms of caspase 8 are produced 
during activation. An outline of the cleavage products of caspase 8 can be seen in 
Figure 1-16. Pro-caspase 8 can be cleaved at aspartic acid residues 374 and 384 
between the two enzymatic sub-domains to form what is known as the p43/41 
fragment (a and b isoforms respectively) as well as free p10 catalytic domain – 
these cleavage products typically appear first after activation (Chang et al., 
2003). The p43/41 fragment has been shown to be catalytically active, stable, and 
capable of activating some downstream events including caspase 3 cleavage and 
BID cleavage and represents a key stage in apoptosis signal transduction (Hughes 
et al., 2009). When studying caspase 8 cleavage, the stability of the p43/41 
fragment makes it a good marker for caspase 8 cleavage while detection of other 
fragments can be more challenging. 
Cleavage can also occur at aspartic acid residues in the linker region between the 
pro-domain and the catalytic domain (Asp210 and Asp 216) to form the p26/24 
fragment (a and b isoforms respectively) as well as the p30 fragment which consist 
of the two catalytic sub-domains. This p30 fragment has been shown to play a role 
in sensitising cells towards death receptor-induced apoptosis (Hoffmann et al., 
2009). Further processing of caspase 8 occurs via cleavage at the remaining 
aspartic acid residues yet to be cleaved in each fragment, ultimately producing 
more of the p26/24 fragment, as well as p10 and p18 fragments. p10 and p18 
fragments combine to form a hetero-tetramer which is referred to for simplicity 
in this report as p18 (caspase 8), and this form is catalytically active and 
responsible for the majority of downstream cleavage events mediated by caspase 
8 and is formed at the DISC and released into the cytosol (Lavrik et al., 2003) 
which is regarded as the most up to date view and contrasts with earlier evidence 
that the p18 hetero-tetramer forms in the cytosol rather than at the DISC itself 
(Medema et al., 1997).  
Caspase 8 cleavage has been shown to occur by three different methods: 
intramolecular processing within the same pro-caspase 8 molecule, intermolecular 
processing between pro-caspase 8 molecules associating with the same DISC 
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(intradimer processing) and intermolecular processing between pro-caspase 8 
molecules associated with different DISCs (interdimeric) (Kallenberger et al., 
2014). Furthermore, mathematical modelling which was supported by 
experimental work demonstrated that the cleavage that occurs between the two 
catalytic sub-domains p18 and p10 occurs as a result of interdimeric processing, 
while the cleavage between the pro-domain and the p18 domain occurs as a result 
of intradimeric processing (Kallenberger et al., 2014). Overall, their model 
suggests that this dual mechanism of caspase 8 activation ensures that low TRAIL 
concentrations trigger weak signalling while higher concentrations of the ligand 
promoted activation which provides a significant level of precision to the 
apoptosis response. This study also provided insight into the role of the FLIP 
proteins which are able to form hetero-dimers with pro-caspase 8 in a manner 
which does not promote apoptosis signalling due to the restrictions on the ability 
for caspase 8 to be cleaved by interdimer processing (Kallenberger et al., 2014; 
Riley et al., 2015).  
More recently it has been discovered that cFLIP may also play a cooperative role 
in caspase 8 activation rather than simply an antagonist role. This was shown to 
depend on the isoform of cFLIP, with the short variant (cFLIPS) acting only in an 
antagonistic fashion while the long form (cFLIPL) was able to promote and inhibit 
caspase 8 activation (Hughes et al., 2016). By reconstituting the DISC and using 
structure-guided mutagenesis, Hughes and colleagues discovered that pro-caspase 
8 hetero-dimerizes  with cFLIP and the activation of pro-caspase 8 was controlled 
by the ratio of unbound cFLIPL/S to pro-caspase 8 which in turn regulates the 
composition of the pro-caspase 8:cFLIP heterodimer. Formation of pro-caspase 
8:cFLIPL demonstrated enzymatic activity and was able to promote pro-caspase 8 
activation while pro-caspase 8:cFLIPS lacked activity and readily blocked pro-
caspase 8 activation (Hughes et al., 2016). Thus, the levels of the different 
isoforms act as a regulator of pro-caspase 8 oligomerisation and cleavage and 
targeting either isoform may represent key therapeutic targets. 
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Figure 1-16 Caspase 8 Cleavage Products.  
This diagram shows the key fragments of caspase 8 that form following its cleavage at specific 
aspartic acid residues within its amino acid sequence. Pro-caspase 8 consists of two DED domains 
as well as a catalytic domain which is composed of two subdomains, p18 and p10. Cleavage of 
caspase 8 can occur by two pathways and both result in the formation of active p18 caspase 8 which 
consists of a hetero-tetramer of p10 and p18 subunits. Cleavage of the p55/53 (isoform a and b 
respectively) full-length caspase 8 can occur at aspartic acid residues in the linker between the two 
catalytic sub-domains to produce p43/41 and p10 fragments, or between the pro-domain and the 
catalytic domain to produce p26/24 and p30 fragments. p43/41 ad p26/24 have been shown to 
possess catalytic activity and an ability to mediate cleavage of some downstream components. 
Cleavage of the other linker region at aspartic acid residues of the processed fragments results in 
the formation p26/24, p18 and p10 fragments, with the latter two fragments combining to form the 
active form known as p18, which is responsible for the majority of downstream cleavage events. p18 
caspase 8 is released from the DISC into the cytosol. 
1.3.4.2 Caspase 8 Ubiquitination by Cullin 3 
Caspase 8 was shown in 2009 to be regulated by ubiquitination by cullin 3 in what 
was demonstrated to be a critical modification that occurs at the DISC. This 
ubiquitination was shown to be polyubiquitin via K63 and K48 linkages on a lysine 
within the C-terminal domain of caspase 8, more specifically, within the p10 
catalytic sub-domain (Jin et al., 2009). The work by Jin and colleagues was 
extensive in elucidating the importance of cullin 3 in caspase 8 activation, showing 
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that cullin 3 interacts with the DISC and demonstrating that reduction in cullin 3 
expression resulted in a reduction in caspase 8 ubiquitination, while 
overexpression of cullin 3 increased caspase 8 modification (Jin et al., 2009). The 
interaction of cullin 3 was dependent on its interaction with RBX1, and the de-
ubiquitinating enzyme A20 was shown to reverse this modification. The role of A20 
as a regulator of this pathway was further investigated more recently and the 
polyubiquitination by K48 and K63 linkages were shown to be counteracted by A20 
thus providing another regulator of caspase 8 activity (Lim et al., 2017).  
In addition to the role of cullin 3 in caspase 8 ubiquitination, Jin and colleagues 
also provided insight into a role for the scaffold protein p62 (Jin et al., 2009). p62 
is a ubiquitin-binding protein, which binds polyubiquitinated proteins via its UBA 
domain and has been shown to play a role in interactions with protein aggregates 
as well as targeting proteins for degradation (Seibenhener et al., 2004). It was 
shown that in the context of caspase 8 activation, p62 interacts with the DISC and 
promotes aggregation of cullin 3-modified caspase 8 in ubiquitin-rich foci in the 
cytosol. This aggregation enhances activity and promotes the auto-proteolytic 
release of caspase 8 into the cytosol (Jin et al., 2009). The role of p62 was shown 
to enhance interaction with A20 to mediate the de-ubiquitination of pro-caspase  
8 suggesting that p62 may play a role as an adaptor between pro-caspase 8 and 
A20 (Lim et al., 2017). As yet, no research has been undertaken into determining 
the substrate adaptor for the cullin-3/RBX1-based CRL complex, and no work has 
been done in studying the effect of neddylation inhibition or the role of the DCNL 
protein family in the ubiquitination of caspase 8 – the present research aims to 
investigate the link between cullin 3 polyubiquitination of caspase 8 and the 
neddylation pathway. 
1.3.4.3 Caspase 8 In Disease 
The role of caspase 8 in the apoptosis pathway has been described in detail, 
however its importance in normal physiology and role in disease requires more 
analysis. Caspase 8 is often dysregulated in human cancers, given its role in 
promoting cell death it is perhaps unsurprising that a characteristic of many 
cancers is an inactivation of the protein through a variety of mechanisms including 
epigenetic modulation and posttranslational modifications. While the frequency 
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of mutations in caspase 8  in cancers is low, there have been instances of mutated 
caspase 8 which is unable to transduce death signals by acting as a dominant 
negative inhibitor of death in colorectal carcinomas (ref Kim et al, 2003) and in 
head and neck carcinomas, in this latter case due to a lengthening of the protein 
by 88 amino acids (Mandruzzato et al., 1997). In hepatocellular carcinomas, the 
caspase 8 gene was found to be frequently inactivated due to a frameshift somatic 
mutation which caused a two base-pair deletion resulting in premature 
termination of translation in the p10 catalytic subunit and thus a loss of caspase 
8 and therefore cell death function (Soung et al., 2005). 
There exist various caspase inhibitors, many of which are used routinely in 
studying caspase cleavage in cell, and some which are available for use clinically, 
for example emricasan which was developed to protect liver cells from excessive 
apoptosis. Caspase 8 inhibitors have been shown to work cooperatively with other 
drugs that target the apoptosis pathway to induce necroptosis in acute myeloid 
leukaemia cells which are often resistant in the absence of caspase 8 inhibition 
(Brumatti et al., 2016) indicating therapeutic benefits to targeting caspase 8. 
Caspase 8 inhibitors have also been used to reduce the outgrowth of lung tumours 
which was in part caused by a reduction in the release of pro-inflammatory 
cytokines including IL-6, IL-1α and TNFα (Terlizzi et al., 2015). Given the 
complexity of the pathway governing caspase 8 activation, and the many different 
regulators and interactions that occur in apoptosis, developing specific drugs to 
inhibit caspase 8 activation or drugs to promote its activation represent a key 
challenge. This thesis aims to elucidate additional regulation in the caspase 8 
activation pathway by DCNL5 which may in future represent a therapeutic target. 
 
1.4 Thesis Aims 
The overall aim of this thesis was to characterise the role of DCNL5 in the 
apoptosis response. While  the initial work planned to validate and  further 
investigate  the recent discovery that DCNL5 has a unique function amongst the 
DCNL protein family in the DNA damage response, it became clear during this study 
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that DCNL5 plays additional roles in vitro including in the extrinsic branch of the 
apoptosis pathway. To date, few unique functions for the DCNL proteins have been 
described and definitively characterised and the present work aimed to 
comprehensively detail the role DCNL5 plays in cell death signalling, in what 
appeared to be a cullin-dependant manner. 
The role of DCNL5 in the apoptosis response was investigated using an array of 
activators of the pathway, and apoptosis induction was detected using an ATP-
based luciferase assay. The cleavage of caspase 8, which is a key marker for 
apoptosis induction, was analysed by western blotting and we specifically aimed 
to optimise for the detection of the p18 form of cleaved caspase 8. It has already 
been comprehensively shown that caspase 8 cleavage impairment results in 
diminished apoptosis induction and thus cell death, and the importance of DCNL5 
in the signalling mechanism  was investigated through siRNA-mediated 
manipulation of DCNL5 levels.  
Cullin 3  has been shown to be required for the successful cleavage of caspase 8 
in death receptor signalling, so we wanted to confirm this finding in U2OS cells 
and a variety of other cancer cell lines. Finally, the role of DCNL5 was 
characterised in a variety of cancer cell lines by western blotting following siRNA-
mediated gene silencing, as well as by establishing a stable CRISPR/Cas9 KO cell 
line using H460 cells and validating these cells by genome DNA sequencing in 
addition to testing their ability to undergo caspase 8 cleavage.
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2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents and Kits 
Catalogue number preceded by ‘#’. 
Abcam, Cambridge, UK 
QVD-OPh, caspase inhibitor (# ab141421 
Recombinant human TRAIL protein (# ab9960) 
Staurosporine (#ab120056) 
Active Biochem, Kowloon, Hong Kong 
MLN-4924 (Pevonedistat) (#A-1139) 
Bio-Rad Laboratories Ltd., Hertfordshire, UK 
40% Acrylamide/Bis Solution, 37.5:1 (#1610148EDU) 
Precision Plus Protein All Blue Pre-Stained Protein Standards (# 1610373) 
Corning Inc., Maine, USA 
6 well polystyrene TC-treated cell culture plate (# CLS3516) 
12 well polystyrene TC-treated cell culture plate (# CLS3513) 
24 well TC-treated cell culture plate (# 3526) 
75cm2 Polystyrene Cell Culture Flask (# CLS430641) 
150cm2 Polystyrene Cell Culture Flask (# CLS430825) 
96 well clear flat bottom polystyrene TC-treated microplates (# CLS3596)  
Fisher Scientific, ThermoFisher Scientific, Leicestershire, UK 
Ammonium Persulfate (#A/6160/60) 
Bovine Serum Albumin (#BP9702-100) 
Glycerol (#G/0650/17) 
Tris Base (#BP152-1) 
GE Dharmacon, Little Chalfont, UK 
ON-TARGETplus Non-targeting siRNA #1, 5 nmol (#D-001810-01-05) 
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Individual ON-TARGETplus DCUN1D5 siRNA (number 1) 
SMARTpool: ON-TARGETplus CUL3 siRNA  
Gibco by ThermoFisher Scientific, Paisley, UK 
Dulbecco’s Modified Eagle Medium (DMEM) (#11965084) 
Fetal Bovine Serum (#10100147) 
L-Glutamine (#25030081) 
Opti-MEM Reduced Serum Medium (#31985062) 
Phosphate Buffered Saline (PBS) (#10010023) 
Penicillin-Streptomycin (#15140130) 
RPMI (#21875034) 
0.05% Trypsin-EDTA (#25300054) 
Formedium, Norfolk, UK 
Tryptone (#TRP02) 
Yeast Extract Powder (#YEA02) 
Invitrogen by ThermoFisher Scientific, Leicestershire, UK 
Dynabeads™ Protein A (#10001D) 
NuPAGE™ MES SDS Running Buffer (20X) (#NP0002) 
NuPAGE™ MOPS SDS Running Buffer (20X) (#NP0001) 
Invivogen, California, USA 
Recombinant Human TNFα (#rcyc-htnfa) 
Melford Laboratories Ltd., Suffolk, UK 
Dithiothreitol (DTT) (#MB1015) 
Merck, Darmstadt, Germany 
cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail (#11836170001) 
Immobilon Western Chemiluminescent HRP Substrate (#WBKLS0500) 
PhosSTOP™ (#4906845001) 
New England Biolabs, Massachusetts, USA 
BamHI-HF (#R3136S) 
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Gel Loading Dye, Purple (6X), no SDS (#B7025S) 
NotI-HF (#R3189S) 
Quick-Load® Purple 1 kb Plus DNA Ladder (#N0550S) 
Q5® High-Fidelity DNA Polymerase (#M0491S) 
T4 DNA Ligase (#M0202S) 
Promega, Wisconsin, USA 
Magne® HaloTag® Beads (#G7281) 
QuantiLum® Recombinant Luciferase (#E1701) 
Wizard® Genomic DNA Purification Kit (#A1120) 
Wizard® Plus SV Minipreps DNA Purification Systems (#A1330) 
Qiagen, Hilden, Germany 
Blood & Cell Culture DNA Mini Kit (#13323) 
QIAquick Gel Extraction Kit (#28704) 
QIAquick PCR Purification Kit (#28104) 
Sartorius, Gottingen, Germany 
Minisart 0.2 um pore size syringe filter (#16534K) 
Sigma-Aldrich, Dorset, UK 
Ammonium Persulfate (#A3678) 
Ampicillin Sodium Salt (#A0166) 
Β-Mercaptoethanol (#M6250) 
BIS-TRIS (#B9754) 
Bromophenol Blue (#B0126) 
Calcium Chloride Solution (1M) (#21115 
Cycloheximide (#01810) 
Doxorubicin Hydrochloride (#D1515) 
Doxycycline Hyclate (#D9891) ( 
Ethidium Bromide Solution (#E1510) 
Iodoacetamide (#l1149) 
Magnesium Chloride Solution (#M1028) 
Neocarzinostatin (from Streptomyces carzinostaticus) (#N9162) 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) (#T9281) 
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NP-40 Substitute (#74385) 
Poly-D-Lysine Hydrobromide (#P6407) 
Sodium Pyrophosphate (#221368) 
Staurosporine (from Streptomyces) (#S5921) 
Tetracycline (#87128) 
Triton X-100 (#T9284) 
TWEEN 20 (#P7949) 
1,10 Phenanthroline (OPT) (#131377) 
STARLAB, Milton Keynes, UK 
StarTub Reagent Reservoir 55ml (#E2310-1010) 
Synchem, Felsberg, Germany 
D-Luciferin free acid (#s039) 
Stratech, Cambridge, UK 
Bleomycin Sulphate, (#S1214-SEL) 
Etoposide (#S1225-SEL) 
ThermoFisher Scientific, Illinois, USA  
Lipofectamine 2000 Transfection Reagent (#52887) 
Lipofectamine™ RNAiMAX Transfection Reagent (#13778100) 
Mr Frosty™ Freezing Container (#5100-0001) 
Pierce BCA Protein Assay Reagent A (#23228) 
Pierce BCA Protein Assay, Reagent B (#23224) 
Pierce™ Protein A/G Magnetic Beads (#88802) 
Pierce™ Protein G Magnetic Beads (#88847) 
Thermo Scientific™ Shandon™ Immu-Mount™ (#10622689) 
UltraPure Agarose (#16500500) 
VWR Chemicals, Leicestershire, UK 
Sodium Chloride (#27810.295P) 
Sodium Dodecyl Sulphate (442444H) 
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2.1.2 Specialist Equipment 
Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Protein gel casting and Western blotting equipment (Mini Protean III) 
Agarose gel casting equipment (Mini-Sub/Wide Mini-Sub Cell GT gel system) 
BMG-Labtech, Offenburg, Germany 
FLUOstar Omega microplate reader 
Carl Ziess Ltd, Cambridge, UK 
LSM Exciter laser scanning microscope 
AxioVision light microscope 
Sartorius, Gottigen, Germany 
IncuCyte® SX1 live-cell analysis system and software 
ThermoFisher Scientific, Illinois, USA  
Mr Frosty™ Freezing Container (#5100-0001) 
Nanodrop™ spectrophotometer 
XCell SureLock Mini-Cell apparatus 
2.1.3 Commercially Derived Cell Lines 
Name Disease/Origin Supplier 
A375 Skin, Malignant 
Melanoma 
A gift from Professor 
George Baillie’s 
Laboratory 
DU-145 Prostate; derived from 
metastatic site: brain 
A gift from Professor 
George Baillie’s 
Laboratory 
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HeLa Cervix A gift from Professor 
Kostas Tokatlidis’s 
Laboratory 
HEK 293 Human Embryonic Kidney 
Cells 
ATCC, Virginia, USA 
H460 Lung Carcinoma ATCC, American Tissue 
Culture Collection 
(ATCC), Virginia, USA 
Virginia, USA 
MCF-7 Mammary gland tissue 
derived from metastatic 
site; Adenocarcinoma 
A gift from Professor Neil 
Bulleid’s Laboratory 
U2OS Osteosarcoma ATCC, Virginia, USA 
22Rv1 Prostate Carcinoma A gift from Professor 
George Baillie’s 
Laboratory  
Table 1 List of Commercially Obtained Cell Lines 
2.1.4 Plasmids 
Identity Description Source 
PCDNA3.1(+)-Empty Empty pcDNA3.1(+) 
mammalian 
expression plasmid 
 
Made by Dr. Matthew 
Keuss 
PCDNA3.1(+)-DCUN1D5- pcDNA3.1(+) mammalian 
expression plasmid 
containing un-tagged 
Made by Dr. Matthew 
Keuss 
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functional DCNU1D5 
gene 
sequence 
PCDNA3.1(+)-
DCUN1D5(D195A A219R 
D225A) 
pcDNA3.1(+) mammalian 
expression plasmid 
containing un-tagged 
functional DCNU1D5 
(DAD mutant) gene 
sequence 
Made by Dr. Matthew 
Keuss 
pcDNA5 FT/TO GFP Puro pcdna5-FRT/to-GFP with 
a puromycin cassette 
45825 
MRC-PPU Reagents, 
University of Dundee 
pcDNA5 FT/TO GFP Puro 
DCUN1D5 
DCUN1D5 gene cloned 
into pcdna5-FRT/to-GFP 
with a puromycin 
cassette 45825 
MRC-PPU Reagents, 
University of Dundee 
pcDNA5 FT/TO GFP Puro 
DCUN1D5 (D195A A219R 
D225A) 
DCUN1D5 gene (DAD 
mutant) cloned into 
FRT/TO GFP with 
puromycin cassette. 
45825 DAD Patch Mutant 
MRC-PPU Reagents, 
University of Dundee 
pCAG -CAS9-2A-GFP WT  A gift from Professor Neil 
Bulleid’s Laboratory – 
originally sourced from 
Dr. Adam West 
Table 2 List of Plasmids 
2.1.5 Antibodies 
2.1.5.1 Primary Antibodies 
Antibody dilutions described below are for western blotting unless otherwise 
stated. 
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Epitope Host 
Species 
Dilution (in TBS-T) Catalogue # Supplier 
Actin (Clone 
C4) 
Mouse 1:5000 in 5% Milk  MAB1501 Merck Millipore 
α-Tubulin Rabbit 1:1000 in 5% Milk 2125 Cell Signalling 
Technology 
Caspase 3 Mouse 1:5000 in 5% Milk  9662 Cell Signalling 
Technology 
Caspase 8 
(1C12) 
Mouse 1:5000 in 5% BSA  9746 Cell Signalling 
Technology 
Caspase 8 
p18 (d7) 
Mouse 2μg/ml of protein 
lysate?? 
sc-393776 Santa Cruz 
Biotechnology 
Cullin 3  Rabbit 1μg per 
immunoprecipitation 
NB100-
58788 
Novus 
Biologicals 
Cullin 3 
(Clone C3) 
Mouse 1:1000 in 5% Milk or 
1μg per 
immunoprecipitation 
611848 BD Bioscience 
Cullin 3 (N 
Terminal) 
Sheep 1:1000 in 5% Milk N/A UofDundee MRC 
PPU 
Cullin 4A Rabbit 1:1000 in 5% Milk 2699 Cell Signalling 
Technology 
DCNL5 Sheep 1:2000 in 5% Milk or 
1μg per 
immunoprecipitation 
N/A UofDundee MRC 
PPU 
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FADD Rabbit 1:1000 in 5% Milk ab124812 Abcam 
GAPDH Mouse 1:1000 in 5% Milk Ab110305 Abcam 
GFP Chicken 1:5000 in 3% BSA Ab13970 Abcam 
IκBα (N 
Terminal) 
Mouse 1:1000 in 5% Milk 4814 Cell Signalling 
Technology 
PARP1 Rabbit 1:1000 in 5% Milk 9532 Cell Signalling 
Technology 
TNFR1 
(C25C1) 
Rabbit 1:1000 in 5% Milk 3736 Cell Signalling 
Technology 
TRADD 
(Clone 37) 
Mouse 1:1000 in 5% Milk 610572 BD Bioscience 
Ubiquitin 
(Clone Ubi-
1) 
Mouse 1:1000 in 5% Milk MAB1510 Merck Millipore 
Table 3 List of Primary Antibodies 
2.1.5.2 Secondary Antibodies 
Antibody Catalogue # Supplier 
Anti-mouse IgG HRP 1705047 Bio-Rad Laboratories  
Anti-protein G HRP 1706425 Bio-Rad Laboratories  
Anti-rabbit IgG HRP 1705046 Bio-Rad Laboratories  
Anti-sheep IgG HRP A3415 Sigma-Aldrich 
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Table 4 List of Secondary Antibodies 
2.1.6 Standard Solutions 
(v/v) denotes volume per volume, (w/v) denotes weight per volume. 
All solutions were made up using distilled water unless specified otherwise. 
Denaturing Immunoprecipitation Lysis Buffer 
30mM Tris HCl pH 7.5 
150mM NaCl 
2mM CaCl2 
2mM MgCl2 
10mM Iodoacetamide 
1% SDS (w/v) 
1% Triton-X 100 (v/v) 
0.5% NP40 (v/v) 
Protease Inhibitor Cocktail (Roche) 
4x Laemmli Sample Buffer (LSB) 
250mM Tris pH 7.5 
8% SDS (w/v) 
10% Glycerol (w/v) 
0.5nM EDTA 
0.2% Bromophenol Blue (w/v) 
Ponceau S 
0.1 % Ponceau (w/v) 
5% acetic acid (v/v) 
TAE Buffer 
40 mM Tris Acetate 
1 mM EDTA 
TN Lysis Buffer 
20mM Tris HCl pH 7.5 
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150mM Na Cl 
1mM MgCl2 
0.5% Triton X-100 (v/v) 
1% NP40 (v/v) 
10mM Iodoacetamide 
10μM OPT 
Phospho-stop Inhibitor Tablet (Roche) 
Protease Inhibitor Cocktail (Roche) 
Transfer Buffer (Tris-Glycine) 
25mM Tris 
192mM Glycine 
20% Methanol (v/v) 
Tris Buffered Saline (TBS) 
20mM Tris pH 7.5 
150mM NaCl 
pH Adjusted to 7.6 prior to use 
Tris Buffered Saline with Tween 20 (TBS-T) 
TBS with 0.1% Tween 20 (v/v) 
2YT Medium 
1.6% (w/v) Tryptone 
1% (w/v) Yeast Extract 
0.5% (w/v) NaCl 
Autoclaved prior to use 
2.1.7 Computer Software 
GraphPad Prism (versions 5 and 7) were used to make all graphs as well as perform 
statistical analysis. Error bars were plotted using the standard error of the mean 
and 1 or 2-way ANOVA tests were used for statistical analysis. 
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2.2 Methods 
2.2.1 Cell Culture Methods 
2.2.1.1 Cell Growth Media 
Immortalised cancer cell lines were all grown in high glucose Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10%v/v foetal bovine serum (FBS) and 
1% v/v penicillin-streptomycin (P/S).  
2.2.1.2 Growth and Subculturing of Cancer Cells 
U2OS, H460, HeLa, 22rv1, DU-145, A375 and MCF7 cells were grown in T-75 flasks 
and kept in a sterile and humidified incubator at 5% CO2, 37°C. The cells were 
grown until they reached 80-90% confluency, at which point they were washed 
with pre-warmed phospho-buffered saline (PBS), detached using 3ml of trypsin-
EDTA while incubating in the aforementioned incubator for 4 minutes (for all cell 
lines except H460 and MCF-7, which required 6-8 minutes). DMEM was used to 
quench the trypsin activity and cells were either passaged at ratios of between 
1:10 and 1:3, per ATCC protocols, or plated for use in experiments. Media was not 
changed between passages except for A375 cells which were monitored and 
changed when required. 
2.2.1.3 Plating of Cells 
Following trypsinization of cells and inactivation of the trypsin, as described in 
2.2.1.2, cells were either counted by hand using a haemocytometer or counted 
using an automated cell counter (Countess II, ThermoFisher). Cells were plated at 
densities of approximately 65000 cells/ml to 800000 cells/ml, depending on 
treatment and when the cells were to be harvested. For seeding using 96-well 
plates, multichannel pipettes were used to transfer cells from a reservoir to the 
wells. Cells were always plated at least 24 hours prior to harvesting. In the case 
of the inducible rescue cell lines, 5ng/ml of doxycycline was added 24 hours prior 
to any drug treatments.  
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2.2.1.4 Resurrection and Cell Thawing 
Cryogenic vials of cells were thawed in a 37°C water bath for 1 minute before 
transferring the contents to 50ml Falcon tubes containing 10ml of pre-warmed 
culture media. Cells were spun at 500g for 5 minutes before removing the media, 
re-suspending the cell pellet in 15ml of cell culture media and transferring this to 
T75 flasks (or T25 flasks for DCNL1 WT and KO cell lines which struggled to grow 
at low densities). Thawed cells were typically passed within 48 hours, in the cases 
where cells were not confluent in that time, the media was changed to remove 
dead cell debris. 
2.2.1.5 Cryopreservation of Cells 
Following trypsinization of cells and inactivation of the trypsin, as described in 
2.2.1.2, the cells were pelleted at 1000RPM for 5 minutes in 15ml or 50ml Falcon 
tubes. Following aspiration of the media/trypsin solution, the cell pellet was re-
suspended in freeze media (DMEM with 5% DMSO v/v) and 1ml was aliquoted for 
each cryogenic vial (typically 3 vials per confluent T75 flask of cells). These vials 
were placed in a Mr Frosty™ freezing container (topped up with isopropyl alcohol) 
and stored at -80°C overnight or for up to a few weeks, before transferring the 
vials to liquid nitrogen storage. 
2.2.2 Molecular Biology Methods 
2.2.2.1 Genomic DNA Extraction 
Approximately 5x106 cells were grown in 10cm dishes and harvested for each cell 
that line required sequencing. A genomic DNA extraction kit (Promega) was used 
according to the manufacturer instructions (eluting at the final stage in a 100μl 
volume) and the concentration of each sample of genomic DNA was measured 
using a nanodrop. 
2.2.2.2 Polymerase Chain Reaction (PCR) and Agarose Gel Analysis 
PCR reactions were set up using the different genomic DNA samples as follows: 
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Volume (μl) Reagent 
10 10x Reaction Buffer 
1 dNTPs (25mM) 
2.5 Primers (10μM solution of forward and 
reverse) 
0.5 Q5 polymerase 
2 (volume required for 100ng) cDNA template  
34 Nuclease-free water 
Table 5 List of PCR Components 
PCR reactions were carried out in a thermocycler by performing 12 cycles 
touchdown PCR at 72°C followed by conventional PCR for 25 cycles at 62°C. 
DCNL5 Forward Sequence: 5’-CTGTCTCTGGGAACTGGGTG  
DCNL5 Reverse Sequence: 5’-GCAGGGCACGTAGACTCTTA 
The PCR products were analysed by 1% agarose gel electrophoresis; gels were cast 
using ethidium bromide and resolved for 40 minutes at 100V in a Mini-Sub Cell GT 
gel system (Bio-Rad). Agarose gel bands for the PCR products were excised and 
processed using a QIAquick extraction kit (QIAgen) according to the manufacturer 
instructions, using a final volume of 45μl for elution of the product. The DNA was 
then cleaned up using a QIAquick PCR purification kit (QIAgen) according to the 
manufacturer instructions. 
2.2.2.3 Restriction Digest and Ligation 
pcDNA3.1 vector as well as the cleaned-up PCR products were digested using 
BamHI and NotI enzymes (NEB) using approximately 1μg of vector and 500ng of 
insert in each reaction. Band intensities were calculated to allow for the accurate 
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measurement of vector:insert rations for the subsequent ligation reaction. We 
used a 3:1 vector to insert ratio and used T4 ligase (NEB) to catalyse the ligase 
reactions overnight. Ligated DNA was stored at -20°C when not in use. 
2.2.2.4 Transformation, Expression and Mini-Prep 
Competent cells (XL1-blue) were thawed on ice for approximately 15 minutes, 
after which 5μl of DNA was added to each 50μl tube of competent cells and 
allowed to incubate on ice for a further 10 minutes. The cells were then heat-
shocked in a 42°C water bath for 45 seconds before incubating the cells on ice for 
another two minutes. SOC media (200μl) was then added to the tubes and these 
were transferred to a 37°C tube rack and shaken at 600RPM for 1 hour. Following 
this incubation, the mixture was poured onto agar plates which contained 
ampicillin for selection pressure, and spread using a sterile spreader, before 
incubating the plates (upside down) at 37°C overnight. 
4 single colonies from each plate were picked and used to inoculate separate vials 
of 2YT media (5ml volume) containing 0.1mg/ml ampicillin. These universal tubes 
were then incubated overnight at 37°C while shaking to allow for growth of 
bacteria expressing the vector. DNA was purified from these colonies using a kit 
(Promega Wizard® Plus SV miniprep) per the manufacturer’s instruction, eluting 
the DNA with 50 rather than 100μl of nuclease free water. and the concentration 
was measured using a Nanodrop spectrophotometer. The eluted DNA was sent for 
sequencing at the MRC PPU Sequencing centre in Dundee, the rest was stored at -
20°C for future use. 
2.2.3 Plasmid Transfection of Cells 
U2OS, H460 and HeLa cells were plated in 6 well plates at a density of 75000 
cells/ml 24 hours prior to transfection. The normal cell culture media was 
aspirated from each well and replaced with 1.5ml of Opti-MEM prior to addition 
of any reagents. 100μl of Opti-MEM was combined with 2μl of Lipofectamine 2000 
in an Eppendorf tube, while 100μl of Opti-MEM was combined with 1μg of DNA in 
a separate tube. If multiple samples were needed these were scaled appropriately 
These separate Eppendorf tubes were allowed to incubate for 5 minutes at room 
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temperature before they were combined, mixed gently and allowed incubated for 
a further 15 minutes. The Lipofectamine/DNA solution was added to the relevant 
well of cells and mixed up and down. A control reaction was always performed 
using Lipofectamine with 1μg of empty DNA vector per experiment. The 
transfections were performed for 4-5 hours before the media in each well was 
changed back to normal cell culture media. 48 hours later, cells were treated and 
harvested for analysis. 
2.2.4 RNA Interference 
For siRNA-mediated knockdowns, SMARTpool siRNA oligos were used against 
human DCNL5 and cullin 3 or a non-targeting control (Dharmacon). The 
transfections were performed using RNAiMAX (ThermoFisher) similar to the 
method described in 2.2.3, except cells were plated at 100000 cell/ml the day 
before transfection, 3μL of siRNA (at a stock concentration of 10μM) was used per 
reaction and the cells were allowed to grow for 72 hours rather than 48 hours after 
transfection, before treating cells and harvesting for analysis. 
2.2.5 CRISPR/Cas9 
3μg of guide RNA vector for exon 1 of DCNL5 which was generated previously by 
mutagenesis PCR of pEsgRNA (refs Munoz et al, 2014 and Keuss et al, 2016) with 
the target sequence 5’-GCAGCAGTAGCGGAAGACGGAGG-3’ (plus strand) was pre-
incubated with 3μg of GFP-tagged Cas9 (pCAG -CAS9-2A-GFP WT) in 500μl of Opti-
MEM. This solution was then combined with 500μL of Opti-MEM containing 10μl of 
lipofectamine 2000 and incubated together for 15 minutes. This solution was then 
added to a 10cm dish of 70% confluent H460 cells in 5ml of Opti-MEM for 5 hours 
at 37°C. Following this, the media was changed to normal culture media and the 
dish was cultured at 37°C for a further 48 hours. The cells were then trypsinized, 
with emphasis on breaking up any clumps of cells, counted, and then plated at 
densities of 10 cells/ml and 100 cells/ml in 96 well plates. Single colonies were 
selected for after 2 weeks, transferred to and grown in T-25 flasks before 
analysing DCNL5 expression by western blot from cell lysates, ensuring the 
selected cell colonies continued to grow in flasks. We found that we only had 
partial KO of DCNL5 in our selected clones, so we repeated the process with one 
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of the potential KO clones, re-plating in 96 well plates and re-selecting for single 
colonies and validating them by western blot. We further validated the success of 
the process by sequencing the genomic DNA from the successful clones.  
2.2.6 DNA Damage Induction 
Stocks of the DNA damage-inducing agents were made up as follows: 
Drug Stock 
Concentration 
Working 
Concentrations 
Treatment 
Time 
Bleomycin 
Sulphate 
10mg/ml 50-1000μg/ml 24-72 
Hours 
Doxorubicin 
Hydrochloride 
10mg/ml 1-10μg/ml 24 Hours 
Etoposide 100mM 0.25-1mM 24 Hours 
Neocarzinostatin 0.5mg/ml 0.6-2.5μg/ml 24 Hours 
Table 6 List of DNA Damage-Inducing Agents 
The drugs in Table 6 were used for the indicated times and diluted to working 
concentrations using DMEM culture media. The diluted drugs were added directly 
to wells containing attached cells plated at the required density. 
2.2.7 Neddylation and Proteasome Inhibition 
The NEDD8 activating enzyme inhibitor MLN4924 and the proteasome inhibitor MG-
132 were used at concentrations of 3μM and 25μM respectively, for 1-hour pre-
treatments prior to addition of apoptosis-inducing drugs to plated cells. 
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2.2.8 Apoptosis Induction 
2.2.8.1 Cycloheximide and TNFα  
Cycloheximide stock was prepared using PBS at a concentration of 4mg/ml, while 
TNFα was made up to a 100μg/ml stock using distilled water. Subsequent dilutions 
into working concentrations were performed using DMEM culture media. 
Cycloheximide was used at concentrations of either 5 or 10μg/ml and was added 
to cells 1 hour before TNFα was added, in the cases of combination treatment. 
TNFα was used at concentrations ranging from 12.5-200mg/ml and treatment 
times ranged from half an hour up to 24 hours depending on the assay. Cells were 
harvested at the end of the desired treatment time. 
2.2.8.2 TRAIL 
Recombinant human TRAIL was prepared by re-suspending the lyophilised protein 
in 0.5ml of distilled water to a final concentration of 0.5mg/ml. Working dilutions 
were performed using DMEM culture media. The drug was added to cells for 
treatment times of 0.5 to 24 hours depending on the assay. 
2.2.8.3 Staurosporine 
Lyophilised staurosporine was dissolved in DMSO to make a 2mM stock solution, 
which was then diluted to working concentrations using DMEM. The drug was 
added to cells at concentrations of 100-200nM. 
2.2.9 Lysate Preparation 
2.2.9.1 Preparation of Cell Lysates for Western Blotting 
Cells were grown in 10cm dishes, 6cm dishes, 6-well plates or 12-well plates 
depending on the application. Following treatments, cells were harvested in 
either TN lysis buffer or directly in 2x sample buffer. In the case of TN lysis buffer, 
cells were initially washed with ice cold PBS before adding the desired volume of 
TN buffer and incubating on ice or at 4°C for 15 minutes, rotating the dish half 
way through to ensure complete lysis of cells. The cells were subsequently scraped 
using cell lifters and transferred to 2ml Eppendorf tubes and incubated on ice for 
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a further 10 minutes. The lysates were then clarified by centrifugation at 13000g 
and supernatants were transferred to fresh 1.5ml Eppendorf tubes and then were 
stored at -80°C or the protein concentration was measured by BCA. For cells 
harvested in sample buffer, they were scraped either using cell lifters or using a 
pipette tip directly, transferred to Eppendorf tubes, 10% v/v mercapto-ethanol 
was added and the samples were boiled and shaken at 1000rpm before storing at 
-20°C for use in SDS-PAGE gels at a later time. 
2.2.9.2 Preparation of Cell Lysates for Immunoprecipitation 
Cells that had been cultured and treated in 10cm dishes, were removed from 
incubators and washed twice with ice cold PBS before adding TN lysis buffer 
(typically 200μl) and incubating on ice or at 4°C for 15 minutes, rotating the plates 
half way through. Cells were then scraped using cell lifters and transferred to 2ml 
Eppendorf tubes (typically 2 or 3 10cm plates were combined for each cell type 
and each reaction) and lysed on ice for a further 10 minutes. The cell lysates were 
then clarified by centrifugation at 13000g and supernatants were transferred to 
1.5 ml Eppendorf tubes and stored at -80°C or used immediately for protein 
concentration determination and immunoprecipitation. 
2.2.9.3 Preparation of Cell Lysates for Immunoprecipitation Under Denaturing 
Conditions 
Cells that had been cultured and treated in 10cm dishes, were removed from 
incubators and washed once with ice cold PBS before adding 300μl of PBS to the 
dishes. The cells were scraped using cell lifters and transferred to 2ml Eppendorf 
tubes (as before, multiple 10cm dishes were used per treatment) before pelleting 
the cells at 600g for 15 minutes. The supernatant was removed and discarded, and 
the pellet was re-suspended in denaturing IP lysis buffer containing 1% SDS. The 
cell suspension was then boiled at 95°C while under constant agitation of 750RPM. 
The supernatant was then transferred to fresh tubes and either stored at -80°C or 
used immediately for protein concentration determination and 
immunoprecipitation. 
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2.2.10 BCA Protein Assay 
Cell lysates were diluted 1:5 in distilled H2O and 25μl of each sample was added 
to a well of a clear 96-well plate. Samples were analysed in duplicate. Standards 
of bovine serum albumin (BSA) at concentrations of 2, 1, 0.5, 0.25 and 0 mg/ml 
were made up and diluted using distilled H2O. 25μl of each standard was added to 
a well of the same 96-well plate, also in duplicate. Reagent A and reagent B 
(ThermoFisher) were mixed at a ratio of 1:50 in a sufficient volume to add 200μl 
to each well of protein sample and protein standards. The 96-well plate was then 
incubated at 37°C for 30 minutes before measuring the absorbance at 570nm (due 
to technical constraints of the machine) using a pre-defined BCA protocol (which 
included a 10 second shake prior to reading the absorbance). The dilution of the 
samples was automatically taken into account and the protein concentration was 
calculated by the Optima software. 
2.2.11 Immunoprecipitation 
2.2.11.1 Non-denaturing Immunoprecipitation 
Protein lysates prepared were prepared as described in 2.2.9.2. Where possible, 
2mg of protein lysate was used for each immunoprecipitation reaction. A pre-
determined amount of lysate was transferred to separate tubes for use as whole-
cell lysate and combined with 4x sample buffer (containing 10% β-mercapto-
ethanol) and subsequently boiled at 95°C and spun down and stored at -20°C. 
Antibody was added to the lysate in 2ml tubes (the amounts are summarised in 
Table 3 List of Primary Antibodies which were then rotated overnight at 4°C. The 
following day, magnetic beads (protein A or G depending on which antibody had 
been used) were prepared by washing twice with PBS and twice with lysis buffer 
(absent of inhibitors) with the aid of a magnetic rack. 50μl of beads were required 
to be added per immunoprecipitation reaction therefore a sufficient volume of 
bead-slurry was washed and prepared, ultimately resuspending in the same 
volume as initially removed from the vial of beads. Once the re-suspended beads 
were added to the IP reactions, the tubes were returned to 4°C and rotated for a 
further hour. In this time the antibody should have bound to the magnetic beads, 
however washes are required to remove any non-specific binding. The beads were 
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washed once with distilled water, 3 times with lysis buffer (absent of inhibitors) 
and 3 times with PBS. The beads were spun briefly to ensure all the beads were 
at the bottom of the tubes, before removing the last of any PBS present. The 
beads were then eluted by re-suspending them in 2x sample buffer (containing 
10% β-mercapto-ethanol) gently, ensuring no air bubbles were introduced. The 
bead-sample buffer suspension was left at room temperature for 20 minutes for 
the protein complex to be eluted, before boiling the samples at 95°C and spinning 
down, ready for loading onto SDS-PAGE gels or to store at -80°C. 
2.2.11.2 Denaturing Immunoprecipitation 
Protein lysates prepared were prepared as described in 2.2.9.3. Generally, 1mg 
of protein lysate was used for the immunoprecipitation. Prior to adding antibody, 
a pre-determined amount of lysate was transferred to separate tubes for use as 
whole-cell lysate and combined with 4x sample buffer (containing 10% β-
mercapto-ethanol) and subsequently boiled at 95°C and spun down. Unlike with a 
normal immunoprecipitation, due to the relatively high concentration of SDS 
present in the protein lysate (1% w/v), a 10-fold dilution was required to be 
performed in order to enable the antibody to bind to the protein in the lysate. 
Each sample of lysate was diluted using 10-times more denaturing IP lysis buffer 
(absent of inhibitors) in 10ml Falcon tubes. Antibody was then added to the diluted 
lysates (per amounts shown in Table 3) and the tubes were then rotated at 4°C 
overnight. The following day, magnetic beads (protein A or G depending on which 
antibody had been used) were prepared by washing twice with PBS and twice with 
lysis buffer (absent of inhibitors) with the aid of a magnetic rack. 50μl of beads 
were required to be added per immunoprecipitation reaction therefore a 
sufficient volume of bead-slurry was washed and prepared, ultimately 
resuspending in the same volume as initially removed from the vial of beads. Once 
the re-suspended beads were added to the IP reactions, the tubes were returned 
to 4°C and rotated for a further hour. Due to the large volume of protein lysate 
(diluted in buffer), the supernatant-bead solution was removed and transferred 
to 2ml tubes in rounds until all the beads had bound to the side of the tube. The 
beads were then washed once with distilled water, 3 times with lysis buffer 
(absent of inhibitors) and 3 times with PBS. The beads were spun briefly to ensure 
all the beads were at the bottom of the tubes, before removing the last of any 
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PBS present. The beads were then eluted by re-suspending them in 2x sample 
buffer (containing 10% β-mercapto-ethanol) gently, ensuring no air bubbles were 
introduced. The bead-sample buffer suspension was left at room temperature for 
20 minutes for the protein complex to be eluted, before boiling the samples at 
95°C and spinning down, ready for loading onto SDS-PAGE gels or to store at -
80°C. 
2.2.12 HALO-TUBE Pulldowns 
Similarly to normal immunoprecipitation reactions, protein lysates were prepared 
as described in 2.2.9.2. Typically, 0.75-1.5 mg of protein lysate was used per 
reaction, and as with immunoprecipitation reactions, a sample of lysate was 
removed initially for use as whole-cell lysate to run on SDS-PAGE gels. The 
magnetic HALO-TUBE beads, as well as control HALO beads were washed and 
prepared in the same fashion as for immunoprecipitation reactions detailed in 
2.2.11.1. The beads were then added to the protein lysates and rotated at 4°C for 
2 hours. The protein-bound beads were then washed and eluted the same way as 
described in 2.2.11.1. 
2.2.13 SDS-Polyacrylamide Gel Electrophoresis Analysis 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using 1mm thick gels cast by hand using Bio-Rad Mini-Protean III gel 
units. 1M Bis-Tris solution was made by dissolving 20.9g of Bis-Tris in 100ml of 
distilled water and setting the pH to between 6.5-6.7. Ammonium persulfate was 
dissolved in distilled water to make a 10%w/v solution. Stacking and resolving gels 
were made up as 100ml solutions and stored at 4°C: 
 14% 10% 8% Stacking Gel 
1M Bis-Tris 
pH 6.5-6.7 
30ml 30ml 30ml 30ml 
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40% 37.5:1 
Acrylamide 
(5%) 
31.5ml 22.5ml 18ml 11.2ml 
Distilled 
Water 
28.5ml 37.5ml 42ml 48.8ml 
Table 7 Components of SDS-PAGE Gels 
For 2 gels, 10ml of the required resolving gel was mixed with 60μl APS (of a 10% 
w/v stock in distilled water) followed by 0.25% (v/v) tetramethylethylenediamine 
(TEMED). The solution was vortexed before pouring approximately 4.5 ml of the 
solution into the casting plates and covering with 70% ethanol to allow for the 
polymerisation to occur. Once the gel had set, the ethanol was poured off and the 
gels were washed with distilled water, ensuring all water was removed using 
blocking paper before processing to the next step. 5ml of stacking gel solution was 
mixed with 30μl of APS (10% w/v stock) followed by 0.2% (v/v) of TEMED, vortexed, 
then poured on top of the resolving gel to the top of the short plate. The combs 
were then immediately inserted between the plates. Once the stacking gel had 
set, the gels were either loaded into Bio-Rad gel tanks for electrophoresis or 
stored at 4°C between moist blue roll and wrapped in clingfilm for up to a week. 
Pre-cast 4-12% gradient gels were also used (NuPAGE®), and preparation for 
loading samples simply involved washing the gels in water, removing the comb, 
filling the wells with running buffer and inserting the gels into XCell SureLock Mini-
Cell apparatus (ThermoFisher). The non-gradient gels run in the Bio-Rad apparatus 
were ran at a constant voltage of 120V, either until the dye front at reached the 
bottom of the gel and achieved good separation, or until the dye front had run off 
the gel for proteins that required better separation. The gradient gels were run 
at a constant voltage of 200V for 35 minutes. 
2.2.14 Western Blotting 
2.2.14.1 Transfer of Proteins onto Membranes 
Following SDS-PAGE, described in the previous section, proteins required the 
transfer to a membrane to allow for the detection of specific proteins using 
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antibodies. Assembly of the transfer ‘sandwich’ involved the use of a cassette, 2 
sponges, 3 layers of filter paper for each side of the gel and a membrane. 2 types 
of membrane were used throughout this project, nitrocellulose and PVDF, and 
both were of pore size 0.45μm. PVDF requires activation, so the membrane was 
submerged in methanol for 30 seconds prior to its use. 6.5cm x 9cm rectangles of 
membrane were used in combination with 7cm x 9cm rectangle of Whatman filter 
paper. The filter paper and sponges used in the transfer process were pre-wetted 
in transfer buffer and stored at 4°C prior to the transfer process. Transfer buffer 
was made fresh and chilled on ice prior to use.  
The gel was removed from its assembly and laid out on top of the pre-wetted filter 
papers which themselves were on top of one of the sponges. Next, the membrane 
(activated, in the case of PVDF) was laid on top of the gel and bubbles were 
removed using a roller. Finally, 3 more layers of filter paper were added on top, 
as well as the second sponge, and the cassette was closed and inserted into a Bio-
Rad transfer tank. Transfers were run on ice using pre-chilled transfer buffer, and 
typical transfer times were 60-100 minutes at 100V. For gradient gels, these were 
always run at 100V for 100 minutes. For nitrocellulose membranes, efficiency of 
the transfer as well as the loading was verified by submerging the membrane in 
ponceau solution for 1 minute and de-staining with water to remove non-specific 
staining. 
2.2.14.2 Blocking of Membranes and Incubation with Primary Antibodies 
Following the transfer process and optional ponceau staining, membranes were 
washing in TBST twice for 10 minutes while rocking gently. To reduce non-specific 
binding, membranes were then incubated in 5% milk (w/v) TBST for 1 hour at room 
temperature while shaking gently. Following the blocking step, appropriate 
dilutions of primary antibody were made up in a falcon tube using either 5% milk 
TBST or 5% BSA TBST, as detailed in Table 3 . The membrane was cut into portions 
using the molecular weight marker as a guide in cases where the same membrane 
was probed for different proteins. Membranes were incubated at 4°C overnight in 
the falcon tubes while rotating on a roller. 
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2.2.14.3 Incubation of Membranes with Secondary Antibodies and 
Immunodetection of Proteins 
Following incubation with primary antibody overnight, membranes were washed 
twice for 10 minutes in TBST while shaking gently. Secondary anybody was 
prepared in the same way as the primary, according to the dilutions summarised 
in Table 4. Membranes were incubated with secondary antibodies in 5% milk TBST 
for 1 hour at room temperature while rotating, after which the membranes were 
washed 3 times in TBST for 10 minutes. HRP-conjugated secondary antibodies 
were imaged using a chemiluminescent reaction induced by exposing the 
membranes to an equal parts mixture of Luminol Reagent and Peroxide Solution 
(Millipore). This was achieved by adding approximately 1ml of the combined 
solutions to the membrane (which can be dried using paper towel to increase 
absorption of the solution). This solution was allowed to absorb into the membrane 
for anywhere from a few seconds to up to 5 minutes for weaker signals. Membranes 
were then transferred to transparent sheets and held in place inside an imaging 
cassette using tape. The membranes were developed on X-ray film using an X-
OMAT imager. Film exposure time varied depending on the strength of the signal 
anticipated. All western blotting experiments were performed 3 times using 
biologically independent samples (n = 3) unless otherwise stated in figure legends. 
Representative western blots are shown in all cases. 
2.2.15 Luciferase Assay 
2x Lysis and ATP Assay Buffer was made up as follows:  
50mM Tris/Phosphate pH 7.8  
16mM MgCl2 
2mM DTT 
2% v/vTriton-X-100 
30% v/v Glycerol 
1% w/v BSA 
BSA was dissolved fully before proceeding to the next reagents. 
0.25mM D-Luciferin  
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8μM Sodium Pyrophosphate Tetra-basic Decahydrate 
500ng/ml Luciferase. 
This viability assay was always performed using a 96-well format (using black, 
clear bottom plates), and cells were grown in media containing phenol red. Phenol 
red-free media can be used when plating cells for treatments and measurement 
of viability which should increase the signal detected, however this was not an 
issue in this project. Cells were plated at a volume of 100μl per well at the 
required density for the required duration of time. Treatments were added 
directly to the wells, ensuring the volume of drug added to each well was 
previously removed in order to ensure the volume remained a constant 100μl. 
Following drug treatments, the plates were removed from the humidified 
incubators and 100μl of 2x ATP lysis buffer was added to each well using a multi-
channel pipette, before shaking the plate at 900RPM for 10 minutes at room 
temperature to ensure full lysis of the cells. The plate was imaged using FLUOstar 
microplate reader set to measure the absorbance from above the wells. Cell 
viability was measured in relation to vehicle control treatments in duplicate or 
triplicate. 
2.2.16 Immunofluorescence Microscopy 
U2OS cells were plated on coverslips which had been coated with 10μg/ml Poly-
d-lysine and after 24 hours, coverslips were treated with TRAIL for different 
amounts of time at 37°C. Cells were then washed once in ice-cold PBS then fixed 
with ice-cold methanol for 1 minute. The coverslips were then washed 3 times 
with PBS and then blocked for 1 hour with 3% BSA in PBS at room temperature. 
The coverslips were then washed 3 times in PBS before incubating the coverslips 
with GFP antibody (1:5000 dilution) overnight in 3% BSA. The coverslips were then 
washed 3 times in PBS, before incubating them with anti-chicken antibody (1:1000 
in 3% BSA) for 30 minutes at room temperature. The coverslips were then washed 
3 times with PBS before counter-staining with Red Dot (1:200 in H2O) for 10 
minutes at room temperature and washing twice with PBS. The coverslips were 
then mounted onto slides with Shandon™ Immu-Mount™ (Thermo Scientific) and 
imaged on a Zeiss LSM 710 confocal microscope. Images were processed using 
ImageJ. 
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2.2.17 FACS/Fluorescence Viability Analysis 
WT and KO DCNL5 cells were seeded on 96 well plates, and 24 hours later 
recombinant TRAIL was added to the relevant wells at the relevant 
concentrations. A 3-hour staurosporine treatment was started to coincide with the 
end of the 24-hour TRAIL treatment, at which point the plates were processed for 
annexin V and propidium iodide staining per manufacturer instructions (MabTag 
AnxF100PI). Briefly, this involved removing the culture medium from the plates, 
resuspending the cells in 90μl of annexin-V buffer and then adding 5μl of annexin-
V conjugate and 5μl of propidium iodide solution. The plates were then incubated 
in the dark for 20 minutes, before imaging the plates with an IncuCyte® S3 live 
cell analysis system (Sartorius). The proprietary software was then used to 
generate images of representative wells showing the fluorescence of WT and KO 
cells in response to the apoptosis-inducing agents. 
2.2.18 Statistical Analysis 
Results presented are expressed as mean + SEM. Statistically significant 
differences were calculated using one or two-way ANOVA and a p value of <0.05 
was considered significant. Prism ® software version 7 was used to perform the 
statistical analysis as well as generate the graphs presented in this study. N (n) 
numbers are indicated in the figure legends. 
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3 The Role of DCNL5 in the Apoptosis Response 
3.1 Introduction 
3.1.1 DCNL5 Involvement in the DNA Damage Response 
Previous data from Keuss and colleagues (Keuss et al., 2016), highlighted in Figure 
3-1 below, demonstrated a novel role for DCNL proteins in the DNA damage 
response. Figure 3-1A shows that the DCNL5 KO cells are significantly more 
sensitive to the gamma irradiation and that expression of WT or DAD-mutant 
DCNL5 in inducible cell lines rescues that sensitivity such that they respond the 
same, if not slightly less than WT cells to the treatment. Additionally, DCNL5 was 
shown to be recruited to sites of DNA damage following UV irradiation in what is 
known as a laser stripe experiment. Figure 3-1B shows bands of GFP-tagged DCNL5 
appearing within 5 minutes of UV treatment and importantly both WT DCNL5 as 
well as the cullin non-binder DAD-mutant DCNL5 are recruited to the sites of UV 
irradiation, which causes dsDNA breaks and damage, further confirming the role 
for DCNL5 in the DNA damage response, independently of its ability to bind its 
canonical binding partner: cullin proteins. The significance of this finding was that 
perhaps there exist other targets for the DCNL protein family. DNA damage-
induction has been shown to trigger the programmed cell death response known 
as apoptosis, and in studying DNA damage we will also analyse whether apoptosis 
is occurring and if DCNL5 plays a role here. 
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Figure 3-1 DCNL5 involvement in DNA damage is independent of cullin binding.  
(A) This graph (Kurz, unpublished) shows the survival rates in different cell lines following gamma 
irradiation.  The DCNL5 KO cells are highly sensitive to the irradiation, however the survival rate is 
recovered with the WT and DAD patch DCNL5 cells.  (B) This fluorescence microscopy image shows 
that both WT and DAD patch mutated DCNL5 are recruited to DNA damage sites following micro-
irradiation with a laser (Keuss et al., 2016). 
The finding that DCNL5 involvement in the DNA damage response may occur 
independently of its interaction with cullin proteins is novel, however it is 
important to remember that cullin proteins are known to play roles in the DNA 
damage response. Cullin proteins interact with RING proteins to form the cores of 
cullin-RING-ligase (CRL) complexes which are the largest family of ubiquitin E3 
ligases. CRLs are responsible for 20% of the global ubiquitination of intracellular 
proteins via the ubiquitin proteasome system (UPS) (Zhao and Sun, 2013) and cullin 
proteins themselves are often found to be overexpressed in tumours. Cullin 4A has 
been implicated in the DNA damage response and is found to show higher 
expression in cancer cells.  
Cullin 4A interacts with the adaptor protein DNA domain binding protein DDB1 as 
well as the RING protein RBX1 to mediate the ubiquitination and degradation of 
numerous DNA-damage responsive proteins as well as proteins that mediate DNA 
methylation (Zhao et al., 2010). Cullin 4A is also found to be overexpressed in 
various cancers including liver cancer (Chen et al., 2018) and breast cancer (Chen 
et al., 1998), and therefore represents an important therapeutic target. Cullin 4A 
knockdown has been shown to increase DNA damage repair following induction of 
damage which results in reduction in cancerous mutations (Liu et al., 2009). It can 
therefore be inferred that high levels of cullin 4A may be a hallmark of some 
cancerous cells. In the context of DNA damage induction and DNA repair cullin 4A 
A B 
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represents a key protein to focus on and in the present study cullin 4 levels may 
correlate with apoptosis induction. Tumour cells are known to be resistant to cell 
death via pathways including apoptosis and thus studying and analysing cullin 
proteins in the context of DNA damage and apoptosis is an important consideration 
in understanding cancer signalling pathways. Some cullin proteins can be targets 
of caspases and degraded during the apoptosis response, which will be an 
important marker in the present work. 
3.1.2 Aims: 
Initially we wanted to further elucidate the role of DCNL5 in the DNA damage 
response by using chemical inducers of damage. In doing so we discovered that 
DCNL5 KO cells showed a defect in the apoptosis response and we then aimed to 
establish and characterise the role of DCNL5 in this pathway. 
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3.2 Results 
3.2.1 DCNL5 Appears to have no Effect on Sensitivity to dsDNA 
Damage-Inducing Agents  
In order to investigate the finding by Keuss and colleagues that DCNL5 was 
required in the DNA damage response following radiation  treatment (Keuss et al., 
2016), we initially wanted to induce double-stranded DNA breaks using chemical 
agents. From the outset we anticipated that we may not be able to achieve the 
same results using chemical inducers of DNA damage given the different treatment 
durations and mechanisms underlying DNA damage induction. DNA damage 
inducting agents can induce both single stranded and double-stranded DNA breaks, 
the latter of which can lead to deleterious effects on a cells genetic make-up, 
resulting in a global DNA damage response which is complex and multifaceted and 
leads to DNA repair mechanisms followed eventually by apoptosis if repair is 
unsuccessful (Roos and Kaina, 2006). 
In order to measure the effect of the DNA-damage inducing drugs, we opted to 
use an ATP-based cell viability assay which can be measured using a 
spectrophotometer (see Figure 3-2). 24 hour treatments with 3 different drugs, 
doxorubicin, etoposide and neocarzinostatin, were performed in 96-well plates 
using U2OS cell lines either stably expressing GFP (with WT DCNL5, referred to 
herein as ‘WT’) or lacking DCNL5 expression (CRISPR-Cas9 knock out cells referred 
to as ‘KO’). As highlighted in Figure 3-3, KO cells show no increase in sensitivity 
to any of the drugs, in fact in the case of etoposide the KO cells appear slightly 
less sensitive to the treatment. This suggests that at least over a 24-hour period, 
DCNL5 expression has no major effect on cell viability following treatment with 
these DNA-damage inducing drugs. This contrasts with the results from Keuss and 
colleagues who showed that DCNL5 was required in the DNA damage response 
using the same U2OS cell lines. In our data, we did not include a positive control 
to indicate DNA damage induction, so we are unable to confirm whether DNA 
damage was successfully induced, however the loss of viability does appear to 
indicate that cell death is occurring which is typically a direct consequence of 
damage to the DNA backbone. 
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Figure 3-2 Luciferase ATP Viability Assay.  
This simple diagram summarises the key principle behind the viability assay employed in this 
chapter. Viable cells produce ATP, and this can react with luciferin present in the lysis buffer to 
produce oxy-luciferin, AMP, inorganic phosphate, carbon dioxide and most importantly, light. The 
reaction in catalysed by the luciferase enzyme which originates from fireflies (Lampyridae family) 
which is also present in the lysis buffer. The amount of light emitted correlates with the number of 
cells that are alive in each well of a 96-well plate, and this can be quantified using a 
spectrophotometer. 
 
A 
B C 
’ 
’ 
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Figure 3-3 WT and DCNL5 KO Cells are Similarly Sensitive to dsDNA Damage-Inducing 
Agents.  
ATP-based luciferase viability assays performed using doxorubicin (A), etoposide (B) and 
neocarzinostatin (C) for 24 hours showed no major difference in response of WT or KO DCNL5 cells 
to the treatments. DCNL5 KO cells appear to be slightly less sensitive to etoposide treatment, more-
so at the highest concentration tested. Data shown represent the mean + SEM from 3 independent 
experiments.   
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3.2.2 DCNL5 KO Cells are Resistant to Cell Death in Response to 
Bleomycin Sulphate Treatment 
Using the same luciferase assay mentioned in the previous section, we subjected 
U2OS cells to treatment with bleomycin sulphate which is a known inducer of 
dsDNA breaks (Nagai et al., 1969; Stubbe and Kozarich, 1987; Claussen and Long, 
1999) with a mechanism that is still not fully understood.  Treatment for 72 hours 
with bleomycin, as shown in Figure 3-4A, was able to induce a clear response in 
cells through the significant detectable loss of cell viability. Unexpectedly, only 
the WT cells responded to the drug, resulting in less than 20% of cells remaining 
viable at the highest concentration of the drug (800μg/ml) while the KO cells were 
almost entirely resistant at over 80% viability at the same concentration. The 
response of the WT cells to bleomycin was dose-dependent, increasing in a linear 
fashion with the increase in drug concentration. At all drug concentrations the 
difference between WT and KO cells was statistically significant (p<0.001). 
As well as the WT and KO DCNL5 cells, we also used inducible Flp-In™ DCNL5 KO 
cells which can express either GFP-tagged WT DCNL5 (referred to moving forward 
as WT-rescue or ‘WT-R’ cells) or a GFP-tagged version of the cullin non-binding 
mutant DAD-DCNL5 (referred to as DAD-rescue or ‘DAD-R’ cells) following 
induction with doxycycline. These cells allow for the re-introduction of DCNL5 
expression in a controlled and simple to use manner without the need for 
transfection. We subjected WT, KO, WT-rescue and DAD-rescue cells to 72 hour 
bleomycin treatment for the same viability assay and the results are shown in 
Figure 3-4B. Two concentrations of bleomycin sulphate were used, 1 and 0.5 
mg/ml, and in both cases the response of each cell line was similar. As before, 
WT cells were highly sensitive (<25% viable) to the treatment while the KO cells 
were significantly (p<0.001) more resistant (~75% viable). The WT-rescue cells 
were almost as sensitive as the WT cells (the difference was statistically 
insignificant) while the DAD-rescue cells showed the same resistance as the KO 
cells and this resistance was statistically significant when compared to the WT 
cells (p<0,001). Overall, this data provides compelling evidence that DCNL5 plays 
a role in mediating cell death. This data suggests a role for DCNL5 that involves 
its DAD-patch which is in contrast to the results from Keuss and colleagues, where 
they described a DAD-independent role for DCNL5 in the DNA damage response 
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(Keuss et al., 2016) which is likely a different mechanism to what we see here.  
The mechanism of cell death is unclear at this point, but it may include apoptosis. 
It is also possible that the KO cells fail to metabolise bleomycin which may explain 
the lack of response. What is evident from this data is that the role of DCNL5 
requires its DAD-patch and thus cullin-binding properties. 
 
Figure 3-4 Bleomycin sulphate was able to induce cell death in WT but not DCNL5 KO cells, 
in a cullin-dependent manner.  
(A) ATP-based viability assays showed that WT cells were sensitive to the bleomycin treatment 
compared to vehicle treatment, in a dose-dependent manner. KO Cells, in contrast, were relatively 
unaffected even at the highest concentrations. To further investigate this response, WT and DAD 
mutant rescue cell lines (induced with doxycycline) were treated with bleomycin alongside the WT 
and KO cell lines. (B) This viability data shows that the WT Rescue, but not the DAD-mutant rescue 
cells, were sensitive to the treatment. Data shown represent the mean + SEM from 3 independent 
experiments, analysed by 2-way ANOVA comparing WT to KO, WTR or DADR cells  for indicated 
treatments and statistical significance of p<0.001 was achieved. 
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3.2.3 Bleomycin Treatment Causes a Reduction in Cullin 4 Protein 
levels and Induces Apoptosis 
Cullin proteins have many roles within the cell but they are often known for their 
functions in controlling and regulating progression through the cell cycle as well 
as their roles in the DNA damage response. Given the duration of the bleomycin 
sulphate treatment described previously, we suspected initially that there may be 
some dysregulation of the cell cycle and therefore wanted to establish whether 
the neddylation state of the cullin proteins were affected in the KO cells or by the 
treatment. We also wanted to focus in particular on cullin 4, given its well-known 
role in the DNA damage response, which is likely to be involved at least to a certain 
extent in this situation. Given that DCNL proteins regulate cullins by neddylation, 
we wanted to determine whether the neddylation status of this family proteins 
was affected in the KO cells, which may in turn influence cell cycle progression.  
We found that the neddylation of the cullin proteins 3, 4 and 5 were largely 
unaffected in the WT and KO cells, as shown in Figure 3-5A and as previously 
reported (Keuss et al., 2016). Bleomycin treatment had no effect on the protein 
levels of cullin 3 following treatment, however cullin 4A and 4B showed a 
reduction in protein amount in WT but not KO cells (see Figure 3-5A and B), 
indicating that DCNL5 is required for this loss of CUL4A. Interestingly, cullin 5 
levels appear to increase in response to the treatment but this finding was not 
further investigated. The data presented in Figure 3-5A lacks independent 
experimental repeats and a loading control so interpretation requires caution, 
furthermore cells were harvested directly in sample buffer for these experiments 
therefore protein concentration determination was not possible and therefore 
even loading of the SDS-PAGE was diffucult.  
Bleomycin has been shown to induce the apoptosis response (Vernole et al., 1998; 
Mungunsukh et al., 2010) so it was possible that the levels of cullin 4 varied 
between the cell lines due to differing induction of apoptosis. Apoptosis involves 
the cleavage of a variety of proteins within the cell by a family of proteases known 
as caspases. While cullin 4A has a well-characterised role in the DNA damage 
response, we also suspected that cullin 4A and 4B may be degraded via the 
apoptosis pathway, likely by one of more of the caspase proteins. 
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Figure 3-5 Cullin 4 Protein Levels are Reduced Following Bleomycin Treatment in WT but not 
DCNL5 KO Cells  
(A) Immunoblot showing 72 hour bleomycin treatment at a concentration of 0.5mg/ml lead to a 
reduction in cullin 4A and 4B levels in DCNL5 WT but not KO cells, while the other cullin protein 
levels were largely unchanged, however there is an indication that cullin 5 levels may increase with 
treatment. This experiment lacks an appropriate loading control as well as independent repeats 
therefore interpretation is difficult. (B) This immunoblot is representative of 2 independent 
experiments (referred to henceforward as n = 2),  and  shows that cullin 4A levels appear to be lower 
in WT cells than KO cells following 72-hour bleomycin treatment. KO cells appear to undergo almost 
no cullin 4A degradation in response to bleomycin. There appears to be slightly less protein in the 
WT treated cells based on the reduction in band size of the actin loading control. IB = immunoblot  
The possibility that cullin 4A and 4B were being degraded by the apoptosis 
pathway was investigated over two ways. First, we checked for any caspase 3 
cleavage sites (since this is one of the key executioner caspases) within the amino 
acid sequences using a predictive programme called ScreenCap3 (Fu et al., 2014). 
We found that both cullin 4A and cullin 4B contained multiple cleavage sites 
predicted with relatively high degrees of certainty (0.98 to 0.72) while for 
reference, cullin 3 contained no predicted caspase 3 cleavage sites. This data 
indicates that the reduction in cullin 4 levels may occur as a result of cleavage by 
caspase 3 (and possibly other caspases) due to the bleomycin treatment and is not 
A 
B 
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as a result of lack of DCNL5 expression. Lack of DCNL5 may prevent cullin 4 
cleavage by caspases and DCNL5 could therefore be important in caspase-
mediated cleavage or caspase cleavage directly which is a required step in caspase 
activity. In addition, lack of DCNL5 does not significantly affect the neddylation 
of cullins 3 or 5 in vivo which is consistent with existing data. 
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Figure 3-6 Cullin 4A and B Contain Predicted Caspase 3 Cleavage Sites.  
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ScreenCap3 software (ref Fu et al 2014) indicates multiple predicted cleavage sites within cullin4A 
and 4B amino acid sequences while none are present in cullin 3. This indicates that cullin 4 is 
degraded as a result of apoptosis. 
The data presented thus far indicates that bleomycin appears to initiate apoptosis  
as determined by loss of cell viability which we detected using the ATP assay, and 
by potential caspase cleavage in occurring WT but not KO cells (based on the 
predicted caspase cleavage sites for cullin 4). We wanted to confirm that other 
caspase substrates are cleaved in response to bleomycin treatment to interrogate 
the hypothesis that DCNL5 KO cells lack caspase activity. We therefore decided to 
track the levels of two proteins that are cleaved following the induction of the 
apoptosis pathway: caspase 3 and PARP1. Caspase 3 is known as an ‘executioner’ 
caspase and is the last in a series of caspase activation reactions and is a key 
mediator of the downstream effects of apoptosis. PARP1 is cleaved by caspases 
and has downstream apoptotic effects and is also used as a marker for apoptosis.  
In order to determine whether bleomycin induces apoptosis, we used only the WT 
cells which we have shown are responsive to treatment (in terms of loss of 
viability), to analyse caspase 3 and PARP1 cleavage by western blotting. Figure 
3-7 shows that following bleomycin treatment of WT cells, cullin 4A levels drop – 
this reduction is visible after 48 hours but after 72 hours the protein levels are 
almost entirely depleted. Interestingly, we can observe an increase in molecular 
weight of cullin 4A after 48 hours, possibly indicating an increase in neddylation 
following DNA damage induction. Pro-caspase 3 and full length PARP1 levels are 
entirely gone following 72-hour bleomycin treatment, along with cullin 4A, 
supporting the notion that treatment is causing the cells to undergo apoptosis. As 
a further experimental control, cycloheximide and TNFα were used in combination 
to induce apoptosis (this is a well-described control for the pathway) and this 
treatment caused reductions in pro-caspase 3 and to a lesser extent PARP1, while 
also causing a reduction in cullin 4A levels. This is a further indication that 
bleomycin is inducing apoptosis in WT U2OS cells and that cullin 4A is degraded as 
a result of this process – perhaps directly by caspase proteins. 
MLN4924 was shown to inhibit neddylation by the presence of only the lower 
molecular weight, un-neddylated form of cullin 4A being present following 
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treatment (comparing lanes 1 and 5 in Figure 3-7). It is interesting to note that in 
the figure, the neddylation inhibitor MLN4924 appears to protect cullin 4A from 
being degraded, since the higher molecular weight portion (likely neddylated 
cullin 4A) is still present. MLN4924 treatment also appears to reduce caspase 3 
cleavage but not PARP1 cleavage. The overall significance of this is unclear, it is 
possible that MLN4924 may inhibit caspase cleavage and activation which thus has 
a protective effect on cullin 4A. The fact that we observe what may be neddylated 
cullin 4A with treatment using MLN4924 is counterintuitive but may be explained 
by the inhibitor preventing interaction between caspases and cullin 4A. Given the 
duration of bleomycin treatment (72 hours), it is perhaps unsurprising that cullin 
4A can be neddylated since MLN4924 is likely not effective for that duration – 
perhaps it simply delays caspase cleavage and thus cullin 4 degradation. This 
finding was not investigated further. 
The data presented in this section provides an indication that bleomycin is 
inducing the apoptosis response in cells after prolonged treatment, as we see 
similar reductions in full length caspase 3 and PARP1 which are known to be 
downstream cleavage products of this pathway. Furthermore, it is likely that cullin 
4A and 4B are being degraded by caspase 3 (or other caspases) as a result of 
apoptosis induction, based on the predicted caspase 3 cleavage sites within cullin 
4 amino acid sequences. The lack of cullin degradation in KO cells likely occurs as 
a result of a lack of apoptosis occurring rather than due to a specific interaction 
of cullins with DCNL5. It seems plausible therefore that DCNL5 plays a role in the 
apoptosis response, and this hypothesis is probed in the following sections.  
113 
 
 
 
 
Figure 3-7 Bleomycin Treatment of WT U2OS Cells Causes Apoptosis.  
In this representative western blot (n = 2), WT cells are shown and cullin 4A levels decrease as 
bleomycin (0.5mg/ml) treatment time increases, with almost no protein present after 72 hours. In a 
similar fashion, pro-caspase 3 levels as well as PARP1 levels are entirely gone following 72-hour 
bleomycin treatment. Cycloheximide (10μg/ml) in combination with TNFα (50ng/ml) is used to induce 
apoptosis , and this treatment causes reduction in caspase 3 and PARP1 levels while also causing 
a reduction in cullin 4A levels, indicating that loss of cullin 4A likely occurs as a result of apoptosis. 
The NEDD8-activating enzyme inhibitor MLN4924 was used in order to quickly investigate whether 
neddylation had a role in cullin 4A degradation and it appears as though MLN made no difference. 
In cells not treated with bleomycin (UT) but treated with MLN4924 (3μM) we see a larger lower 
molecular weight band representing un-neddylated cullin 4A which confirms the drug worked. 
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3.2.4 DCNL5 is Required for Caspase Activity in Extrinsic but not 
Intrinsic Apoptosis 
We next tested whether DCNL5 is required for apoptosis - there are two main 
branches of the apoptosis pathway, the extrinsic branch and the intrinsic branch. 
We wanted to establish whether both branches were affected in the DCNL5 KO 
cells or if the defect in the pathway was restricted to a single branch. The 
translational inhibitor cycloheximide is used in combination with the cytokine 
TNFα to induce the extrinsic branch of the pathway specifically due to 
cycloheximide specifically inhibiting an endogenous inhibitor of apoptosis called 
cFLIP. There is some overlap and crosstalk between extrinsic and intrinsic 
branches however (which are discussed in section 3.3), which is very difficult to 
fully overcome. 24-hour treatment with CHX and TNFα, as measured by luciferase 
assay, caused 80% loss of viability for WT cells while only about 40% loss in the KO 
cells. A variety of TNFα concentrations were tested with some data shown in 
Figure 3-8A, however overall the KO cells were on average 3-times as resistant to 
the treatment . Figure 3-8B shows optimisation of the concentration of CHX to be 
used in subsequent experiments; 10μg/ml of CHX and 50ng/ml of TNFα were 
generally used in further experiments, unless stated otherwise. 
Unlike with CHX/TNFα treatment, staurosporine activates the intrinsic branch of 
the apoptosis pathway. Staurosporine is a protein kinase inhibitor that causes 
cytochrome C release from the mitochondria in cells and caspase 9 activation, 
resulting in downstream caspase cleavage which can be detected by western 
blotting. Its precise mechanism and specificity towards activating the intrinsic 
pathway remains unclear however (Stepczynska et al., 2001). 24 hour 
staurosporine treatment caused a drop in viability in both WT and KO cells (drops 
of 50% and 60% respectively) at 100nM concentration and the difference was 
statistically significant (p<0.01), while 200nM caused an even larger, statistically 
significant response in the KO cells (which were only 20% viable) than the WT cells 
(which were 40% viable). This indicates that the DCNL5 KO cells are not resistant 
to intrinsic apoptosis stimulation. 
In order to establish whether the defect in KO cells was related to a lack of caspase 
activity, we monitored the cleavage of caspase 3 and PARP1 by western blot 
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following stimulation of both extrinsic and intrinsic branches of the apoptosis 
pathway using the same drugs as above, only for shorter time periods (24 hours 
was found to be too long to detect cleavage due to degradation of the cleavage 
products). CHX/TNFα treatment for 6 hours led to cleavage of both caspase 3 and 
PARP1 in WT cells but not KO cells (Figure 3-8D and Figure 3-8E), which was 
consistent with the WT cells undergoing more apoptosis than the KO cells as shown 
in Figure 3-8A. As shown in Figure 3-8E, Staurosporine treatment for 6 hours 
caused cleavage of caspase 3 and PARP1 in both WT and KO cell lines, which was 
again consistent with the viability data from Figure 3-8C which indicates that 
DCNL5 cells are resistant to extrinsic apoptosis only.  
The role of the DAD-patch and thus potential cullin binding was confirmed with 
CHX/TNFα treatment in addition to the bleomycin data already shown. Figure 3-9 
shows that DAD-mutant DCNL5 rescue cells are equally resistant to the induction 
of extrinsic apoptosis as KO cells, while both WT and WT-rescue cells are more 
sensitive. Overall, this data indicates that the resistance of DCNL5 KO cells to 
apoptosis is restricted to extrinsic branch of the pathway, and that this resistance 
is likely conferred due to a lack of caspase activity given that caspase 3 and PARP1 
fail to undergo cleavage and are therefore unable to mediate some of the 
downstream effects of apoptosis. As with bleomycin, DAD-rescue cells respond the 
same as KO cells, in this case to CHX/TNFα treatment, while WT-rescue cells are 
as sensitive to the treatment as WT cells (the difference between the two is 
statistically insignificant). This further supports a role for cullin binding by DCNL5 
in its role in mediating cell death, and this role is limited to the extrinsic branch 
of the apoptosis pathway which is induced by both CHX/TNFα treatment and 
bleomycin treatment. 
116 
 
 
 
 
Figure 3-8 WT Cells are Sensitive to Extrinsic and Intrinsic Apoptosis While DCNL5 KO Cells 
Are Only Sensitive to Intrinsic Apoptosis.  
A B 
C 
D 
E 
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(A) Luciferase viability assay shows that DCNL5 KO cells are more resistant to combination 
CHX/TNFα treatment than WT cells (extrinsic apoptosis). A concentration of 50ng/ml TNFα was 
deemed optimal for subsequent experiments due to the largest difference in response between the 
two cell lines. The pan-caspase inhibitor QVD-OPh was used as a control to ensure that it had no 
effects on viability of the cells for use in later experiments. (B) CHX concentration was also optimised 
in combination with TNFα concentration – unless stated otherwise CHX was used at 10μg/ml and 
TNFα was used at 50ng/ml. (C) Staurosporine (intrinsic apoptosis) cased a reduction in viability of 
both WT and KO cells, with the KO cells appearing slightly more sensitive at the highest 
concentration. (D) This representative western blot shows that CHX (10μg/ml) and TNFα (50ng/ml 
for 6 hours) combination treatment causes caspase 3 cleavage in WT but not KO cells. Staurosporine 
(100nM, 6 hours) on the other hand causes cleavage in both WT and KO cells. (E) This 
representative western blot, with drug treatments and treatment times indicated, shows that as with 
caspase 3, CHX/TNFα treatment causes cleavage of PARP1 in WT cells but not KO cells. This 
cleavage appears stronger after 6 hours rather than 3, despite the lower concentration of TNFα. 
Staurosporine causes PARP1 cleavage in both cell lines, again this cleavage is seen most after 6 
hours with only a small amount being visible after 3. Bleomycin treatment for 72 hours is likely too 
long to detect the cleaved product which will be degraded in that time. Data shown in (A), (B) and 
(C) represent the mean + SEM from 3 independent experiments, analysed by 2-way ANOVA 
comparing WT to KO cells for indicated and statistical significances of p<0.001 and p<0.01 were 
achieved, as indicated on the graphs. IB = immunoblot 
 
Figure 3-9 DAD-Patch Interaction is Required for DCNL5 Role in Apoptosis.  
As with bleomycin, DAD-mutant cells behave the same as KO cells and are resistant to CHX/TNFα 
treatment while expression of WT DCNL5 rescues the sensitivity of the KO cells. This suggests that 
the DAD-patch is required for this function of DCNL5 which may represent cullin interaction. Data 
shown represent the mean + SEM from 2 independent experiments, analysed by 1-way ANOVA 
comparing WT to KO, WTR and DADR cells for indicated treatments and statistical significances of 
p <0.01 were achieved. n.s = not significant 
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In order to further confirm the finding that lack of caspase cleavage is the 
mechanism underlying the DCNL5 KO cells’ resistance to extrinsic apoptosis 
induction, we used a pan-caspase inhibitor QVD-OPh (Abcam) to inhibit the action 
of caspases in the cells. 1 hour pre-treatment at a concentration of 40μM was 
shown to reduce the sensitivity of WT cells to CHX/TNFα treatment (Figure 3-10A) 
and Figure 3-10B and C show the effect of the inhibitor on WT and KO cells 
following stimulation with CHX and TNFα for 24 hours. The WT cells are rendered 
almost 200% less sensitive to CHX/TNFα treatment with the use of the inhibitor 
while KO cells are about 50% less sensitive. Interestingly, WT cells pre-treated 
with the caspase inhibitor respond the same as KO cells without the inhibitor, 
strongly indicating that the KO cells have significant caspase activity impairment 
in the extrinsic branch of the pathway.  
QVD-OPh also has an effect on WT cells that have been stimulated with 
staurosporine, but to a lesser extent. Figure 3-10D shows that this effect is more 
visible and more statistically significant (p<0.001 vs p<0.01) at the highest 
concentration of the drug where cells are almost 100% more viable. Figure 3-10D 
also shows that KO cells exhibit almost no change in response to staurosporine 
with caspase inhibition at 100nM and 200nM staurosporine concentrations not 
statistically significant for both), suggesting perhaps that these cells are dying via 
caspase-independent pathways. It is possible that KO cells undergo caspase-
independent cell death due to their compromised caspase activity and thus 
inhibiting caspases with QVD has little effect. This result requires further 
investigation. 
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Figure 3-10 The Pan-Caspase Inhibitor QVD-OPh Increases Resistance of WT Cells to 
Apoptosis More Than DCNL5 KO Cells, in Relative Fold-Change Terms.   
A 
B C 
D 
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(A) We tested the broad-spectrum caspase inhibitor QVD-OPh (Abcam) at a concentration of 20μM 
and 40μM for 1 hour prior to apoptosis induction with CHX/TNFα and found that 40μM was the better 
concentration to use given its increased effectiveness. (B) QVD treatment increased the viability of 
WT cells from just over 20% to over 60% relative to untreated (-QVD) cells. (C) QVD increased the 
viability of KO cells from 60% to just over 80% relative to untreated (-QVD) cells. This indicates that 
inhibition of caspase activity in WT cells renders their sensitivity the same as KO cells without the 
use of the inhibitor. (D) QVD reduces the sensitivity of WT cells to in a statistically significant manner, 
with the effect more noticeable at higher concentrations. QVD has much less of an effect on KO cells, 
with no statistically significant effect on KO cell viability with the inhibitor at either STS concentration). 
Data shown represent the mean + SEM from 3 independent experiments analysed by 2-way ANOVA 
comparing -QVD to +QVD and statistical significances of p<0.001 and p<0.01 were achieved, as 
indicated on the graphs. ns = not significant. 
  
121 
 
 
 
3.2.5 DCNL5 knockout cells are not impaired in their response to 
CHX or TNFα  
Having established that DCNL5 KO cells have an impairment in the extrinsic branch 
of the apoptosis pathway and that this impairment is likely caused by a defect in 
caspase activation, we wanted to verify that the KO cells responded the same as 
the WT cells to cycloheximide and TNFα separately. The combination treatment 
of the two drugs induces extrinsic apoptosis but we wanted to ensure that the lack 
of response by KO cells was due only to the lack of apoptosis signalling and not 
due to a lack of response to the cytokine TNFα and/or to the protein synthesis 
inhibitor cycloheximide. Cycloheximide causes protein translation arrest, which 
results in a global reduction in protein synthesis and allows for monitoring of 
steady state protein levels. We used a cycloheximide chase experiment to quantify 
the steady state decay of TNF receptor I (responsible for interacting with TNFα) 
in order to verify that WT and KO cells exhibit a similar response, and that 
turnover of the receptor isn’t a factor in response of KO cells to TNFα signalling, 
as well as confirming that global expression of TNF receptor is similar between 
the two cell lines.  
Figure 3-11A shows a western blot tracking levels of TNF-receptor 1 (TNFR1) during 
the 1-hour cycloheximide chase experiment. This western blot appears to indicate 
globally lower TNFR expression in KO cells, however the half life was estimated 
based on the reduction in relative protein amount following CHX stimulation, and 
this was calculated to be 48 and 39 minutes for WT and KO cells respectively. 
While there is a difference, the values are similar enough to suggest that the 
difference in sensitivity of KO cells is likely not due to a different half life of the 
receptor, however further work is required to substantiate this finding and it is 
possible that this discrepancy may account for some of the difference in response. 
Figure 3-11C from a separate experiment which was performed twice 
independently (also shown in Figure 3-13D a few pages later) shows that the TNFR 
levels in WT and KO cells are broadly similar in response to 1-hour CHX treatment 
further supporting the finding that the receptor levels and half life are similar in 
both cell lines and likely have no impact on the lack of apoptosis in KO cells. This 
half life experiment was only done once and therefore requires repeating and 
further optimising to draw more significant conclusions. 
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Figure 3-11 TNFR1 Steady State Level Decay is Largely the Same in WT and DCNL5 KO Cells 
Following CHX Chase.  
(A) This western blot (n = 1) shows the steady state levels of TNFR1 following a CHX chase, globally 
less receptor was detected in the KO cells but the reduction in levels appears similar. The difference 
in actin levels in the KO cells appears to be a result of incomplete staining with the antibody since 
tubulin levels are consistent between cell lines. (B) Quantification of TNFR half life based on the 
decrease in protein (pixel) levels following CHX stimulation. The equations of WT and KO trendlines 
were y = -290 + 26000 and y = -180 + 13000 for WT and KO cells, respectively. The half life of TNFR 
in WT cells was calculated to be 48 minutes while the half life in KO cells was 39 minutes. (C) This 
representative western blot (n = 2) shows that after 1-hour cycloheximide treatment, the reduction in 
TNFR1 level appears to be similar in WT and KO cell lines. 
In addition to observing the effect of cycloheximide on TNFR levels and half life 
in WT and KO cells (which appear to be largely similar), we wanted to establish 
whether the KO cells were able to respond the same as the WT cells to TNFα 
ligand. TNFα stimulation causes the phosphorylation and subsequent 
ubiquitination and degradation of IκBα which allows for the nuclear translocation 
of NF-κB which normally exists in complex with IκBα. This degradation thus allows 
for transcription of genes involved in immune signalling by NF-κB (Miyamoto et 
al., 1994). We tested for TNFα sensitivity by tracking the protein levels of IκBα by 
western blot for 1 hour after stimulation with recombinant TNFα. A normal 
response involves the phosphorylation and subsequent ubiquitination and 26S 
A B 
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proteasome-mediated degradation of IκBα (summarised in Figure 3-12B) which 
allows for NF-κB nuclear translocation and gene expression regulation as 
mentioned previously. As can be seen in Figure 3-12A, in both cell lines we saw an 
increase in molecular weight of IκBα after 10 minutes, representing the 
phosphorylation of the protein, followed by strong reduction in levels after 30 
minutes with levels beginning to return after 60 minutes as new protein is made. 
Importantly, DCNL5 WT and KO cells exhibit the same response to the TNFα signal 
which indicates that the KO possess functional receptor and have no impairment 
in recognising the ligand. Additionally, this confirms that this particular ubiquitin 
E3 ligase activity is unaffected by the absence of DCNL5. SCFβ-TrCP is the ligase 
responsible for the degradation of IκBα (Kanarek and Ben-Neriah, 2012) and DCNL5 
KO cells exhibit normal processing of the protein. The cullin core of SCF requires 
neddylation which is mediated by one of the 5 DCNL proteins in humans and likely 
depends on the sub-cellular localisation of the CRL complex. Overall, this data 
suggests that the fault in downstream caspase activity and apoptosis response lies 
downstream of the TNFα/TNFR ligand-receptor interface and upstream of caspase 
3 cleavage. 
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Figure 3-12 WT and DCNL5 KO Cells Undergo Normal IκBα Degradation and Respond the 
Same to TNFα Stimulation.  
(A) This representative western blot shows that both WT and KO cells undergo phosphorylation and 
proteosomal degradation of IκBα following TNFα stimulation, indicating normal and succesful 
reponse to the ligand. (B) This outline visualises the phosphorylation, ubquitination and subsequent 
26 proteosome-mediated degradation of IκBα which allows for nuclear translocation of NF-κB and 
pro-inflammatory gene signalling.  
A 
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3.2.6 Caspase 8 is not Fully Activated in DCNL5 KO Cells 
Having established that the defect in downstream apoptosis events occurs 
upstream of caspase 3 cleavage but downstream of the TNFα receptor-ligand 
interface, we wanted to determine whether caspase 8, one of the initiator 
caspases and the one which is activated immediately downstream of the TNFα 
receptor, undergoes cleavage in the DCNL5 KO cells. TNFα signalling initially leads 
to the formation of a receptor-bound complex known as complex I consisting of 
the death domain containing protein TRADD as well as proteins including TRAF2 
and RIPK1. For apoptotic signalling, a second complex, known as complex II, is 
formed in the cytosol and the core consists of TRADD, FADD and pro-caspase 8 
(summarised in Figure 3-13B). This complex mediates the activation of caspase 8 
through proteolytic cleavage into different intermediates ultimately leading to 
formation of its active form, known as p18, which is a hetero-tetramer of two 
subunits (p18 and p10).  
We stimulated WT and KO cells using the combination treatment of cycloheximide 
and TNFα and used the neddylation inhibitor MLN4924 as well as the caspase 
inhibitor QVD-OPh to investigate their effects on caspase 8 cleavage. Figure 3-13A 
shows the cleavage of caspase 8 detected via western blot, and it is clear that the 
WT cells undergo cleavage to form both p43/41 and the active p18 forms of 
caspase 8 while KO cells appear to undergo no processing of the protein. 
Interestingly, MLN pre-treatment appears to inhibit formation of the p18 fragment 
of caspase 8 in WT cells, while the pan-caspase inhibitor QVD has a similar effect. 
This suggests a role for NEDD8 in the full processing of caspase 8 but perhaps not 
in the initial cleavage to the p43/41 fragment. Caspase inhibitors such as QVD-
OPh work by binding to the catalytic site of caspases to inhibit their activity, and 
the data here indicates that caspase 8 is able to be processed to its p43/41 form 
but not the catalytically crucial form p18, suggesting that initial processing of 
caspase 8 occurs independently of the catalytic activity of the protein. This 
western blot lacks independent repeats as well as appropriate loading controls, 
thus the conclusions drawn here require caution and these data provide only an 
indication of what may be happening.   
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Given that caspase 8 is just one of the components of complex II in TNFα signalling, 
we wanted to determine whether any of the other proteins in the complex where 
affected by the absence of DCNL5 expression. Global levels of TRADD (the first 
and death domain-containing protein recruited to the TNFR1) as well as FADD (the 
death domain-containing protein recruited to the second complex along with pro-
caspase 8) were unaffected by CHX/TNFα treatment (Figure 3-13C and D) 
indicating that at the very least these proteins are expressed and present in both 
WT and KO cells. Co-IP experiments would have been able to determine whether 
recruitment of these proteins to complex II are affected in the DCNL5 KO cells 
compared to the WT cells, and would thus be useful experiments to do in future 
work. Figure 3-13D also shows that TNFR1 levels drop significantly after TNFα 
treatment which, as well as being due to an increase in the steady-state decay of 
the receptor, arises due to the rapid internalisation of the receptor following 
signalling. 
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Figure 3-13 Caspase 8 Cleavage is Impaired in DCNL5 KO Cells While TRADD and FADD 
Levels are Unaffected by CHX/TNFα Treatment  
CHX was used at 5μg/ml while TNFα was used at 50ng/ml. (A) This western blot lacks loading 
controls or independent experimental repeats (n = 1), but it appears to show that CHX/TNFα induces 
caspase 8 cleavage to p43/41 and p18 fragments in WT but not KO cells. MLN and QVD treatments 
inhibit formation of the p18 fragment in the WT cells. (B) This diagram illustrates the formation of a 
receptor-bound complex (I) followed by formation of a cytosolic complex (II) containing proteins 
including TRADD, FADD and importantly pro-caspase 8. It is this complex that is responsible for the 
cleavage and activation of caspase 8. (C) Representative western blot (n = 2) showing that TRADD 
protein levels are the same in WT and KO cells and unchanged by CHX/TNFα treatment. (D) 
Representative western blot (n = 2) showing that FADD protein levels are also unaffected by 
treatment and the same in both cell lines. TNFR1 levels drop significantly after TNFα stimulation due 
in part to the internalisation and degradation of the receptor. 
  
A B 
C D 
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3.2.7 DCNL5 KO Cells are Resistant to TNF-Related Apoptosis-
Inducing Ligand (TRAIL) Stimulation 
In order to confirm that the extrinsic branch of the apoptosis pathway is 
compromised in the absence of DCNL5 expression in U2OS cells, we used another 
inducer of the pathway, TNF-related apoptosis inducing ligand (TRAIL). As before, 
we used an ATP-based viability assay and 24 hour treatment times to induce 
apoptosis in the U2OS cells, and the result is shown in Figure 3-14A. 200ng/ml was 
deemed to be an appropriate concentration moving forward. DCNL5 KO cells are 
more resistant in viability terms to the treatment with respect to WT cells, as 
shown in panel B. This finding is very important – KO cells are strongly resistant to 
TRAIL-induced apoptosis and corroborates the findings with CHX/TNFα. Figure 
3-14B also shows that the resistance of DCNL5 KO cells can be rescued by re-
expression of WT DCNL5 but not DAD-mutant DCNL5 which is consistent with the 
data for CHX/TNFα treatment as well as bleomycin treatment. Interestingly, the 
DAD-mutant cells appear to be even more resistant to TRAIL than the KO cells, 
while WT-rescue cells appear more sensitive than the WT cells. This result held 
up during repeats of the experiment and indicated that expression of DAD-mutant 
DCNL5 may have more of an effect on viability than merely the absence of DCNL5 
– perhaps DCNL5 interaction via the DAD-patch binds and sequesters proteins that 
are required for apoptosis and thus renders these cells even less sensitive to cells 
simply lacking DCNL5 expression. Figure 3-14C shows the expression of DCNL5 and 
GFP-DCNL5 in the rescue cell lines – DCNL5 levels are slightly higher in the rescue 
cell lines than the WT cells, which may account for the higher sensitivity of the 
WT-rescue cells to TRAIL with respect to the WT cells. 
While not entirely identical the TNFα and TRAIL signalling pathways share many 
common aspects and mechanisms - one of these is caspase 8 cleavage, with both 
pathways converging on this key protein. We treated the U2OS cell lines with 
100ng/ml of TRAIL for 1 and 3 hours and analysed these samples by immuno-
blotting for caspase 8 as well as probing for cullin 3 and caspase 3. Cullin 3 has 
been shown to be a key regulator of caspase 8 activity and is known to ubiquitinate 
and promote cleavage and thus warranted investigation in our work (Jin et al., 
2009). The resulting western blot is shown in Figure 3-14D. Cleavage of p41/41 
forms of caspase 8 are reduced significantly in DCNL5 KO and DAD-mutant cells 
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compared to WT and WT-rescue ones. Catalytically active p18 caspase 8, while 
harder to detect, shows the same reduction in protein levels in the KO and DAD-
mutant cells. This data is consistent with the TNFα data in 3.2.6, indicating that 
DCNL5 is required for caspase 8 cleavage in TRAIL signalling as well. Global levels 
of cullin 3 and pro-caspase 3 were largely similar between cell lines. We did not 
probe for cleaved caspase 3 so cannot say whether this was affected but we 
anticipate that we would have seen a similar reduction in cleavage that we 
observed for TNFα signalling. 
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Figure 3-14 DCNL5 KO Cells are Resistant to TRAIL and Exhibit a Reduction in Caspase 8 
Cleavage.  
A B 
C 
D 
* * 
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(A) This kill curve using a range of TRAIL concentrations indicates that U2OS cells are sensitive to 
treatment and that 200ng/ml was the optimal concentration to use moving forward. Data shown 
represent the mean + SEM of 2 independent experiments. (B). Viability assay shows that DCNL5 
KO and DAD-mutant cells are resistant to TRAIL. DAD-mutant cells are even less sensitive to the 
drug than KO cells. WT-rescue cells are more sensitive than WT cells suggesting perhaps that 
increased DCNL5 expression leads to increased sensitivity to the ligand. Data shown represent the 
mean + SEM from 3 independent experiments. (C) This representative western blot confirms 
expression of DCNL5 in WT cells, lack of expression in the KO cells and expression of GFP-tagged 
DCNL5 in the rescue cell lines. The rescue cells overall express slightly more DCNL5 than the WT 
cells and may indicate that DAD-DCNL5 has a dominant negative effect. (D) This representative 
western blot shows that caspase 8 cleavage is reduced in DCNL5 KO and DAD-mutant cells, for 
both p41/41 and p18 fragments. p18 is harder to detect and is highlighted (*) in the WT and WT-
rescue cells. Global levels of pro-caspase 3 and cullin 3 appear largely the same between the cell 
lines. IB = immunoblot 
3.2.8 DCNL5 KO Cells Demonstrate Resistance to Apoptosis by 
TRAIL Using Annexin V and Propidium Iodide Staining 
Another method to detect apoptosis in cells is to use annexin V and propidium 
iodide staining, in combination with flow cytometry or fluorescence imaging to 
detect the level of each marker following treatment with a drug that causes cell 
death. Annexin V is a marker for early-stage apoptosis; it binds to 
phosphatidylserine on the cytoplasmic side of the plasma membrane, which is 
translocated to the extracellular side of the membrane during early-stage 
apoptosis and therefore detectable using fluorescence imagery. Propidium iodide 
(PI) is a nuclear marker and its signal can be detected once the nuclear envelope 
has been degraded and the contents of the nucleus have been released from the 
cell during late-stage apoptosis and necrosis and therefore typically represents 
dead or dying cells.  
We incubated cells plated in 96-well plates with annexin V and PI following 24-
hour TRAIL stimulation and imaged the plates using a Sartorius InuCyte® live cell 
analysis system. Individual wells of the 96-well plate were imaged, and 
representative examples are shown in Figure 3-15. The WT cells show a dramatic 
increase in signal of both FITC-conjugated annexin V as well as propidium iodide, 
indicating that TRAIL causes apoptosis in these cells and is sufficient to cause 
death. The KO cells, however, show almost no signal for either marker indicating 
that these cells are entirely unaffected by the treatment and are unable to 
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undergo apoptosis or necrosis as a result of the TRAIL treatment over a 24-hour 
period. This data represents an additional read-out and experimental 
determination of the level of apoptosis and further highlights quite how significant 
the role of DCNL5 is in this response. 
 
Figure 3-15 DCNL5 KO Cells are AV and PI Negative After 24 Hour TRAIL Stimulation.  
These representative fluorescent images, taken from individual wells of a 96-well plate, show bright 
field images along with annexin V (conjugated to FITC) and PI fluorescence in cells following 24-
hour treatment with 200ng/ml of TRAIL. TRAIL treatment causes a dramatic increase in annexin V 
positive cells which show a characteristic ‘bubbling of their membranes due to the translocation of 
annexin V allowing for the fluorescence to be detected. The fluorescence of propidium iodide is also 
very strong in WT cells indicating that both early and late stage apoptosis and cell death is occurring. 
The KO cells, in stark contrast, show almost no AV or PI signal which suggests that these cells are 
not undergoing apoptosis or dying at all in response to the TRAIL treatment. 
  
WT KO 
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3.2.9 DCNL1 KO Cells Undergo Apoptosis in Response to TRAIL 
and CHX/TNFα Treatments 
Given the functional complementation of the DCNL family of proteins, at least in 
vitro, where it has been shown that loss of individual DCNL expression has little 
effect on global cullin neddylation and that each DCNL protein can neddylate each 
cullin protein (Keuss et al., 2016), we anticipated that the phenotype we observed 
in the DCNL5 KO cells is due to a unique role for DCNL5 in caspase 8 activation. 
This role likely cannot be performed by other DCNL proteins since we anticipate 
that if this were not the case, we would not see such a severe phenotype. In order 
to investigate this, we used DCNL1 KO cells to test for sensitivity to TNFα and 
TRAIL. DCNL1 is the most widely expressed of the DCNL family members in terms 
of tissue distribution as well as subcellular localisation and is also the best studied 
and the best characterised DCNL protein. It is localised in both the nucleus and 
the cytoplasm with generally high levels of expression across tissue culture cell 
lines and tissues. To test whether DCNL1 has similar apoptosis requirements as 
DCNL5, we subjected DCNL1 KO and WT cells (which were generated in parallel 
during the CRISPR/Cas9 process) to CHX/TNFα and TRAIL treatments in the same 
way as for DCNL5 cell lines.  
Figure 3-16A shows the result of the 24-hour TNFα and TRAIL treatments on DCNL1 
cells. The combination treatment of cycloheximide and TNFα appears to induce 
more death in the DCNL1 KO cells than the WT cells, while TRAIL is equally potent 
to both cell lines.  Figure 3-16B shows a viability assay following 24-hour TRAIL 
treatment of all the DCNL5 cell lines along with DCNL1 WT and KO cells. As before 
DCNL5 KO and DAD-mutant cells are almost entirely resistant to the treatment 
while WT and WT-rescue cells are highly sensitive. DCNL1 WT and KO cells are 
even more sensitive to the treatment than DCNL5 cells, confirming that DCNL1 
does not play the same role in the apoptosis pathway as DCNL5. Had we seen the 
same resistance to treatments, it would have indicated a more general role for 
DCNL proteins as a whole, however this process is likely dependent on DCNL5 
specifically. 
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Figure 3-16 DCNL1 KO Cells Are Sensitive to Both CHX/TNFα and TRAIL-Mediated Apoptosis. 
(A) This viability assay shows the effect of both CHX/TNFα and TRAIL treatments on DCNL1 WT 
and KO cells. The KO cells appear more sensitive to the TNFα treatment than the WT cells while 
TRAIL kills both WT and KO cells entirely.(B) This viability data shows the effect of TRAIL on all of 
the DCNL5 cell lines used thus far as well as WT and KO DCNL1 cells. As before, DCNL5 KO cells 
are much more resistant to the treatment than WT cells, the DAD-mutant even more-so. The DCNL5 
WT-rescue cells respond the same as WT cells. The same treatment completely kills both DCNL1 
WT and DCNL1 KO cells, confirming that DCNL1 does not have the same effect as DCNL5 in this 
pathway. Data shown in (A) and (B) represent the mean + SEM from three independent experiments. 
  
A B 
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3.3 Discussion 
3.3.1 Summary 
The results presented in this chapter provide evidence for a novel role for DCNL5 
in the apoptosis pathway. We have shown that DCNL5 is required in the extrinsic 
but not intrinsic branch of the apoptosis pathway and that this role of DCNL5 does 
depend on its DAD-patch region and thus potentially cullin protein interaction. We 
have demonstrated that the role of DCNL5 lies downstream of the ligand-receptor 
complex and upstream of the executioner caspase activities and provide evidence 
for the strong reduction in caspase 8 cleavage in the apoptosis resistant cell lines. 
DCNL1 KO cells are no less sensitive to the same treatments, suggesting that the 
role of DCNL5 is unique amongst the DCNL protein family in mediating this 
function, which would represent a potentially novel function of DCNL5. 
3.3.2 Efficacy of Chemical Inducers of DNA Damage Was Largely 
Unaffected by DCNL5 Expression 
The initial hypothesis that we were investigating in this chapter was the potential 
role of DCNL5 in the DNA damage response, which was thought to occur 
independently of its ability to interact with its usual binding partners, members 
the cullin protein family (Keuss et al., 2016). Initial experimental work aimed to 
induce dsDNA damage in order to replicate the UV and gamma irradiation 
experiments performed by Keuss and colleagues. Neocarzinostatin is known for 
being an ionising radiation mimetic and induces dsDNA breaks through binding to 
the minor groove of DNA (Povirk, 1996; Smith, Bauer and Povirk, 1994) and thus 
represented a good drug to use to attempt to mimic the DNA damage those 
researchers were able to induce. Etoposide is able to induce dsDNA breaks through 
its interaction with DNA topoisomerase II by causing a covalent interaction 
between the enzyme and DNA, which inhibits the re-ligation step in the transient 
repair of DSBs and locks the enzyme to the DNA backbone (Burden and Osheroff, 
1998). Doxorubicin also induces dsDNA damage through its interaction with 
topoisomerase II through a similar but less well understood mechanism to 
etoposide (Pommier et al., 2010). 
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We used the same U2OS cells used in previous research (Keuss et al., 2016), and 
immediately found that WT cells were similarly sensitive (as determined by 
viability assay) to these 3 different DNA-damage inducing agents compared to 
DCNL5 KO cells. This was unexpected and in clear contrast to the results reported 
by Keuss and colleagues who had shown that in the absence of DCNL5 expression, 
cells were much more sensitive to DNA damage induction. They used gamma and 
UV irradiation to induce damage and showed that the role of DCNL5 occurred 
independently of its ability to bind cullin proteins. Our data here using chemical 
anti-cancer agents indicated that DCNL5 may not play a significant role however 
a clear distinction needs to be made here between short pulses of treatment with 
ionising radiation and 24 hour-long treatments with these anti-cancer drugs. The 
increased treatment duration we employed in this research coupled with the 
diverse range of effects caused by these drugs over longer periods of time make 
it likely that dsDNA damage is not the only process occurring in the cells following 
these treatments. Furthermore, we did not include a positive control to confirm 
successful induction of DNA damage.  
The experimental limitation for this research was a lack of access to UV and 
gamma irradiation sources which is why we employed the use of chemical inducers 
of DNA damage. Further work would need to be undertaken to better optimise the 
chemical dsDNA treatments and to validate the findings by Keuss and colleagues 
that DCNL5 is an essential protein in the DNA damage response. This would be 
achieved through the employment of UV and gamma irradiation of WT and KO cells 
and subsequent detection of DNA damage could be analysed using a variety of 
assays (Collins and Azqueta, 2012). Our preliminary data suggests that DCNL5 may 
not be absolutely required in the DNA damage response however the treatments 
we used, and methods of analysing DNA damage were different to previous 
research and proper controls are required to draw stronger conclusions. 
3.3.3 DCNL5 is Required for Extrinsic Apoptosis 
Another drug we used to attempt to induce DNA damage was bleomycin sulphate, 
which is used clinically in the treatment of cancer including squamous cell 
carcinomas and testicular cancers (Hecht, 2000). Bleomycin is able to induce both 
ssDNA breaks and dsDNA breaks in the presence of the required cofactors (Nagai 
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et al., 1969; Stubbe and Kozarich, 1987; Claussen and Long, 1999), and while its 
mechanism has been studied, it is not fully clear how the drug functions at a 
molecular level (Chen et al., 2008). We found that 72-hour treatment with the 
drug caused a statistically significant (p<0.001) reduction in viability in WT cells 
and inducible WT-rescue cells compared to DCNL5 KO cells as well as DAD-mutant 
DCNL5 cells. We suspected that given the relatively long duration of the bleomycin 
treatment we were using, it was likely that this response was not due directly to 
the DNA damage induction and therefore a different mechanism to the reported 
role of DCNL5 in the DNA damage response. Bleomycin is also known to affect 
progression through the cell cycle (Twenytman, 1983) and more relevantly to the 
present study, is known to activate the apoptosis pathway, specifically the 
extrinsic branch (Vernole et al., 1998; Mungunsukh et al., 2010). It seemed 
possible then that bleomycin was inducing apoptosis in the cells, and the DCNL5 
KO and DAD-mutant cells were unable to undergo this process. Our findings 
indicate a potential mechanism of chemotherapy resistance in bleomycin treated 
cancers mediated by DCNL5 which would be an avenue worth investigating in 
future study. 
DCNL proteins have been shown to exhibit a significant overlap in function in cells, 
siRNA-mediated knockdown of individual DCNL proteins had little effect on the 
neddylation of all cullin proteins (Keuss et al., 2016). This was also shown to be 
the case for DCNL1 and DCNL5 KO cell lines. We showed in WT but not DCNL5 KO 
U2OS cells that bleomycin treatment  specifically caused reductions in cullin 4 
protein levels. Crucially, we were able to show that the loss of cullin 4A and 4B is 
likely due to apoptosis and is mediated by the cleavage of caspase 3, since we 
detected cleavage sequences in cullin 4A and 4B but not cullin 3, which was 
unaffected by the bleomycin treatment. This data was supported by the 
combination treatment of CHX and TNFα, used as a control for apoptosis induction 
(Paja̧k, Gajkowska and Orzechowski, 2005; Wang, Du and Wang, 2008), which, like 
bleomycin, caused reductions in the levels of un-cleaved caspase 3 and PARP1 
which are activated during apoptosis. This apoptosis response was largely absent 
in the KO cells and the DAD-mutant cells. There is a small chance that the 
reduction in cullin 4A levels may be a cause rather than a result of apoptosis since 
overexpression of the protein is associated with tumour cells and downregulation 
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of expression has been associated with reduced cell invasion and an increase in 
apoptosis (Chen et al., 2018). The DCNL5 KO cells here show resistance to the 
drug and exhibit unchanged cullin 4A levels indicating that this resistance may be 
conferred by the higher cullin expression. It seems much more likely, especially 
given the supporting CHX/TNFα data, that the KO cells are lacking the ability to 
undergo apoptosis and caspase cleavage which is what we have shown in this work. 
We determined that DCNL5 KO cells are deficient  only in extrinsic apoptosis, 
lacking caspase 3 cleavage and cell death. This phenotype was mirrored in DAD-
mutant cells, indicating a requirement for the DAD-patch and thus potential cullin 
binding for this role. It remains a possibility that the DAD-patch may confer binding 
to a protein other than a cullin family member. Co-immunoprecipitation 
experiments with WT cells would be able to tell us whether DCNL5 shows an 
increased interaction with a cullin protein in response to the CHX/TNFα treatment 
and if so, which one. This would provide confirmation that DCNL5 interacts with 
a cullin in order to mediate its role in the extrinsic apoptosis response and support 
the DAD-mutant data we have obtained in the present study.  
TNFα stimulation on its own typically promotes the phosphorylation of IκBα, which 
is normally bound to the transcription factor NF-κB. This phosphorylation then 
leads to the ubiquitination of IκBα which is mediated by the E3 ligase SCFβ-TrCP  
(Kanarek and Ben-Neriah, 2012). This promotes its proteasome-mediated 
degradation which allows for the nuclear translocation of NF-κB and the 
transcription of genes involved in immune signalling (Miyamoto et al., 1994). We 
showed that WT and KO cells undergo IκBα phosphorylation and subsequent 
degradation which serves to upregulate pro-inflammatory genes (Karin, 1999). 
This is important in not only confirming that the KO cells are able to recognise the 
TNFα ligand and transduce the signal, but it also seems to support the finding that 
lack of DCNL5 does not affect the activity of most CRL complexes  including SCFβ-
TrCP   which is the ligase responsible for ubiquitinating IκBα in response to TNFα 
stimulation, however we did not independently validate this assertion. SCF 
requires neddylation for its activity (Amir, Iwai and Ciechanover, 2002) and DCNL5 
KO cells therefore do not lack neddylation of cullin 1 in this context. Other DCNL 
proteins mediate this neddylation event. 
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CHX has been known for decades to inhibit the elongation phase of eukaryotic 
translation through direct binding to the ribosome (Obrig et al., 1971). We showed 
that CHX stimulation alone in a CHX-chase experiment had a similar effect on TNF-
receptor homeostasis in both cell lines, however this finding needs to be validated 
by more independent repeats of the experiment. Importantly, we demonstrated 
that the half life of TNF receptor 1 was similar in both cell lines indicating that 
the sensitivity difference to CHX/TNFα between the cell lines was not caused by 
different responses to either CHX or TNFα. Overall, this data strongly supports the 
hypothesis that DCNL5 plays a role unique to DCNL proteins in the caspase enzyme 
cascade resulting from extrinsic apoptosis induction and the absence of caspase 
activity confers resistance to treatments inducing the extrinsic apoptosis pathway. 
We used TRAIL as another independent inducer of the extrinsic apoptosis pathway  
(which is more commonly used in studying this pathway) and found that DCNL5 KO 
and DAD-mutant cells were even less sensitive to the treatment compared to WT 
cells than with the CHX/TNFα combination treatment.  
We found that DCNL5 was required for caspase 8 cleavage following both TNFα 
and TRAIL stimulation, and the role of DCNL5 was dependent on cullin binding 
since DAD-mutant cells showed the same and arguably even less cleavage than 
DCNL5 KO cells. The lack of caspase 8 activity is likely to account for the lack of 
downstream cleavage of caspase 3 and PARP1 observed during TNFα stimulation 
(Stennicke et al., 1998). We have managed to locate the level at which extrinsic 
apoptosis is compromised in the KO cells and thus discovered a novel role for 
DCNL5 in promoting caspase 8 activity.  
The finding that DCNL5 KO and DAD mutant cells were more resistant to TRAIL 
than to TNFα-induced apoptosis was interesting. While both ligands are inducers 
of the extrinsic apoptosis pathway, they differ in the downstream proteins 
recruited and complexes formed. TNFα recruits the death domain-containing 
protein TRADD (Locksley, Killeen and Lenardo, 2001) as part of the receptor-bound 
complex (complex I) which in turn is responsible for recruiting RIP, TRAF2 and 
FADD. A second complex (complex II) is formed in the cytosol, which consists of 
TRADD, RIP, FADD and caspase 8, and this complex is responsible for the activation 
of caspase 8 to mediate the downstream apoptosis events and is known as the 
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death inducing signalling complex (DISC) (Micheau and Tschopp, 2003; Peter and 
Krammer, 2003). TRAIL signalling differs in that FADD and caspase 8 are recruited 
directly to the receptor-bound complex at one of 2 death receptors (DR4 or DR5) 
to form the DISC, and this complex is sufficient for caspase 8 activation (Walczak 
and Krammer, 2000). Furthermore, TRADD has been shown to be indispensable for 
TNFα-mediated apoptotic signalling while FADD is not, whereas FADD is absolutely 
required for TRAIL-mediated apoptosis.  
TRAIL signalling often leads to higher levels of apoptosis in cells compared to TNFα 
(80% vs 60% in multiple myeloma cell lines, (Gazitt, Shaughnessy and Montgomery, 
1999)) and in the present work we found that DCNL5 KO cells undergo 40-60% 
apoptosis (depending on concentrations used) following TNFα treatment and 
closer to only 20% apoptosis following TRAIL stimulation. The reason our KO cells 
are more sensitive to CHX/TNFα treatment compared to TRAIL treatment, to 
which they are almost entirely resistant, may be in part due to the order of DISC 
formation. Caspase 8 is recruited and activated at the DISC and in TNFα signalling 
this occurs at the second, cytosolic complex. We have shown that caspase 8 
cleavage is lacking in KO cells therefore it is likely that the role of DCNL5 is in 
promoting caspase 8 cleavage and since this occurs at the second complex, there 
are preceding events that may contribute to cell death in TNFα signaling or rather 
events that may dilute the importance of DCNL5 in caspase 8 activation. In TRAIL 
signalling, caspase 8 is recruited to TRAIL receptors directly by FADD to form the 
DISC and our data suggests that the role of DCNL5 is immediate and essential in 
this response and therefore results in a higher degree of resistance when DCNL5 
is absent compared to TRAIL compared to TNFα stimulation.  
To further investigate the importance of caspase activity in mediating cell death 
following induction of the extrinsic apoptosis pathway we used a pan-caspase 
inhibitor called QVD-OPh. QVD-OPh uses an N-terminal quinoline group which is 
conjugated to the amino acids valine (V) and aspartate (D) as well as a C-terminal 
ester attached to a phenoxy ring (Caserta et al., 2003). This peptide can 
covalently and irreversibly bind to caspase protein’s active sites and thus QVD-
OPh is a broad-range caspase inhibitor capable of inhibiting caspase 3 and caspase 
8, amongst others. Existing research indicated that  concentration of 10μM was 
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required to inhibit PARP1 cleavage (Kuželová, Grebeňová and Brodská, 2011) 
however we found that 40μM was an optimal concentration to use using U2OS 
cells. Our data indicated that inhibition of caspase cleavage with this drug does 
effectively reduce sensitivity to extrinsic apoptosis, and that KO cells respond less 
to QVD-OPh than WT cells, presumably because caspase activity in these cells is 
already significantly reduced.  
3.3.4 DCNL5 is not Required for Intrinsic Apoptosis 
Staurosporine is widely accepted as a specific inducer of the intrinsic apoptosis 
pathway (Gescher, 2000) and we found that the drug caused cell death in WT and 
KO cells as measured by viability assay and that KO cells were in fact statistically 
more sensitive to the drug at a concentration of 200μM (p<0.001). Our data 
support a model whereby DCNL5 plays a role in extrinsic apoptosis, specifically at 
the level of caspase 8 activation, which is not a required step for intrinsic 
apoptosis. The intrinsic pathway activates downstream caspases via the 
apoptosome which is a caspase 9-activating complex, following mitochondrial 
outer membrane permeabilization and release of cytochrome C (Cain, Bratton and 
Cohen, 2002).  
Caspase 8 can mediate the cleavage of a protein called BID to form truncated BID 
(tBID) which then translocates to the mitochondria and promotes cytochrome C 
release (Li et al., 1998) and this therefore represents a level of crosstalk between 
the extrinsic and the intrinsic pathways. This crosstalk is known to amplify the 
apoptosis induction, however we have shown that the KO cells are specifically 
defective in caspase 8 activation. As a result, there is a lack of both extrinsic 
apoptosis and caspase 9 cleavage and activation via the intrinsic/mitochondrial 
branch of the pathway. Staurosporine specifically activates the intrinsic branch 
and culminates in caspase 3 cleavage and this data reinforces our finding that 
DCNL5 is required for caspase 8 activation, and not for any other caspase proteins.  
142 
 
 
 
3.3.5 The Role of DCNL5 in Extrinsic Apoptosis Appears Unique 
Within the DCNL Family 
Another key finding presented in this chapter is the discovery that the most 
ubiquitously expressed DCNL protein, DCNL1, which is known to localise to the 
cytosol (Keuss et al., 2016), does not play an essential role in the extrinsic 
apoptosis pathway. We found that the DCNL1 KO cells were more sensitive to the 
WT cells following CHX/TNFα treatment and equally sensitive to TRAIL. This is in 
obvious contrast the finding that DCNL5 KO cells were less sensitive to WT cells to 
the same treatments and indicates that DCNL1 does not have the same role in this 
pathway as DCNL5. This finding is interesting because DCNL proteins have been 
shown to overlap significantly in function with regards to cullin interaction, with 
cullins being the main binding partners of DCNL proteins. It has been shown that 
in cells, all DCNL proteins are able to neddylate any cullin protein family member 
(Keuss et al., 2016). siRNA-mediated loss of each individual DCNL proteins had 
minimal impact on the neddylation of any of the cullin proteins and the same 
DCNL1 and DCNL5 KO cell lines used in the present research were previously used 
to demonstrate that total loss of either protein largely had no effect on the 
neddylation state of cullin proteins, showing that there is significant redundancy  
in function  of this family of proteins in cells (Keuss et al., 2016).  
There is precedent for specific roles of DCNL family members in vivo, which 
supports our assertion here that the role for DCNL5 in apoptosis may be specific 
to this family member. DCNL3 has been studied and shown to posses a unique role 
in the neddylation of cullin 3 at the plasma membrane (Meyer-Schaller et al., 
2009). We did not investigate the effect of DCNL3 knockdown, however it would 
be interesting to see if this family member is also unable to compensate for the 
loss of DCNL5 expression since caspase 8 processing at the DISC occurs at the 
plasma membrane following TRAIL signaling (Jin et al, 2009). There is also 
literature supporting a unique  role for DCNL1 in the neddylation of cullin 3 to 
promote midbody localization and activity of a cullin 3-based CRL during 
abscission (Huang et al., 2017). 
The phenotype we have characterised in this chapter is severe: lack of DCNL5 
protein expression results in a significant resistance to Bleomycin, TNFα and 
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TRAIL-mediated cell death while exhibiting a clear reduction in caspase 8 
cleavage. It remains a possibility that the N-terminus of DCNL5, which is predicted 
to be unstructured, provides a function which is specific to that family member. 
We have shown that the DAD-patch is essential for DCNL5 involvement in caspase 
8 cleavage, but the DAD-patch is a highly conserved motif within a highly 
conserved C-terminal region known as the PONY domain which is conserved across 
all DCNL proteins (Monda et al., 2013). Therefore, why can’t the other DCNL 
proteins mediate this function via their respective DAD-patches? DCNL1 and DCNL2 
are cytosolic and DCNL3 can localise to the plasma membrane, where the initial 
stages of apoptosis occur, so it is curious as to why DCNL5 has such a significant 
and unique role in this pathway since DCNL5 is also understood to be a 
predominantly nuclear protein (Keuss et al., 2016; Thomas et al., 2018). It is likely 
that the N-terminal domain of DCNL5 confers the protein with specific binding 
properties that are required for its interaction with as yet unknown proteins to 
promote caspase 8 activity. This feature is likely lacking in other DCNL proteins, 
however in order to critically evaluate this hypothesis, more information about 
the structure of DCNL5 is required. 
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4 The Role of DCNL5 Interaction in Caspase 8 
Activation 
4.1 Introduction 
4.1.1 Caspase 8  
There is some debate as to where in the cell pro-caspase 8 is stored. It has been 
shown that pro-caspase 8 localises to the cytosol (Zhivotovsky et al., 1999) and 
separately it has been shown to localise only to the mitochondria, specifically the 
inner membrane space, the intermembrane and the matrix (Qin et al., 2001). More 
recently, it was shown that pro-caspase 8 does not actually localise to 
mitochondria as had been previously reported; the researchers supported the 
finding that pro-caspase 8 as well as caspases 2, 3, 6,7 and 9 were located in the 
cytosol in 3 different models of apoptosis (van Loo et al., 2002). They concluded 
that separate compartmentalization of pro-apoptotic co-factors such as 
cytochrome c and AIF from silent precursor caspases in the cytosol provides an 
additional regulatory step in the control of the apoptosis response. 
Following TRAIL binding to its receptors (death receptor 4 or 5, DR4/5) which are 
located on the cell surface, cytoplasmic death domain regions of the receptor are 
able to recruit the death domain containing protein FADD which then leads to the 
recruitment of the initiator caspase pro-caspase 8 to form the death induced 
signalling complex (DISC). The DISC is located at the plasma membrane and 
translocates to regions of the plasma membrane termed ‘lipid rafts’. Lipid rafts 
consist of dynamic assemblies of cholesterol and sphingolipid-rich regions of the 
plasma membrane (Simons and Van Meer, 1988; Simons and Ikonen, 1997) which 
are known to be important in promoting and amplifying signal transduction 
(Simons and Toomre, 2000). Lipid rafts have been demonstrated to play key roles 
in Fas and TNFα-related cell death and inflammatory signalling events (Muppidi 
and Siegel, 2004; Legler et al., 2003; Muppidi, Tschopp and Siegel, 2004) as well 
as key roles in TRAIL-mediated apoptosis. 
DISC association with lipid rafts is an essential step in caspase 8 cleavage and 
activation, while association of the DISC in non-rafts is associated with pro-survival 
signalling via NF-κB. cFLIP an the kinase RIP1 are associated with non-rafts and 
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knockdown of cFLIP increases association of the DISC with lipid rafts and increases 
caspase 8 activation (Song et al., 2007). The importance of the association of the 
DISC with lipid rafts is further highlighted by the fact that a TRAIL-sensitive lung 
cancer cell line (H460) was used to generate a resistant sub-population of cells 
and this resistance was shown to be in part conferred by a decrease in 
translocation of DR4/DR5 into lipid rafts compared to the parental cell line 
(Ouyang et al., 2013). Thus, pro-caspase 8 association with the DISC at lipid rafts 
is a crucial step in caspase 8 cleavage. Following multiple processing events 
including ubiquitination by cullin 3, active caspase 8 is released into the cytosol 
where it is able to cleave downstream targets required for successful induction of 
apoptosis. A simple summary of caspase localisation through TRAIL signalling is 
shown in Figure 4-1 below. 
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Figure 4-1 Subcellular Localisation of Caspase 8. 
This schematic diagram shows the subcellular localisation of caspase 8 prior to and during TRAIL-
mediated apoptotic signalling. Pro-caspase 8 is understood to localise to the mitochondrion, 
specifically in the inner membrane and the intermembrane space, as well as the cytosol, in the 
absence of an apoptotic signal. TRAIL binding to death receptor 4 or 5 (1) leads to assembly of the 
death-induced signalling complex (DISC) which includes pro-caspase 8 (2). DISC assembly occurs 
at the plasma membrane in lipid rafts, and following ubiquitination and cleavage (3), active caspase 
8 hetero-tetramers are released from the DISC into the cytosol (4) to mediate downstream cleavage 
events required for apoptosis. 
4.1.2 Caspase 8 Cleavage Requires Ubiquitination Mediated by 
Cullin 3 
We have discussed the importance of the association of the DISC with lipid rafts, 
however another key regulator of caspase 8 activation is also thought to localise 
to these regions: cullin 3. Cullin 3 has been shown to be uniquely responsible for 
the only known direct and positive regulation of caspase 8 activity, in seminal 
work by Jin and colleagues (Jin et al., 2009). They showed that neddylated cullin 
3, in combination with RBX1, mediates the poly-ubiquitination of caspase 8 at 
lysine residue 461 which is located in the C-terminal region of caspase 8, within 
its p10 subunit (see Figure 4-2). They also showed that modified caspase 8 is then 
recognised by the ubiquitin binding protein p62 which translocates ubiquitinated 
caspase 8 to higher molecular weight structures corresponding to ubiquitin-rich 
aggregates. This association with p62 is thought to drive the processing and auto-
proteolytic cleavage of caspase 8 and subsequent release into the cytosol (Jin et 
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al., 2009). They demonstrated that cullin 3 knockdown reduced caspase 8 
ubiquitination however caspase 8 was still able to be recruited to the DISC. Overall 
this work emphasised the importance of this poly-ubiquitination event mediated 
by cullin 3 in promoting caspase 8 cleavage and activation. 
More recent research has shown that the de-ubiquitinating enzyme A20 reversed 
the poly-ubiquitination of caspase 8 mediated by cullin 3 which has the effect of 
impeding caspase 8-dependent cell death (Lim et al., 2017), further reinforcing 
the importance of this ubiquitination event in the activation of caspase 8. Caspase 
8 is ubiquitinated at other residues by different E3 ligases which tend to target 
the protein for degradation and therefore have anti-apoptotic effects, which 
makes studying the activation of caspase 8 complicated. We hypothesize that 
DCNL5 may play a role in the neddylation of cullin 3 which is required for its 
activity as the core of a CRL complex to mediate the poly-ubiquitination of caspase 
8.  
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Figure 4-2 Cullin 3-Mediated Ubiquitination of Caspase 8 Following TRAIL Signalling.  
This schematic overview summarises some of the key stages and interactions involved in caspase 
8 cleavage. FADD associates with death domains present on the intracellular regions of death 
receptors 4 or 5 (DR4/5), these are shown in dark grey. Pro-caspase 8 is then recruited to form the 
DISC and interacts with FADD via death effector domains (DED) shown in orange. The DISC 
translocates to lipid rafts and there cullin 3 mediates the poly-ubiquitination of caspase 8 at lysine 
461 in the C-terminal region of the p10 subunit of caspase 8. Ubiquitination at this residue is essential 
for p62 association which in turn allows for translocation of caspase 8 to ubiquitin-rich aggregates 
which allow for the auto-proteolytic cleavage of caspase 8 to form the hetero-tetramer of p10 and 
p18 subunits (known simply as p18) which is catalytically active and able to mediate downstream 
cleavage events required for apoptosis. 
4.1.3 Aims 
The aims for this chapter were initially to examine the temporal and spatial 
distribution of DCNL5 in response to TRAIL stimulation, to determine whether 
DCNL5 is located in the cytosol and whether the protein can interact with cullin 3 
in vivo. Following this, we wanted to determine whether caspase 8 ubiquitination 
was affected in the absence of DCNL5 expression, or whether ubiquitination as a 
whole was affected. Finally, we wanted to investigate whether neddylation plays 
a role in the process of caspase 8 cleavage and activation. 
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4.2 Results 
4.2.1 DCNL5 Translocates to the Cytosol Following TRAIL 
Stimulation 
Caspase 8 is a key component of the death inducing signalling complex (DISC) and 
its cleavage occurs at the plasma membrane as well as in the cytoplasm. DCNL5 
has been shown to be a predominately nuclear protein and contains a nuclear 
localisation sequence in its N-terminus, however we suspected that given the 
results thus far, DCNL5 must travel from the nucleus to the cytoplasm in response 
to TRAIL stimulation. In order to determine whether this was the case, we used 
fluorescence microscopy to track the localisation of GPF-tagged DCNL5 following 
treatment with TRAIL. We used treatment times of up to 6 hours to follow the 
movement of DCNL5 and found that the DCNL5 appeared in the cytoplasm within 
1 hour, at which point the levels appeared to be the highest, and as treatment 
time increased the amount of DCNL5 in the cytoplasm decreased. This suggested 
that DCNL5 may be shuttled out of the nucleus in response to the TRAIL stimulation 
and either shuttled back into the nucleus or degraded once the signal was no 
longer being transduced. 
While the levels of fluorescence haven’t been calculated, the images shown in 
Figure 4-3 are fairly clear and representative of what was visible under the 
microscope. GFP-tagged DCNL5 co-localises with the red dot marker as they are 
both nuclear. It can be seen clearly that after 1 hour of TRAIL treatment there is 
green fluorescence outside the nucleus which was not there in the absence of 
ligand stimulation. This experiment lacks a useful GFP-only  negative control to 
support the finding that DCNL5 is specifically responsible for the localisation of 
the detectable fluorescence. Despite this, our findings here are the first clear 
indication that DCNL5 can localise outside the nucleus and supports its role in the 
cleavage and activation of caspase 8 which occurs at the plasma membrane and 
in the cytosol. It appears that it is only a small proportion of DCNL5 that localises 
to the cytosol, however it likely only requires a small amount of the protein to 
mediate activation of caspase 8. 
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Figure 4-3 DCNL5 Localises to the Cytoplasm Following TRAIL Stimulation.  
Representative fluorescent images of GFP-tagged DCNL5 show here were obtained following plating 
of cells on coverslips and fixing them with methanol and incubating them with anti-GFP antibody as 
well as red dot nuclear stain. TRAIL was used at a concentration of 200ng/ml for treatment times of 
up to 6 hours, shown here is a 1 hour of treatment. DCNL5 co-localises with the red dot stain in the 
nucleus. Following 1-hour TRAIL treatment we can see GFP fluorescence outside the nucleus of 
cells. These images are representative of the majority of cells that were observed.  
  
151 
 
 
 
4.2.2 DCNL5 Interacts with Cullin 3 in vivo 
The established mechanism for caspase 8 activation involves its ubiquitination, 
followed by its cleavage into intermediate forms, ultimately resulting in formation 
of the catalytically active p18 hetero-tetramer. It is generally understood that this 
ubiquitination of caspase 8 is mediated by cullin 3 specifically. Various 
modifications of caspase 8 occur, including ubiquitination by other proteins, and 
the modifications can have broad effects on caspase 8 activity. Ubiquitination by 
cullin 3 is likely one of the only modifications that increases and is essential for 
caspase 8 activity. The primary binding partners of DCNL proteins are cullins, and 
given that we have already shown that the role of DCNL5 is likely not only unique 
amongst the DCNL proteins, but also requires the DAD-patch to confer sensitivity 
to TRAIL (and TNFα) (since the DAD-mutant cells are as resistant if not more-so 
than KO cells), we suspected that DCNL5 may be directly required for cullin 3 
neddylation and thus its activity as part of the ubiquitin E3-ligase complex. 
It has already been shown that all DCNL proteins can interact with all cullin 
proteins in vitro (Monda et al., 2013; Keuss et al., 2016), however little evidence 
exists for specific roles for individual DCNL proteins in cells. We set out to 
determine if there is any interaction between DCNL5 and cullin 3 by co-
immunoprecipitation. We started by precipitating cullin 3 and probing for 
interaction with DCNL5 by western blot. As can be seen in Figure 4-4, faint bands 
at approximately 27kDa and 52kDa can be seen in the WT and WT-rescue cells 
respectively. These have been highlighted using red asterisks for clarity as the 
DCNL5 poly-antibody produces a lot of unspecific bands. These bands at 27kDa and 
52kDa represent DCNL5 and GFP-tagged DCNL5 in the inducible rescue cell line 
and are absent in KO cells and DAD-mutant cells, the latter of which are unable 
to bind to cullin proteins, in this case cullin 3.  
There appears to be interaction of the two proteins prior to stimulation with 
TRAIL, and this interaction increases somewhat with TRAIL treatment although it 
is hard to say accurately. This represents the first evidence for a specific 
interaction of DCNL5 with cullin 3 in cells and supports its potential role in 
mediating the neddylation of the protein in order to enable ubiquitination of 
caspase 8. The interaction that we have been able to detect here is weak, and 
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this is likely due to the small amounts of both DCNL5 and cullin 3 that are 
interacting in response to TRAIL stimulation. The amount of DCNL5 that diffused 
out of the nucleus was small, and it is known that specific subcellular pools of 
cullin proteins mediate specific functions. DCNL5 will also interact with other 
cullin protein to mediate other functions, while other DCNL proteins will interact 
with cullin 3 in other cellular processes. Further experimental work is required to 
better elucidate this interaction between DCNL5 and cullin 3 and to determine if 
this interaction increases with TRAIL treatment. 
 
Figure 4-4 Cullin Interacts with DCNL5 in vivo.  
This representative western blot (n = 2) shows the result of immunoprecipitating cullin 3 (using 1μg 
of antibody) and its interaction with DCNL5 following 100ng/ml TRAIL treatments. The 
immunoprecipitation was successful and the amount of cullin 3 that was pulled down was consistent 
across treatment time points and cell lines. There appears to be no major change in amounts of 
neddylated (upper band) and un-neddylated (lower band) cullin 3. The red asterisks highlight bands 
at 27 and 52kDa representing DCNL5 and GFP-DCNL5 which are expressed in WT and WT-rescue 
cells, respectively. DCNL5 KO cells do not express the protein and therefore show no interaction 
with cullin 3, while the DAD-mutant rescue cells are unable to bind cullin proteins and therefore no 
interaction is detected here. This represents a good control for the cell line. The western blot has a 
lot of unspecific bands. IP = immunoprecipitation, IB - immunoblot 
We also wanted to confirm the reverse of this interaction by pulling on DCNL5 and 
detecting whether cullin 3 co-immmunoprecipitates with it. We were able to 
detect cullin 3 as an interactor by western blot as shown in Figure 4-5, however 
the interaction was very weak. The neddylated (upper band) and un-neddylated 
(lower band) forms of cullin 3 have been highlighted as the bands are faint and 
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hard to detect. This weak interaction is due in part to likely low amounts of DCNL5 
being immunoprecipitated, as well as the relatively small pools of both DCNL5 and 
cullin 3 that are interacting. The low amounts of cullin 3 make it difficult to 
determine whether there is an increase in interaction following TRAIL treatment 
– although this appears to be the case and is consistent with what we saw in the 
previous figure. Also shown in the figure are the inputs, and the reduction in pro-
caspase 8 indicates successful induction of the pathway and cleavage of the 
protein. This data along with the data in Figure 4-4 provide evidence of the 
interaction (albeit a weak one) between DCNL5 and cullin 3 in cells. Further work 
would be required to investigate if this interaction changes with treatment and if 
so by how much, including crosslinking, which could be employed to stabilise 
transient interactions and may thus allow for improved detection of interaction 
between cullin 3 and DCNL5.   
 
Figure 4-5 DCNL5 Co-IP Shows Interaction with Cullin 3.  
DCNL5 was immunoprecipitated prior to TRAIL treatment (of 200ng/ml) and following 1 hour of 
treatment and cullin 3 was shown to interact weakly (red boxes) in both cases, as shown here by a 
representative western blot.The upper, neddylated band of cullin 3 as well as the lower un-
neddylated band can be seen. Cullin 3, DCNL5 and caspase 8 inputs were analysed by western blot 
and the reduction in full length caspase 8 is consistent with induction of apoptosis. IP = 
immunoprecipitation, IB = immunoblot 
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4.2.3 DCNL5 KO and DAD-Mutant Cells Exhibit Less Caspase 8 
Interaction with Cullin 3 
In this project we have already shown that DCNL5 KO cells and DCNL5 DAD-mutant 
cells exhibit a resistance to TRAIL-induced apoptosis and a reduction in caspase 8 
cleavage. Cullin 3 is responsible for mediating the ubiquitination of caspase 8 and 
these two proteins are known to interact directly. We wanted therefore to confirm 
this interaction in U2OS cells and to see if there were any differences in this 
interaction in DCNL5 KO or DAD-mutant cell lines. We investigated the interaction 
of caspase 8 with cullin 3 by co-immunoprecipitation and the results are shown in 
Figure 4-6 below. Caspase 8 was shown to interact with cullin 3 in all cell lines, 
most of the interaction was mediated by the full length p55/53 fragment of the 
protein. Overall, there is little difference in the amount of p55/53 caspase 8 
interacting with cullin 3 between the cell lines or treatment times, there is 
possibly a small drop between 1 and 3 hours of TRAIL stimulation in the WT cells 
but further optimisation would be required to state this definitively.  
1 hour of TRAIL treatment seems to result in no interaction between p43/41 
caspase 8 to and cullin 3. Despite this we can observe more pronounced 
differences in the amount of p43/41 caspase 8 that co-precipitated with cullin 3 
after 3 hours of TRAIL treatment (highlighted by red asterisks in Figure 4-6). There 
appear to be lower levels of this fragment precipitating in KO cells than WT and 
WT-rescue cells, while DAD-mutant cells have almost no protein at all. This is 
largely consistent with previous data which shows that caspase 8 cleavage is 
impaired in DCNL5 KO cells. It is difficult to interpret the significance of this result 
but it is clear that there is a difference between WT and KO cells which is even 
more pronounced in the DAD-mutant cells. We can also conclude that the lack of 
DCNL5 expression has no effect on the interaction of cullin 3 with caspase 8. 
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Figure 4-6 DCNL5 KO and DAD-Mutant Cells Appear to Show a Reduction in p43/41 Caspase 
Interaction with Cullin 3 Following TRAIL Stimulation.  
This cullin 3 co-immunoprecipitation experiment confirmed interaction of caspase 8 with cullin 3 in 
vivo using U2OS cell lines. The amount of full-length caspase 8 (p55/53) that interacts with cullin 3 
is largely unchanged across treatment times and cell lines. There is possibly a reduction between 1- 
and 3-hour treatment in the WT cells. The cleaved form of caspase 8, p41/41, appears to interact 
more strongly with cullin 3 following 3 hours of TRAIL treatment in WT and WT-rescue cells, less so 
in KO cells and there is almost no protein present in the DAD-mutant cells. These results hint at a 
difference in cleaved caspase 8 interaction with cullin 3 between WT and KO DCNL5 cells but overall 
confirm that interaction of full-length caspase 8 with cullin 3 is unaffected by DCNL5 expression. IP 
= immunoprecipitation, IB = immunoblot 
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4.2.4 Caspase 8 Does Not Co-Precipitate with DCNL5 
It remained a possibility that DCNL5 can bind directly to caspase 8 in some sort of 
structural role, so we wanted to investigate whether the two proteins interact. 
We performed another IP using caspase 8 and probed for DCNL5 in the same way 
as we did for the cullin 3 co-IP reaction. The resulting western blot is shown below 
in Figure 4-7. The IP was successful as caspase 8 is present in the immunoblot and 
the amount of protein in each lane is relatively similar. Blotting for DCNL5 
revealed non-specific bands (indicated on Figure 4-7 with asterisks) however no 
DCNL5 was co-precipitated. DCNL5 is present in the input confirming that this was 
not due to an issue with the antibody. It is possible that the level of DCNL5 present 
was too low to detect, or simply that DCNL5 does not interact in a complex with 
caspase 8. This experiment lacks a useful positive control to confirm successful 
immunoprecipitation (such as cullin 3), and given the small amounts of DCNL5 that 
are involved in interacting with caspase 8 in this process, it perhaps unsurprising 
that we were unable to detect interaction of any sort with caspase 8 if this 
interaction is bridged by cullin 3.  
 
Figure 4-7 DCNL5 Does Not Interact Directly with Caspase 8.  
This western blot shows the result of a caspase immunoprecipitation experiment. The IP appears to 
have worked given the presence of caspase 8 in the IP samples. DCNL5 appears not to interacts as 
there is no protein present in the IP samples – non-specific bands of similar sizes are present and 
have been highlighted using a red asterisk for clarity. The expected size of DCNL5 is 27kDa and a 
corresponding band is present in the input (WT cells) for this experiment. IP = immunoprecipitation, 
IB = immunoblot 
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4.2.5 Caspase 8 Co-Precipitates with a Ubiquitinated Protein in WT 
but not KO Cells 
Caspase 8 ubiquitination is essential for its activation and we suspected that in 
DCNL5 KO cells there may be a lack of this modification occurring. A useful way 
to observe ubiquitination of proteins is to perform immunoprecipitation reactions 
under denaturing conditions, which disrupts binding to other proteins but still 
allows for the interaction of covalent modifications such as the addition of 
ubiquitin. We used lysis buffer containing 1% SDS to denature protein lysates 
before diluting the lysates down to 0.1% SDS and incubating overnight with 
antibody. Due to the loss of tertiary structure under denaturing conditions, we 
used a caspase 8 antibody that had been shown to bind successfully following 
denaturing of the protein lysate (ref Lim et al, 2017). Previous work looking at 
caspase 8 ubiquitination by denaturing immunoprecipitation used TRAIL 
stimulation at 4°C in order to stabilise aggregate formation and improve detection 
of modifications (Jin et al., 2009). We did not do this which may account for the 
lack of signal and difficulty obtaining consistent results for this experiment.  
Several attempts at this experiment were made and one set of results is shown 
below in Figure 4-8 – the results presented are not conclusive however provide 
some insight into what may be happening in the KO cells. In Figure 4-8A we probed 
for caspase 8 by immunoblot to confirm the immunoprecipitation was successful. 
The amount of caspase 8 present in all lanes is very low, which was a consistent 
theme in optimisation of this experiment, and furthermore the level varied 
between cell lines and treatment times. WT untreated cells precipitated 
significantly more caspase 8 than any of the other conditions. Figure 4-8B shows 
an immunoblot probing for ubiquitin and we were able to detect ubiquitin ‘smears’ 
(indicated by the red bracket); it is clear that the levels of ubiquitin bound to 
caspase 8 varies. WT cells appear to show a drop in ubiquitination following TRAIL 
stimulation for 30 minutes but factoring in how much less caspase 8 was 
precipitated in the 30 minute time point compared to untreated, it is likely that 
there is little change in ubiquitination following treatment, or perhaps even an 
increase.  
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The discrepancy in the amount of caspase 8 that was precipitated for this 
experiment may arise from the masking of the epitope due to the modification by 
ubiquitination – TRAIL stimulation may indirectly impair the ability of the antibody 
to bind to caspase 8 The DCNL5 KO cells appear to show a significant drop in 
caspase 8 ubiquitination following TRAIL stimulation, and given the similar 
amounts of caspase 8 that were precipitated with and without TRAIL treatment in 
the KO cells, this result seems accurate. When comparing TRAIL treated WT and 
KO cells (lanes 2 and 4 in Figure 4-8B) and factoring in the differences in caspase 
8 that was precipitated (as shown in Figure 4-8A), there does seem to be less 
caspase 8 being poly-ubiquitinated in KO cells compared to the WT cells. There is 
a band just below 100kDa which is present in fairly equal amounts in all lanes 
which is of unknown origin. It is possible that it represents caspase 8 
polyubiquitination (approximately 5 ubiquitin molecules in addition to pro-caspase 
8) or it could also represent some sort of caspase 8 dimer. Given that the levels 
are broadly similar in all lanes it is perhaps non-specific binding by the antibody 
and could therefore be used as an approximate loading control, in which case the 
ubiquitin levels we observe are reasonably comparable. 
Significant caution needs to be advised when interpreting these results, the aim 
for these results was to determine if the KO cells are lacking in caspase 8 poly-
ubiquitination in response to TRAIL, and while there does appear to be a reduction 
in caspase 8 modification, further optimisation and experimental validation is 
required. The overall significance of this is unclear, there are different ubiquitin 
modifications of caspase 8 that occur, so it remains difficult to analyse these 
results in isolation. There appears to be a difference in ubiquitination state of 
caspase 8 following TRAIL stimulation between WT and KO cells, but given that 
this experiment is often done at 4°C it is possible that we are not detecting all of 
the modified caspase 8. Overall, these results indicate that KO cells are lacking in 
ubiquitination of caspase 8 but additional experimental evidence and optimisation 
is required. 
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Figure 4-8 Denaturing Immunoprecipitation Proved Inconclusive.  
(A) This representative caspase 8 immunoblot following denaturing immunoprecipitation shows that 
low levels of caspase 8 were precipitated in all lanes, with significantly more present in WT untreated 
cell than other conditions, perhaps due to the reduced stability of the protein upon ubiquitination. (B) 
Ubiquitination of caspase 8 is shown in this immunoblot and is often referred to as a ubiquitin ‘smear’ 
(indicated by the red bracket) and the levels vary significantly. TRAIL treatment causes a drop in 
ubiquitination in both WT and KO cells, however less caspase 8 was precipitated in WT treated cells 
suggesting that overall, the level of ubiquitination may in fact be the same or even increased with 
treatment. The reduction in ubiquitination in the KO cells following TRAIL stimulation appears to be 
a real result and may indicate a reduced ability of these cells to undergo caspase 8 ubiquitination in 
response to TRAIL, but the reason for this drop is uncertain. IP = immunoprecipitation, IB = 
immunoblot 
A 
B 
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Another method that can be used to analyse caspase 8 ubiquitination involves 
tandem ubiquitin binding entities (TUBEs) which consist of multiple ubiquitin 
binding associated domains (UBAs) which have an extreme high affinity (in the 
nanomolar range) for poly-ubiquitin chains. The UBA domains are derived from 
ubiquilin 1 which is a poly-ubiquitin binding protein that plays a role in protein 
quality control. Ubiquilin proteins consist of a C-terminal UBA domain and an N-
terminal ubiquitin-like (UBL) domain TUBEs can be conjugated to beads of various 
types, and are available to buy commercially, however the ones we used were 
made previously in our laboratory and are conjugated to HALO beads. TUBEs allow 
for the enrichment of poly-ubiquitinated proteins (preferentially over mono-
ubiquitinated proteins) from lysates as well as serving protective purposes to 
inhibit the degradation of these chains. In our experiment, we used TUBEs which 
were previously purified and then conjugated to magnetic HALO beads by Roland 
Hjerpe, a former post-doctoral researcher in the group (Hjerpe et al., 2009). We 
then used these beads in the same way as antibody-conjugated beads for 
immunoprecipitation reactions. 
Figure 4-9A shows a simplified schematic diagram summarising how poly-
ubiquitinated proteins, in this case caspase 8, bind to the TUBE-conjugated beads. 
Individual ubiquitin molecules are added to target substrates to form chains and 
are linked by lysine residues. Poly-ubiquitin chains have various purposes in cells 
and often signals proteins to be degraded by the 26S proteasome. In the context 
of cullin 3-mediated ubiquitination of caspase 8, this modification is a required 
step for cleavage of the protein. These ubiquitin chains have a high affinity for 
the UBA domains of the TUBEs so they bind tightly and form complexes which can 
be eluted from the beads. Given that caspase 8 is known to become ubiquitinated, 
the hypothesis was that we would precipitate much more caspase 8 in WT DCNL5 
cells than the KO cells if the latter lacked modification of caspase 8 as we 
suspected. 
Figure 4-9B confirms the successful application of the HALO-TUBE beads in a 
‘pulldown’-type experiment. We can clearly see large amounts of ubiquitin in WT 
and KO cells before and after TRAIL treatment of 30 and 60 minutes. There is no 
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real difference in ubiquitination, but it is important to remember that this is 
essentially global poly-ubiquitin levels we are detecting here. The amount of 
ubiquitin is much higher in the pulldowns than in the whole cell lysate which is 
expected given that we are strongly enriching for this modification. Having shown 
that the TUBEs had successfully precipitated ubiquitinated proteins, we looked to 
see if we could detect caspase 8 in the enriched lysates. Probing the same samples 
with caspase 8 antibody yielded an unexpected result. As can be seen in Figure 
4-9C, there is no caspase 8 present in any of the KO cell conditions. WT cells also 
lack any caspase 8 in the absence of TRAIL stimulation as well as after 30 minutes 
of stimulation, however after 60 minutes we see the p43/41 caspase 8 fragment 
co-precipitating as well as a small amount of pro-caspase 8. Pro-caspase 8 has 
been highlighted with a red box while a red asterisk indicates the p43/41 fragment 
more clearly. Figure 4-9D shows the inputs from this experiment which confirm 
that global pro-caspase 8 levels are similar in both cell lines and at all treatment 
time points. 
If we were detecting modified caspase 8, we would expect to see a ‘smear’ of 
protein of higher molecular weight representing poly-ubiquitinated protein, likely 
similar but less strong than the ubiquitin blot shown in Figure 4-9B. Instead we are 
seeing unmodified caspase 8, and mostly the intermediate cleaved form at that. 
This indicates that pro-caspase 8 and p43/41 caspase 8 are interacting with a 
protein that is poly-ubiquitinated in response to TRAIL in WT but not KO cells. The 
fact that we detect mostly p43/41 caspase 8 is unsurprising since this form is more 
stable and associates with the DISC while the fully active p18 form is unstable and 
is not associated with the DISC. The presence of pro-caspase 8 in WT cells indicates 
that this un-cleaved form of caspase 8 interacts with ubiquitinated protein(s). 
Since pro-caspase 8 is also present in KO cells as we have shown previously, the 
lack of caspase 8 cleavage may arise due to a lack of the interaction between un-
modified caspase 8 and a ubiquitinated protein which may be a significant finding.  
As with the denaturing immunoprecipitation reactions in this section, TRAIL 
treatment can be performed at 4°C which tends to amplify signal and preserve 
caspase 8 ubiquitination and prevents degradation which may have enabled us to 
get a clearer picture of what is happening here. It is possible that we would not 
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only detect more caspase 8 in this experiment at 4°C, but we may also be able to 
detect interaction in KO cells in the event that these cells undergo more rapid 
caspase 8 degradation. We may have also been able to better detect the pro-
caspase 8 fragment. It is also possible that un-modified caspase 8 binds to poly-
ubiquitinated caspase 8 however we are below the detection threshold for the 
modified form. From this data, we can conclude that the KO cells are lacking in a 
ubiquitination event but we cannot say clearly whether this is a lack of caspase 8 
ubiquitination or if is the ubiquitination of a caspase 8-interacting protein such as 
FADD. 
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Figure 4-9 Caspase 8 Co-Precipitates with a Ubiquitinated Protein in WT but not KO DCNL5 
Cells.  
(A) This schematic diagram shows the interaction between poly-ubiquitin chains on caspase 8 and 
the TUBEs which are conjugated to HALO beads. This allows for enrichment of ubiquitinated proteins 
from lysates and more efficient detection of modified proteins. (B) This western blot shows the result 
of incubating protein lysates with HALO-TUBE conjugated beads. Ubiquitin ‘smears’ representing 
total ubiquitinated proteins in the lysate, are present in both cell lines and in the presence and 
absence of TRAIL. The levels are broadly similar in all cases, and the ubiquitin signal is much higher 
in the pulldowns than in the whole cell lysate (WCL). (C) This blot shows the result of probing the 
same samples with caspase 8 antibody. The only lane that shows any protein, apart from the whole 
cell lysate, is WT cells after 60 minutes of TRAIL treatment. Interestingly we detect unmodified p43/41 
caspase 8 mostly as well as a small amount of pro-caspase 8, which may indicate that this co-
precipitates with a protein that is ubiquitinated which was pulled down by the TUBEs. (D) This blot 
shows pro-caspase 8 inputs from this experiment confirming that pro-caspase 8 levels are similar in 
all lanes. Data shown in (B), (C) and (D) are representative of two independent experiments (n = 2). 
IB = immunoblot 
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4.2.6 MLN4924 Treatment Does Not Fully Inhibit Caspase 8 
Cleavage 
The role of cullin 3 in caspase 8 activation has been detailed extensively and it 
has previously been shown that overexpressing cullin 3 increases caspase 8 
ubiquitination while siRNA-mediated knockdown of cullin 3 reduces this 
modification (ref Jin et al, 2009). We explore modulation of cullin 3 and DCNL5 
levels in different cancer cell lines in Chapter 5, however we wanted to determine 
whether the neddylation state of cullin 3 had an affect on caspase 8 cleavage in 
U2OS cells. Cullin proteins required neddylation to form active Cullin-RING ligase 
complexes which mediate ubiquitination. We therefore wished to test if inhibiting 
the neddylation of cullin 3, which would then render the CRL it forms the core of 
inactive, and thus inhibit ubiquitination of caspase 8 By using the neddylation 
inhibitor MLN4924, used previously in this project, we were able to inhibit 
neddylation of cullin proteins, including cullin 3. We pre-treated DCNL5 WT and 
KO cells with MLN for one hour followed by stimulation with TRAIL (and included 
an MLN-free control) and the resulting western blot can be seen in Figure 4-10.  
Cullin 3 shows an upper, neddylated band and a lower, un-neddylated band in the 
absence of MLN treatment. With treatment, only the lower band is present due to 
the global inhibition of neddylation - this can be seen clearly from the cullin 3 
immunoblot. In the WT cells, we observe the presence of p43/41 caspase 8 in the 
absence of TRAIL stimulation. The level increases slightly with 60-minute TRAIL 
treatment while formation of catalytically active caspase 8 (p18) can be seen as 
well. Crucially, pre-treatment with MLN reduces but does not entirely inhibit 
formation of p18 caspase 8 in the WT cells. This suggests that while cullin 
neddylation is important for caspase 8 cleavage, it is not absolutely required. This 
is the first indication that un-neddylated cullin 3 (whose neddylation was inhibited 
by MLN4924) has a function in caspase 8 activation and is also the first indication 
of a functional role for cullin proteins that does not require their neddylation. The 
DNCL5 KO cells show basal p43/41 caspase 8 levels in the absence of TRAIL 
stimulation, like the WT cells, but significantly less. These levels are unaffected 
by TRAIL stimulation or by MLN treatment, further confirming that DCNL5 is 
required for caspase 8 cleavage. This data together suggests that the role of 
DCNL5 is more important than the role of neddylated cullin 3, however the 
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question remains whether the role of DCNL5 and the effect of MLN4924 treatment 
are the same in other cell lines. 
 
Figure 4-10 MLN4924 Treatment Reduces But Does Not Fully Inhibit Caspase 8 Cleavage.  
This representative western blot shows the effect of MLN4924 on cullin 3 neddylation and on caspase 
8 cleavage. Successful inhibition of neddylation can be seen by the presence of only the lower (un-
neddylated) molecular weight band of cullin 3 being present following pre-treatment with the drug. 
60 minutes of TRAIL treatment causes cleavage of caspase 8 to form the active p18 fragment, and 
this is reduced but not entirely inhibited by MLN treatment. This suggests that un-neddylated cullin 3 
can mediate some of the function required to activate caspase 8. DCNL5 KO cells show basal levels 
of p41/41 caspase cleavage, as in the WT cells, only less protein is evident in the KO cells. As has 
been consistent in the data thus far, TRAIL stimulation causes no caspase 8 cleavage in the KO 
cells. It appears that the role of DCNL5 is more crucial for full caspase activation than neddylated 
cullin 3. IB = immunoblot 
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4.3 Discussion 
4.3.1 Summary 
The key aim of this chapter was to begin to establish a mechanism for the role of 
DCNL5 in caspase 8 cleavage and activation. We initially showed that DCNL5 is 
able to translocate from the nucleus to the cytosol upon TRAIL stimulation, 
providing the first piece of evidence for a role of the protein outside of the 
nucleus. We were also able to show that DCNL5 and cullin 3, the known cullin 
protein responsible for caspase 8 activation, were able to interact in cells 
representing one of the first known specific interactions of DCNL5 in cells. We 
detected an indication that there may be reduced levels of caspase 8 interacting 
with cullin 3 by immunoprecipitation in DCNL5 KO and DAD-mutant cells, 
suggesting that the lack of caspase 8 cleavage in these cells may be due to a 
reduced interaction between cullin 3 and caspase 8, however the data was not 
overly clear. From our preliminary data, we were unable to determine whether 
caspase 8 and DCNL5 interact in vivo, further experimental work would be 
required to probe this interaction further.  
We used TUBEs to pull on ubiquitinated caspase 8 in cell lysates treated with and 
without TRAIL and found that DCNL5 KO cells lack interaction with a ubiquitinated 
protein that binds to caspase 8, suggesting that ubiquitination of at least one 
protein within the DISC is lacking in the absence of DCNL5 expression. It is possibly 
that caspase 8 or another protein became de-ubiquitinated during the purification 
of the KO cells however this is unlikely since the presence of the TUBEs are known 
to protect lysates from DUB activity (Hjerpe et al., 2009). Given the importance 
of cullin 3 in mediating the ubiquitination of caspase 8 at the DISC, we sought to 
evaluate the role of neddylation in the process. We used the NAE inhibitor 
MLN4924 to inhibit the neddylation of cullin proteins in WT and KO cells prior to 
TRAIL stimulation. KO cells showed no caspase cleavage following TRAIL treatment 
in the absence of presence of MLN. WT cells showed a reduction but not a total 
loss of caspase 8 cleavage (specifically the p18 fragment) indicating that cullin 
neddylation is not absolutely required for the ubiquitination and activation of 
caspase 8. This last finding suggests that the role of cullin 3 in this pathway may 
somehow occur independently of its ability to form CRL complexes since 
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neddylation is an essential step in that process. The complex may also be present 
but inactive in the absence of neddylation, but it is possible that this particular 
CRL does not require neddylation for its activity. What would the neddylation-
independent role of this CRL be? Perhaps it functions as a nexus for recruitment 
of other proteins which are involved in promoting caspase 8 cleavage and 
ubiquitination. Perhaps another E3 ligase with common components to this cullin-
3 CRL requires anchoring to caspase 8 and thus lack of neddylation of cullin 3 has 
little impact on caspase 8 cleavage. Questions also remain about the half life of 
the complex as well as the substrate adaptors involved in this ubiquitination event 
of caspase 8. 
 
Figure 4-11 Predicted Role of DCNL5 in Caspase8 Activation.  
Based on the data presented in this chapter, it remains possible that DCNL5 is required for the 
neddylation of cullin 3 which in turn allows for the ubiquitination of caspase 8 which leads to its 
cleavage and activation. We have shown that DCNL5 interacts with cullin 3 in vivo and we have 
demonstrated that DCNL5 KO cells lack ubiquitination of a protein which interacts directly with 
caspase 8. This raises the possibility that DCNL5 is involved in mediating the neddylation of another 
substrate which regulates caspase 8 activity, however the finding that MLN4924 does not totally 
ablate caspase 8 cleavage may suggest a cullin-independent mechanism governing caspase 8 
cleavage or a role for cullins which is independent of their neddylation. 
4.3.2 DCNL5 Has Roles Outside the Nucleus 
DCNL5 is known to be a predominantly nuclear protein and contains a nuclear 
localisation sequence in its N-terminus (Keuss et al., 2016). As mentioned in 4.1.1, 
caspase 8 localisation is known to vary prior to and during apoptotic signalling. 
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Pro-caspase 8 is thought to be predominantly localised to the mitochondria, and 
has been shown to be released into the cytosol upon TNFα treatment, however 
other research has shown that pro-caspase 8 is already localised to the cytosol 
prior to any apoptotic stimulation (Zhivotovsky et al., 1999). Caspase 8 is well 
characterised as being cleaved and activated at the DISC in extrinsic apoptosis 
signalling, which is localised at the plasma membrane (Beaudouin et al., 2013). 
Active caspase 8 is then released to the cytosol where it can cleave downstream 
proteins such as caspase 3 and BID.  
We were able to show using fluorescence microscopy that DCNL5 diffuses into the 
cytoplasm following stimulation with TRAIL and that this movement occurred 
within 1 hour of stimulation. This finding supports our model of DCNL5 playing a 
direct role in caspase 8 cleavage and activation and provides new evidence for the 
cytosolic localisation of DCNL5 following initiation of the apoptosis response. 
Furthermore, this finding raises the question of why DCNL1 is unable to mediate 
this function of DCNL5. DCNL1 localises to the cytosol and is known to be able to 
interact with cullin 3 in vivo, and inhibitors targeting the N-terminal acetylation 
site of the NEDD8 E2 UBC12 (UBE2M) specifically reduce cullin 3 neddylation over 
other cullin proteins in cells (Zhou et al., 2017). We have shown that DCNL1 KO 
cells are equally sensitive to TRAIL and more sensitive to TNFα-mediated apoptosis 
compared to WT cells which is at odds with the DCNL5 data. DCNL3, which is 
located at the plasma membrane (Meyer-Schaller et al., 2009) may not be able to 
overcome absence of DCNL5 expression however we have not specifically 
investigated the role of DCNL3 in this response. We hypothesize that given the 
structural similarities and known overlap in function of DCNL proteins in vitro 
(Keuss et al., 2016), we are likely looking at a highly specific role for DCNL5 in the 
activation of caspase 8. This may be mediated by its N-terminus which may be 
required for interaction with the DISC. The fact that MLN4924 treatment shows 
less of an effect than lack of DCNL5 expression indicates we may be observing a 
neddylation-independent function for DCNL5 which is mediated by its N-terminus 
while still requiring its binding to cullins via its DAD-patch. 
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4.3.3 DCNL5 Interacts with Cullin 3 in Cell Extracts  
The established mechanism of caspase 8 cleavage requires its ubiquitination as an 
initial step in its activation and this is mediated by a cullin 3-based E3 ligase in 
combination with RBX1 (Jin et al., 2009). Cullin proteins require neddylation for 
their activation and we had postulated that the role of DCNL5 may be in 
facilitating this neddylation process. In order to test this hypothesis, we needed 
to demonstrate that DCNL5 and cullin 3 were able to interact in vivo. All DCNL 
proteins have been shown to interact with all cullin proteins in vitro (Keuss et al., 
2016) and there have been accounts of specific roles for individual DCNL proteins 
in combination with a specific cullin protein in vivo as discussed in section 4.3, 
however there appears to be little evidence for DCNL5-specific functions, outside 
of its potential role in the DNA damage repair pathway upon which this project 
was initially based.  
We were able to confirm that DCNL5 interacts with cullin 3 in vivo using 
endogenous protein levels, which is the first evidence of this interaction without 
overexpressing the proteins. The interactions appeared to be weak, which is 
perhaps not surprising given the relatively small amounts of DCNL5 we were able 
to detect translocating out of the nucleus in Figure 4-3 and given the specific 
nature of the cullin 3 pools required to mediate ubiquitination of caspase 8. In 
addition to detecting this interaction, we found that there appeared to be a slight 
increase in interaction between DCNL5 and cullin 3 following TRAIL stimulation, 
consistent with an increase in caspase 8 processing and thus further highlighting 
the importance of DCNL5 involvement. This represents a new role for DCNL5 and 
raises the question of why DCNL3 which localises to the plasma membrane and is 
known to interact with cullin 3 (Meyer-Schaller et al., 2009) is unable to 
compensate for the lack of DCNL5 expression in the KO cells to perform the same 
function. Further experiments are required to verify that DCNL3 does not interact 
with cullin 3 in response to TRAIL stimulation is required, perhaps by using siRNA-
mediated gene silencing and examining the level of caspase 8 cleavage when 
DCNL3 expression is inhibited. It remains a possibility that part of the N-terminal 
domain of DCNL5 contains sequences responsible for binding to a specific protein 
or proteins within the DISC which other DCNL proteins do not have. More recent 
evidence has suggested that despite the similarity of the conserved C-terminal 
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PONY domains of the DCNL proteins, not all DCNL protein interact with the NEDD8 
E2 family in the same way (Monda et al., 2013) which suggests that there may be 
unique binding properties of DCNL5 which have yet to be uncovered. DCNL5 crystal 
structure would provide significant insight into the structural differences between 
this protein and the other DCNL family members and may elucidate new binding 
pockets and interaction domains capable of mediating DCNL5’s role in apoptosis. 
Our approach to investigating the interaction of DCNL5 with cullin 3 was inherently 
biased but was based on the well established and well studied role of cullin 3 in 
mediating caspase 8 cleavage and apoptosis induction. Future work needs to be 
undertaken to screen for other protein-protein interactions which are affected by 
the absence of DCNL5 expression, perhaps by looking at more general changes in 
the proteome in DCNL5 KO compared to WT cells in response to TRAIL stimulation 
using a mass spectrometry-based proteomics screen. It may well be that other 
cullins interact with DCNL5 during apoptosis and some of our data in the following 
chapters provides initial evidence of this assertion, and a proteome-wide screen 
would be an invaluable tool in further investigating this in an unbiased manner. 
4.3.4 DCNL5 DAD-Patch Interaction is Required for Caspase 8 
Cleavage 
Previously we showed that DCNL5 KO cells as well as DAD-mutant cells exhibit 
significantly less caspase 8 cleavage than WT cells and this loss of caspase activity 
mirrors the reduced sensitivity to apoptosis when measured using a viability assay. 
The question we wanted to answer was whether caspase 8 is unable to interact 
with cullin 3 in the absence of DCNL5 and whether there are differences in the 
amounts of protein interacting. Given the unique role of DCNL5 in this pathway 
we considered the fact that DCNL5 may play a structural role in anchoring or 
recruiting proteins to the DISC and in the absence of DCNL5 DISC assembly may be 
compromised. 
We performed an immunoprecipitation reaction using cullin 3 to investigate its 
interaction with caspase 8. This interaction has been well studied before in other 
cell lines (Jin et al., 2009) however to our knowledge U2OS cells haven’t been 
used previously. We were able to demonstrate an interaction between cullin 3 and 
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caspase 8 (as shown in Figure 4-6) and we detected a noticeable difference in the 
amount of caspase 8 interacting with the different cell lines. DCNL5 KO and DAD-
mutant cells showed less p43/41 caspase 8 interacting with cullin 3. This form of 
caspase 8 is an intermediate cleavage product and suggests that DCNL5 is not 
required for the interaction of caspase 8 and cullin 3 since the amount of un-
cleaved caspase 8 interacting with cullin 3 is largely the same. DCNL5 does 
however appear to play a role in caspase 8 cleavage and it does this in a cullin-
dependent manner, since DAD-mutant cells show even less p43/41 caspase 8 
interacting with cullin 3 than the KO cells. 
We attempted to verify whether DCNL5 can interact directly with caspase 8, since 
there is precedent for the role of NEDD8 in caspase activation. Caspase 1 has been 
shown to require neddylation for efficient self-cleavage to generate its 
catalytically active subunits following inflammasome activation, however the 
research involved overexpression and as such the result may not be physiological 
(Segovia et al., 2015).  The researchers did show however that MLN4924 was 
capable of diminishing caspase 1 processing and reducing IL-1β maturation which 
occur as a direct result of inflammasome activation. In the present work, we used 
an immunoprecipitation reaction, pulling on caspase 8 and subsequently probing 
for DCNL5 and were unable to detect any interaction. This experiment was only 
performed once, and the amount of caspase 8 which was precipitated was 
relatively low, therefore the likelihood of detecting any interaction with DCNL5 
was also low. Given the small amount of DCNL5 that is present during the apoptosis 
response, it would likely require a lot more material to properly detect an 
interaction and this finding requires further validation. It therefore remains a 
possibility that there is some direct interaction between DCNL5 and caspase 8.  
4.3.5 DCNL5 KO Cells Appear to Lack Ubiquitination in Response 
to TRAIL Stimulation 
As highlighted in section 4.1.2, caspase 8 activation requires its dimerization and 
subsequent cleavage to form catalytically active caspase 8 which is then able to 
induce the downstream events that are required for successful apoptosis. We have 
previously sown that DCNL5 KO and DAD-mutant cells lack caspase 8 cleavage in 
response to TRAIL and TNFα and this lack of caspase 8 activity likely confers 
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resistance to apoptosis as measured by viability assay. In this results chapter we 
present evidence for the interaction between cullin 3 and DCNL5 in vivo which 
supports a mechanism whereby DCNL5 is required for the neddylation of cullin 3 
in its complex with RBX1 and as yet unknown substrate adaptors to mediate the 
poly-ubiquitination of caspase 8 at lysine 461 by both K48 and K63 linkages (Jin et 
al., 2009). 
The finding that less cleaved caspase 8 interacts with cullin 3 in KO and DAD-
mutant cells indicates that there is a reduction of caspase 8 cleavage occurring in 
these cell lines. To further investigate this finding we attempted to analyse the 
extent of caspase 8 ubiquitination by using a denaturing immunoprecipitation 
reaction, adapted from the one employed by Lim and colleagues who studied the 
ubiquitination of caspase 8  in cells infected with Helicobacter pylori (Lim et al., 
2017). The premise of performing an IP reaction under denaturing conditions is to 
eliminate all non-covalent interactions between the protein of interest and other 
proteins in lysates that have been treated with apoptosis inducing drugs. In our 
case, we precipitated using a caspase 8 antibody and then used a general ubiquitin 
antibody to determine the amount of caspase 8 which was modified in the 
presence and absence of TRAIL in WT and KO DCNL5 cells. Many repeats of this 
experiment were performed and included using different ubiquitin antibodies 
however we found it difficult to successfully precipitate enough protein to 
consistently visualise caspase 8 ubiquitination. The data from Figure 4-8 did show 
differences in caspase 8 ubiquitination between cell lines and in the presence of 
TRAIL however the differences are possibly attributable to the differing amounts 
of caspase 8 that was precipitated in each lane. Overall, there does appear to be 
less ubiquitination of caspase 8 in KO cells compared to WT cells, but this result 
is difficult to interpret given the different ubiquitination modifications that 
regulate caspase 8 activity.  
Polyubiquitination by cullin 3 is the only known positive regulator of caspase 8 
activity (Jin et al., 2009) while multiple ubiquitination events have been shown 
to inhibit caspase 8 activity and are discussed in the following chapter. A key 
example is the polyubiquitination via K48 linkages by the E3 ligase activity of 
TRAF2 which initiates a shut-off time which targets caspase 8 for degradation and 
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thus serves as a key regulator of caspase 8 activity (Gonzalvez et al., 2012). Thus, 
a reduction in ubiquitination of caspase 8 could also represent a reduction in the 
negative regulation (via TRAF2) and in fact represent an increase in caspase 8 
activity. Great care is required when interpreting caspase 8 ubiquitination data. 
We did attempt to probe for K63-linked polyubiquitination specifically (data not 
shown) however the results were less clear than with a general ubiquitin antibody. 
Optimisation with specific ubiquitin antibodies would allow more accurate 
determination of the different types of ubiquitination occurring and which 
modifications are reduced or increased in KO cells compared to WT cells following 
TRAIL stimulation. Experimentally, these reactions can be performed at 4°C 
instead of in humidified incubators at 37°C which tends to stabilise modified 
caspase 8 and improve the signal that can be detected by western blot (Jin et al., 
2009) and therefore a repeat of this IP reaction under denaturing conditions at 
4°C would likely yield improved signal. 
Another way of evaluating caspase 8 ubiquitination status in WT and KO DCNL5 
cell lines is to using tandem ubiquitin binding entities (TUBEs) as described in 
4.2.5. We used purified TUBEs which had been conjugated to HALO magnetic 
beads to precipitate poly-ubiquitinated proteins in lysates with and without TRAIL 
stimulation. Global levels of ubiquitinated proteins were unchanged following 
TRAIL stimulation since ubiquitination is a common post-translational modification 
and part of normal cell physiology. When we probed for caspase 8, we had 
expected to see a ubiquitin ‘smear’ of high molecular weight following TRAIL 
stimulation, which is generally what has been observed during 
immunoprecipitation-type reactions previously. To our surprise, in WT cells, we 
detected unmodified p43/41 caspase 8 as well as some un-cleaved caspase 8 
following TRAIL stimulation of 1 hour, and no caspase 8 in the absence of 
stimulation. The KO cells were absent of any caspase 8 being detected by western 
blot.  
The finding that unmodified pro-caspase 8 precipitates in WT cells may provide 
some interesting insight into the potential role of DCNL5 in caspase cleavage. We 
have previously shown that the KO cells have similar amounts of pro-caspase 8 to 
WT cells however the TUBE data indicates that there is a lack of ubiquitination of 
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a protein that interacts with pro-caspase 8 in KO cells. It is not a question of the 
KO cells lacking pro-caspase 8, but lacking polyubiquitination of a protein or 
proteins that interact with pro-caspase 8. The lack of such an interaction may 
explain why the KO cells fail to undergo caspase 8 cleavage. It remains a possibility 
that pro-caspase 8 stability is lower in KO cells and thus is unable to be detected 
by the TUBEs – performing the TRAIL treatment at 4°C has been shown to stabilise 
caspase 8 and increase the signal (Jin et al., 2009). Another consideration is the 
possibility that the caspase 8 we detect in WT cells is interacting with 
polyubiquitinated caspase 8. The TUBE result is, to our knowledge, the first-time 
caspase 8 has been studied in this way and supports the fact that ubiquitination 
following TRAIL stimulation is lacking in the DCNL5 KO cells. It remains unclear 
however if caspase 8 itself is unable to be ubiquitinated or whether another 
protein in the pathway, such as FADD or cFLIP, is unable to be ubiquitinated.  
cFLIP is structurally related to caspase 8 but is lacking in proteolytic activity and 
functions as an endogenous inhibitor of apoptosis. cFLIP is able to interact directly 
with FADD and caspase 8 at the DISC following TRAIL-mediated apoptosis induction 
(R Safa, 2013) and is ubiquitinated by the HECT E3 ligase ITCH which has been 
shown to promote DR5/caspase 8 -mediated apoptosis in tumour cells (Le 
Clorennec et al., 2019). Interestingly, another HECT E3 ligase called SMURF1 has 
been shown to require neddylation for its ubiquitin ligase activity and NEDD8 in 
conjunction with UBC12 allows for the auto-neddylation of SMURF1 on multiple 
lysine residues (Xie et al., 2014). As has been stated previously, this was all done 
with overexpression, so these results require verification with endogenous NEDD8 
expression levels. It was later shown that NEDD8 has a non-covalent function which 
is required for the ligase function of SMURF1 (He et al., 2017) highlighting the 
potentially multifaceted and relatively unknown role of NEDD8 in activating E3 
ligases other than CRLs. It is therefore a possibility that NEDD8 may also be 
involved in the regulation of ITCH activity since it too is a HECT E3 ligase. If there 
is a role for DCNL5 in facilitating this process, then the lack of DCNL5 expression 
may account for the reduction in ITCH activity and thus the reduction in cFLIP 
ubiquitination, resulting in a lack of caspase 8 cleavage and apoptosis. Further 
experimental work is required to evaluate this hypothesis however it is clear that 
there is a lack of ubiquitination in DCNL5 KO cells which may responsible for their 
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resistance to apoptosis, however the key question of what protein or proteins fail 
to be ubiquitinated in KO cells still remains. Optimisation of the denaturing IP’s 
we employed would allow us to determine which proteins that associate with the 
DISC are ubiquitinated and by which lysine linkage. This would then allow us to 
build a better picture of the ubiquitination events that may be lacking in KO cells 
and thus pinpoint the precise interaction of DCNL5 which is required to promote 
caspase 8 cleavage in U2OS cells. 
4.3.6 Neddylation Appears not to be Essential for Caspase 8 
Cleavage 
The NAE inhibitor MLN4924 has been used clinically for the treatment of some 
cancers and has shown in vitro  to be a potent inhibitor of neddylation. Given the 
well-established role for cullin 3 in the ubiquitination of caspase 8, we suspected 
that a lack of cullin neddylation would lead to a lack of caspase 8 cleavage and 
activation. Existing work has shown that neddylated cullin 3 is responsible for 
mediating the ubiquitination of caspase 8 (Jin et al., 2009) and as has been 
discussed in the general introduction, cullin proteins require neddylation in order 
to induce structural re-arrangements through increased flexibility of the C-
terminal region of the cullin protein (Duda et al., 2008) which facilitates the 
addition of ubiquitin to target substrates. Un-neddylated cullin proteins are known 
to interact with CAND1 which has been postulated to sequester un-modified cullin 
proteins and function to rapidly exchange substrate receptors for assembly of CRL 
complexes (Wu et al., 2013). At the time of writing, un-neddylated cullin proteins 
are not known to have any specific roles beyond existing in specific subcellular 
pools ready to be neddylated to form active CRL complexes. 
MLN4924 pre-treatment was successful in inhibiting cullin 3 neddylation and in 
DCNL5 KO cells caspase 8 cleavage was absent when cullin 3 neddylation was 
inhibited and when cullin 3 was neddylated. WT cells showed a reduction but not 
a total loss of caspase 8 cleavage when cullin 3 was un-neddylated which indicates 
that in U2OS cells, cullin 3 neddylation and therefore a cullin 3-RBX1-based CRL 
may not be essential to mediate the cleavage of caspase 8 but it does significantly 
increase caspase 8 cleavage. This data indicates two things: either negative 
regulators of caspase 8 ubiquitination are inhibited by MLN as well as the positive 
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regulation by cullin 3, or there exists a role for cullin 3 independent of its 
neddylation state and thus catalytic activity as the core of a CRL. Cullin proteins 
act as scaffolds for CRL assembly and it is therefore possible that they act as 
scaffolds in caspase 8 activation; perhaps cullin 3 serves as a binding partner for 
caspase 8 and mediates its recruitment to the DISC along with FADD. What is 
puzzling is the fact that the role of cullin 3 in H460 cells has been shown to 
required its neddylation since only neddylated cullin 3 interacts with caspase 8 
and the DISC (Jin et al., 2009). However, another interpretation of this is that 
cullin 3 neddylation may not be required, all that has been shown is that cullin 3 
interacting with the DISC is neddylated. Our findings in U2OS cells may indicate 
that there are cell line-specific nuances in caspase 8 ubiquitination and activation 
and is explored further in the following chapter where we test the role of DCNL5 
and cullin 3 in a range of cancer cell lines.  
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5 Confirmation of the General Role of DCNL5 in the 
Extrinsic Apoptosis Response in a Variety of 
Cancer Cell Lines 
5.1 Introduction 
5.1.1 TRAIL Signalling Has Diverse Responses in Different Cell 
Lines 
Apoptosis is an incredibly complex and tightly regulated process that has many 
stages required to initiate the downstream events that mediate cell death. Not 
only is the process complicated, but the exact signalling pathways and proteins 
involved can vary from one cell line to the next. Cancer cells have been shown to 
be more sensitive to TRAIL stimulation than normal cells (Kelley and Ashkenazi, 
2004) which prompted a significant increase into research investigating the 
cytokine’s use in cancer treatment. For example, the TRAIL gene has been shown 
to elicit apoptosis in malignant cells in vivo when transfected using adenoviral 
methods while causing no detectable toxicity in cultured normal fibroblasts or in 
mouse hepatocytes (Kagawa et al., 2001). Despite the initial promise, numerous 
cancer cell lines have been shown to be resistant to TRAIL stimulation through a 
variety of mechanism including loss of caspase 8 expression (Grotzer et al., 2000) 
or high surface expression of functionally inactive decoy TRAIL receptors in MCF-
7 cells (Sanlioglu et al., 2005).  
In the present research, we have shown that DCNL5 plays a role in caspase 8 
activation, likely at the level of ubiquitination of caspase 8 in conjunction with 
cullin 3 or possible another cullin protein. We have mostly used U2OS cells for this 
work, and prior research using these cells has suggested that this cell line is not 
particularly sensitive to TRAIL and often requires co-treatment with drugs such as 
cycloheximide (Garnett, Filippova and Duerksen-Hughes, 2007) or the siRNA-
mediated knockdown of cFLIP (Zhang et al., 2015). In our hands, we found U2OS 
cells to be sensitive to TRAIL stimulation alone (with DCNL5 KO cells being 
resistant), and combination treatment with CHX was found to kill all cells to levels 
below detectable threshold using our luciferase assay. The finding that cell line 
responsiveness to TRAIL can vary highlights the complicated nature of TRAIL 
signalling and sensitivity in tumour cells. In order to determine the general 
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applicability of our findings we decided to test a variety of cell lines for their 
response to TRAIL signalling after loss of DCNL5. All the cell lines we used in this 
chapter undergo caspase 8 cleavage after TRAIL treatment, indicating sensitivity 
to the drug, except for MCF-7 cells, which as mentioned above, are known to be 
resistant to the treatment. This resistance has been shown to be linked to the 
higher expression of decoy TRAIL receptors as well as the increased endocytosis 
of death receptors 4 and 5 (Zhang and Zhang, 2008), effectively increasing the 
ratio of decoy-receptors to functional receptors and thus reducing TRAIL 
effectiveness. MCF-7 cells therefore represent a good control cell line for the 
studies involving the role of DCNL5 and the caspase 8 ubiquitination and cleavage 
in cancer cell lines. 
5.1.2 Caspase 8 Ubiquitination is Regulated by Multiple Ubiquitin 
E3 Ligases 
We have previously discussed the role of caspase 8 ubiquitination, which is 
mediated by cullin 3, and detailed how this modification is unique in being a 
positive regulator of caspase 8 activation (Jin et al., 2009). Caspase 8 
ubiquitination by other E3 ligases is also known to inhibit its activation and act as 
negative regulation for apoptosis, which adds a layer of complexity to studying 
caspase 8 activation. Furthermore, other components of the DISC and downstream 
signalling complexes are known to be regulated by ubiquitination as well as other 
post-translational modifications, making interpretation of results challenging. 
Caspase 8 ubiquitination by cullin 3 has been shown to be required for cleavage 
and activation, this process also requires the activity of the scaffold protein p62 
(Jin et al., 2009). While not strictly related to TRAIL-induced cell death, the RING 
E3 ligases TRIM13 has been shown to mediate K63-linked polyubiquitination of 
caspase 8 (Tomar et al., 2013) which results in its stabilization and activation 
during ER stress, furthermore TRIM13 expression was shown to sensitise cells to 
ER stress-induced death through its ability to translocate caspase 8 to 
autophagosomes (Tomar et al., 2013). Interestingly TRIM13 was shown to act 
synergistically with p62, similarly to the cullin 3-based E3 ligase for TRAIL 
signalling (Tomar et al., 2013).  
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Negative regulation of caspase 8 activity by ubiquitination has also been 
described. Cullin 7 has been shown to promote tumour cell survival (specifically 
HeLa cervical cancer cells) through mediating the ubiquitination of caspase 8 at 
lysine 215 through non-K48-linked polyubiquitin chains (Kong et al., 2019). Cullin 
7 was shown to interact with the DED domain of caspase 8 via its C-terminus, and 
knockdown of cullin 7 protein levels resulted in increased caspase 8 cleavage in 
response to TRAIL. This modification of caspase 8 was shown to be non-
degradative and it was postulated that polyubiquitin chains physically impeded 
caspase 8 activation at the DISC (Kong et al., 2019).  
Caspase 8 polyubiquitination at lysine 215 via K63 linkages has also been shown to 
inhibit caspase 8 cleavage by the HECT E3 ligase HECTD3 in a non-degradative 
manner as well (Li et al., 2013). HECTD3 interacts with the DED regions of caspase 
8 though its DOC region (destruction of cyclin domain) (Li et al., 2013) which is 
involved in substrate recognition and is a similar interaction to the interaction 
between cullin 7 and the DED domain described above. As with cullin 7, siRNA-
mediated knockdown of HECTD3 resulted in increased caspase 8 activation and 
apoptosis in response to activation of the extrinsic branch of the apoptosis 
pathway (Li et al., 2013).  
Another regulator of caspase 8, and one which ties in with the positive regulation 
by cullin 3, is the polyubiquitination mediated by a protein called TNF receptor 
associated factor 2 (TRAF2). TRAF family members are known to possess E3 ligase 
activity and they have been shown to mediate polyubiquitination of a variety of 
substrates, including activation by ubiquitination of the IκB complex (Deng et al., 
2000). TRAF proteins play other roles in in NF-κB signalling (Chen, 2005) ( but 
TRAF2 specifically is responsible for regulating another pathway: caspase 8 
activation during apoptotic signalling (Gonzalvez et al., 2012). TRAF2 has 
previously been shown to be capable of mediating polyubiquitination (Cardamone 
et al., 2012) and has also been shown to interact with caspase 8 at the DISC 
downstream of cullin 3, where TRAF2 mediates the K48-linked polyubiquitination 
of the p18 catalytic subunit of caspase 8 (Gonzalvez et al., 2012). This 
modification targets caspase 8 molecules for proteasomal degradation following 
auto processing and cytoplasmic translocation of p18 and p43 fragments and this 
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functions as a shutoff timer to attenuate the extrinsic apoptosis response 
(Gonzalvez et al., 2012). Overall, there are multiple ubiquitination events which 
regulate caspase 8 activity and thus multiple potential roles for DCNL5 in the 
extrinsic apoptosis pathway. A question still remains about the importance of 
NEDD8 in the process since data from the previous results chapter indicates that 
cullin neddylation may not be essential for the role of DCNL5 in caspase 8 
activation. 
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Figure 5-1 Caspase 8 Regulation by Ubiquitination.  
This diagram outlines some of the major proteins involved in the ubiquitination of caspase 8. 
Ubiquitination of caspase 8 can have both pro-apoptotic and anti-apoptotic roles, depending on the 
residue that is modified. Pro-survival modifications occur at lysine 215 which lies between the DED 
regions of caspase and its p18 domain. Polyubiquitination at this residue by non-K48 linkages 
promotes cell survival and this polyubiquitination is mediated by a cullin 7-based CRL complex as 
well as the HECTD3 E3 ligase. Pro-apoptotic signalling can be triggered by polyubiquitination via 
K63 linkages at an unknown lysine residue within caspase 8 by the E3 ligase TRIM13. This 
modification is known to occur as a result of ER stress and TRIM13 has been shown to act 
synergistically with the scaffold protein p62. The better characterised ubiquitination event regarding 
caspase 8 activity is the polyubiquitination of lysine 461 within the p10 region of caspase 8 via both 
K48 and K63 linkages. This crucial modification occurs as a result of receptor-mediated apoptosis 
induction and has been shown to promote the dimerization and cleavage of caspase 8 as well as its 
subsequent association with p62 in aggregates, no dissimilar to process mediated by TRIM13. This 
pro-apoptotic ubiquitination event is mediating by cullin 3 in combination with RBX1 and is vital in 
promoting downstream apoptosis events. 
5.1.3 The Neddylation Inhibitor MLN4924 Reveals a Role for NEDD8 
in Apoptosis 
Given the well documented importance of ubiquitination in caspase 8 activation 
as discussed above, and the well-established role of multiple cullin proteins in 
mediating this process, it is essential to investigate the importance of NEDD8 in 
extrinsic apoptosis. NEDD8 addition to cullin proteins is an essential step in the 
activation of CRL complexes which mediate ubiquitination (Kawakami et al., 2001; 
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Wu et al., 2002; Sakata et al., 2007). In this chapter, we will present data using 
the NEDD8 activating enzyme inhibitor MLN4924, and while the mechanism and 
function of this drug has already been discussed in terms of its activity in inhibiting 
neddylation, it is important to understand that MLN4924 has been shown to also 
play roles in the apoptosis pathway. MLN has been shown to synergise with TNFα 
during treatments of 6-8 hours to induce apoptosis in a caspase 8 dependent 
manner in rat liver hepatoma cells, however the molecular mechanism underlying 
the role of the neddylation inhibitor remains unclear in this context (Wolenski et 
al., 2015). Research has also shown that MLN is able to heighten apoptotic 
signalling in response to TRAIL stimulation though the degradation of cFLIP in head 
and neck cancer cells (Zhao et al., 2011).  
Other work has been done which shows the MLN treatment in human oesophageal 
squamous cell carcinoma cells resulted in increased DR5-mediated caspase 8 
activation. MLN4924 inhibited the activity of CRLs which lead to the stabilization 
of ATF4 which in turn lead to transactivation of the transcription factor CHOP 
which upregulated DR5 expression and increased downstream caspase 8 activation 
(Chen et al., 2016). In the research by Chen and colleagues they induced apoptosis 
by stimulating cells for 72 hours with MLN4924 while Wolenski and colleagues used 
up to 8 hours and Zhao and colleagues used the drug for 24 hours. In our research, 
we used MLN for 1-hour pre-treatments followed by incubation with TRAIL for 30-
90 minutes, representing a much shorter time period over which cells were 
exposed to the NEDD8 inhibitor. Longer term MLN4924 treatment will affect cells 
drastically since all ubiquitination events mediated by cullins will be inhibited. 
Our relatively short treatments with the inhibitor will provide insight specifically 
on the role of cullins in the apoptosis pathway and have little affect on other 
cellular processes during the treatment duration. One final complication in using 
MLN4924 when studying apoptosis is that it has also been shown to induce 
apoptosis through the intrinsic branch of the pathway (Wang et al., 2015) however 
this generally does not affect caspase 8 cleavage but will impact downstream 
caspase cleavage as well as other downstream events. 
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5.1.4 Aims 
We wanted to determine whether the role of DCNL5 is conserved across different 
cancer cell lines, the phenotype observed in U2OS cells is very strong and given 
the diverse response of cancer cells to TRAIL coupled with the complexity of the 
TRAIL pathway, it would solidify the role of DCNL5 as a key regulator in the 
apoptosis response. We also wanted to investigate the importance of neddylation 
in caspase 8 activation given DCNL5 is a key regulator of neddylation and 
neddylation is required for CRL activity. Linked to this, we wanted to test the 
importance of cullin 3 in a variety of cell lines given its established role as the key 
mediator of caspase 8 ubiquitination. We used a selection of cancer cell lines 
covering a wide range of tumours for this section of work. H460 cells were selected 
because these lung carcinoma cells were used extensively in the seminal work by 
Jin and colleagues who characterised the role of cullin 3 in caspase 8 
ubiquitination (Jin et al., 2009). We used MCF-7 cells as a negative control since 
these cells are not TRAIL sensitive. HeLa cells are a common cell line used to study 
a wide range of cellular processes and represent an important cell line to study 
caspase 8 activity, while DU-145 prostate cancer cells and A375 melanoma cells 
have been shown to be TRAIL sensitive.  
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5.2 Results 
5.2.1 Successful Generation of CRISPR/Cas9 DCNL5 KO H460 
Cells 
A common cell line used to study caspase 8 cleavage and activation is the H460 
lung carcinoma cell line and these cells have been used  extensively in TRAIL-
mediated caspase 8 cleavage research (Jin et al., 2009) and thus represented a 
good additional cell line to investigate the role of DCNL5. We wanted to generate 
a CRISPR/Cas9 KO cell line to directly compare with the KO U2OS cell line we have 
used throughout this project. We transfected a guide RNA vector for exon 1 of 
DCNL5 which was generated previously by mutagenesis PCR of pEsgRNA (Munoz et 
al., 2014; Keuss et al., 2016) with the target sequence 5’-
GCAGCAGTAGCGGAAGACGGAGG-3’ (plus strand) into H460 cells stably expressing 
FLAG-tagged Cas9 which was under tetracycline-inducible promotor control. 
Expression was induced with tetracycline and we then single cell cloned these 
cells. After one round of single cell cloning we analysed a selection of clones to 
evaluate the success of the process and the resulting western blot showing DCNL5 
expression can be seen in Figure 5-2A. 15 individual colonies were screened 
initially and four of these clones appeared to show significant reductions in DCNL5 
expression. These clones were then re-analysed in combination with a loading 
control to more accurately determine whether the reduction in DCNL5 expression 
was significant. Clones 6, 8 and 15 showed major reductions in DCNL5 expression 
however they still showed low levels of DCNL5, suggesting that these clones were 
not complete knockouts and were perhaps mixed populations.  
We then opted to re-grow and re-screen these clones hoping to obtain complete 
KO cells. The result of another round of screening of the initial clone number 6 
can be seen in Figure 5-2B. Out of 34 single colonies that grew successfully we 
found half a dozen potential complete KO clones, which have been underlined in 
the figure. These clones showed a total lack of DCNL5 expression as determined 
by western blot, however a higher molecular weight band appeared to be present 
in most of these. While this band was unexpected, a possible explanation is that 
the polyclonal DCNL5 antibody is binding to another DCNL protein (likely DCNL4) 
or another protein entirely in the absence of DCNL5. If this were to be the case, 
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the size of the band is similar to the size of DCNL4 (34kDa) and this may therefore 
explain the band we see on the western blot. A simple way of confirming that this 
band is indeed not a mutant form DCNL5 would be to perform siRNA-mediated 
silencing of DCNL5 and if the band is still present, it would strongly suggest that 
it not DCNL5. We wanted to confirm the successful generation of DCNL5 KO cells, 
so we analysed the sequence of the DCNL5 gene in these clones. Overall, 2 main 
mutations were present in these clones presumably in each copy of the gene. In 
all cases, premature stop codons were introduced in exon 1 leading to the lack of 
formation of the mature and properly folded protein. Clones that showed no 
reduction in DCNL5 expression were kept and used as WT controls. 
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Figure 5-2 DCNL5 CRISPR Cas9 KO Cells Were Made Following 2 Rounds of Screening.  
(A) Initial screening following single cell plating of cells that had been subject to CRISPR/Cas9-
mediated knockout using gRNA for exon 1 of DCNL5 showed partial reduction in DCNL5 expression 
in 3 clones. These likely represented mixed populations and number 6 (highlighted in red) was used 
for another round of screening. (B) A second round of single colony plating of clone number 6 resulted 
in several clones showing complete lack of DCNL5 expression, which have been underlined. These 
clones were sequenced to confirm successful disruption of the DCNL5 gene.  
A 
B 
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5.2.2 H460 Cells Demonstrate an Increase in Caspase 8 
Ubiquitination Following TRAIL Stimulation 
In the previous chapter we had attempted to optimise a denaturing 
immunoprecipitation reaction to show the changes in caspase 8 ubiquitination 
following TRAIL stimulation. This proved difficult with U2OS cells and we did not 
perform the TRAIL treatment at 4°C which increases the caspase 8 signal and 
stabilises ubiquitinated caspase 8 aggregates. We wanted to see if we could detect 
the modification in H460 cells given that they are one of the cell lines of choice 
for studying caspase 8. We sought to compare this cancer cell line to a non-
cancerous cell line (HEK 293) to highlight the fact that it is only tumour cells and 
cell lines which respond to TRAIL. The sensitivity of cancer cells to TRAIL 
(compared to healthy cells) make it a useful drug in chemotherapy and cancer 
treatments in clinical settings. 
We were able to detect what appears to be an increase in caspase 8 ubiquitination 
after performing a denaturing IP using H460 cells that were stimulated with 
200ng/ml of TRAIL for 30 minutes. The western blot in Figure 5-3 shows an 
increase in caspase 8 modification following stimulation (shown by the ubiquitin 
smear highlighted by the red bracket), although it is possible there is slightly more 
caspase 8 that has been precipitated in that lane. By contrast, HEK cells show 
much less change in caspase 8 ubiquitination which supports the assertion that 
TRAIL is more selective for tumour cells and cell lines. We anticipate that a repeat 
of this experiment at 4°C would dramatically increase the caspase 8 signal due to 
a stabilisation of the modified protein and we predict that U2OS cells would show 
the same increase in modification following treatment when DCNL5 is present, but 
not in its absence. 
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Figure 5-3 H460 Cells Exhibit an Increase in Caspase 8 Ubiquitination While HEK293 Cells do 
not.  
This representative western (n = 2) (low and high exposure above and below respectively) shows 
the result of a denaturing immunoprecipitation reaction performed on H460 and HEK 293 cells with 
and without 30-minute TRAIL stimulation for 30 minutes. In HEK cells we see no increase in caspase 
8 ubiquitination following treatment, however we do see an increase in modification in the H460 cells 
(highlighted by the red bracket) which supports the fact that TRAIL is selective for tumour cells. There 
does appear to be slightly more caspase 8 present in the TRAIL-treated lane, however. This also 
confirms that H460 cells are a useful cell line for studying caspase 8 cleavage and activation. 
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5.2.3 H460 DCNL5 KO Clones and siRNA-Mediated Knockdowns 
Show Reduced Caspase 8 Cleavage Following TRAIL Treatment  
To investigate whether the role of DCNL5 is the same in H460 cells as in U2OS 
cells, we subjected some of the KO clones we generated (see 5.2.1) to TRAIL 
treatment and analysed caspase 8 cleavage by western blot. The resulting western 
blot can be seen in Figure 5-4A. We used two KO clones as well as a WT clone in 
which the CRISPR-mediated gene inactivation had not been successful. The WT 
clone shows cleavage of caspase 8 to form both p43/41 and p18 fragments upon 
TRAIL stimulation. KO clone #22 shows a significant reduction in p18 cleavage 
following treatment compared to the WT clone, while KO clone #27 shows almost 
no p18 protein levels, indicating a significant reduction in caspase 8 cleavage in 
response to the treatment. This data suggests that lack of DCNL5 expression has 
a clear effect in H460 cells however the variation between the two KO clones 
requires further investigation – perhaps there is a very small amount of DCNL5 still 
present which is sufficient to cause some caspase 8 cleavage.  
To further validate the role for DCNL5 in H460 cells we used siRNA-mediated gene 
silencing to inhibit protein expression prior to TRAIL treatment. The result can be 
seen in the western blot in Figure 5-4B, and it is clear that siRNA-treated H460 
cells undergo less caspase 8 cleavage, particularly p18 cleavage, than non-
silenced cells. It actually looks as though DCNL5 expression is a bit lower in the 
treated un-transfected cells than the transfected ones, suggesting that the 
difference in p18 protein levels may in reality be more significant. This reduction 
in caspase 8 cleavage is similar to existing data which suggests that only a small 
reduction in caspase 8 cleavage can represent a significant lack of ubiquitination 
(Jin et al., 2009). Our siRNA data in combination with the reduced response of KO 
clones to TRAIL supports the results found in U2OS cells showing DCNL5 is required 
for cell death and caspase 8 cleavage and provides compelling evidence that the 
function of DCNL5 is not restricted to one cell line. 
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Figure 5-4 H460 DCNL5 KO Clones Show Reduced Caspase 8 Cleavage and DCNL5 
Knockdown has a Similar Effect.  
(A) This representative western blot (n = 2) shows two of the H460 DCNL5 KO clones as well as a 
WT clone (which has normal DCNL5 expression despite subjecting it to CRISPR/Cas9) and their 
response to 60 minutes of TRAIL stimulation at a concentration of 200ng/ml. The WT clone shows 
caspase 8 cleavage to both the p43/41 and p18 forms, while KO clone #22 shows a pronounced 
reduction in p18 fragment levels after TRAIL treatment, and clone #27 shows an almost total lack of 
p18 caspase 8 expression. In both KO clones we do still see p43/41 caspase 8 being formed which 
we saw in U2OS KO cells as well. (B) Representative western blot showing that siRNA-mediated 
knockdown of DCNL5 in H460 cells produced a similar effect. While not as dramatic as with the KO 
clones, we do see a marked reduction in p18 caspase 8 levels after TRAIL treatment when DCNL5 
expression is inhibited.   
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5.2.4 DCNL5 Knockdown Reduces Caspase 8 Cleavage in Cancer 
Cells 
Having now demonstrated a role for DCNL5 in the caspase 8 activation pathway in 
U2OS and H460 cancer cell lines, we wanted to investigate this role in more cell 
lines. We chose A375 cells (skin melanoma), DU-145 cells (prostate carcinoma) 
and HeLa cells (cervix adenocarcinoma), as well as TRAIL resistant MCF7 (breast 
adenocarcinoma) cells as negative controls. We used RNAiMAX (ThermoFisher) to 
transfect each cell line with siRNA targeting DCNL5 for 72 hours (A375 cells were 
only treated for 48 hours) prior to treating the cells with TRAIL for 60 minutes. 
U2OS cells were a good positive control for this experiment since we already knew 
that DCNL5 KO cells exhibit significantly less caspase 8 cleavage than cells 
expressing DCNL5. siRNA treatment of these cells (shown in Figure 5-5A) caused a 
significant drop in p43/41 protein levels as well as a drop in p18 levels, however 
the latter fragment was only faintly visible in un-transfected cells. This 
independently confirms the role of DCNL5 in U2OS cells, which have been used 
extensively in this research.  
Figure 5-5B shows the effect of DCNL5 knockdown in A375 cells and as we have 
seen with H460 cells (Figure 5-4B and Figure 5-5C), we can detect a reduction in 
both cleavage products of caspase 8 following TRAIL stimulation compared to un-
transfected cells. The effect of DCNL5 knockdown is strongest in HeLa cells which 
show a large reduction in p18 caspase 8 compared to un-transfected cells – there 
is almost no active caspase 8 being formed where DCNL5 expression is inhibited in 
this cell line. DU-145 cells show no change in caspase cleavage when DCNL5 
expression is absent, representing the only cell line we tested that is TRAIL-
sensitive to show to no change in caspase cleavage in the absence of DCNL5. 80% 
of the cell lines we were able to test showed at least some reduction in caspase 8 
cleavage in the absence of DCNL5 and previous research has shown that the 
reduction in caspase 8 cleavage in terms of formation of p43/41 and p18 fragments 
does not need to be very large in order for the effects to be significant (Jin et al, 
2019, supplementary data showing cullin 3 siRNA). 
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Figure 5-5 siRNA-Mediated Knockdown in Cancer Cell Lines Reduces Caspase 8 Cleavage. 
DCNL5 expression is confirmed by western blot in all panels. (A) This representative western blot 
shows that inhibition of DCNL5 expression in U2OS cells via siRNA causes a reduction in caspase 
8 cleavage, which is consistent with the data from the KO and inducible rescue cell lines used in 
Chapter 3. (B) Representative western blot showing knockdown of DCNL5 expression in A375 cells 
also causes a slight reduction in p41/41 and p18 caspase 8 levels following TRAIL stimulation with 
respect to non-transfected cells. (C) This representative western blot is the same as the previous 
figure (5-4) and shows reduced caspase 8 cleavage in H460 cells following DCNL5 siRNA. (D) This 
representative western blot shows the response of both HeLa and DU-145 cells to TRAIL. siRNA-
mediated knockdown of DCNL5 in HeLa cells causes a pronounced  reduction in p18 caspase 8 
compared to un-transfected cells. DU-145 cells show no detectable change in caspase 8 cleavage 
in the absence of DCNL5 expression.  
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5.2.5 DCNL5 Overexpression May Increase Caspase 8 Cleavage in 
HeLa Cells 
Having established that knockdown of DCNL5 expression in multiple cell lines 
reduced caspase 8 cleavage in response to TRAIL treatment, we wanted to 
investigate the effect of overexpressing DCNL5 on this process. We initially used 
HeLa cells as they showed the strongest response to siRNA suggesting that these 
cells were susceptible to transient modulation of DCNL5 expression levels. We 
transfected the cells using Lipofectamine 2000 (ThermoFisher) for 5 hours and 
allowed the cells to grow for a further 48 hours before treating the cells with 
TRAIL for 60 minutes. The expression of DCNL5 was greatly increased following 
the transfection as shown by DCNL5 Western Blot in Figure 5-6. TRAIL stimulation 
led to caspase 8 cleavage in the presence of TRAIL, and this cleavage was stronger 
in cells that were overexpressing DCNL5. It is important to note that there does 
appear to be more pro-caspase 8 present when DCNL5 is overexpressed suggesting 
that the increase in detectable caspase 8 cleavage may arise due to more 
precursor caspase 8 being present. Nonetheless, it still appears that there may 
exist a link between the amount of DCNL5 being expressed in cells and the amount 
of caspase 8 processing that occurs in response to induction of apoptosis. Absence 
of DCNL5 results in a reduction of caspase 8 cleavage and increase in DCNL5 
expression may result in more processing of the protein, however further 
validation is required, including using other cell lines. 
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Figure 5-6 Overexpression of DCNL5 in HeLa Cells Appears to Cause an Increase in Caspase  
Cleavage. 
Overexpression of DCNL5 in HeLa cells, confirmed here by the increase in protein levels shown by 
a representative western blot (n = 2), leads to an increase in caspase 8 cleavage following TRAIL 
stimulation. There is an increase of both p43/41 and p18 caspase 8 levels when DCNL5 expression 
is increased. There does appear to be globally more pro-caspase 8 with increased DCNL5 
expression.  
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5.2.6 MLN4924 Treatment Has no Major Effect on the Response of 
a Variety of Cancer Cell Lines to TRAIL 
The established mechanism for caspase 8 activation involves the ubiquitination of 
caspase 8 by cullin 3 which is required for cleavage and aggregate formation. To 
our knowledge, the role of neddylation in this pathway has not been studied, and 
given that cullin proteins require neddylation for their activity and their roles as 
the cores of ubiquitin E3 ligases, we wanted to investigate the effect of inhibiting 
neddylation on the cleavage of caspase 8. We used the neddylation activating 
enzyme (NAE) inhibitor MLN4924 as we have done previously in this project: 1 hour 
pre-treatment at a concentration of 3μM. MLN4924 is used in clinical settings as a 
cancer treatment drug and is actually known to induce apoptosis however in this 
context of treatments of fairly short duration (2 hours total treatment time) we 
postulated that short-term treatment would not significantly affect global CRL-
governed processes including cell cycle regulation. We have previously shown that 
MLN4924 reduces but does not entirely inhibit caspase 8 cleavage in U2OS cells 
and this result is shown again in Figure 5-7B. This result suggested that cullin 3 
neddylation is not absolutely required for cleavage of caspase 8 which represents 
a potentially new role for a cullin protein in its un-neddylated state.  
We performed the same experiment using H460, HeLa and DU-145 cells in order 
to establish whether this result holds up in different cell lines and obtained 
interesting results. Figure 5-7A shows western blots for each cell line and the 
success of the MLN4924 treatment can be seen by the presence of only un-
neddylated (lower molecular weight) cullin 3 in the lanes where cells were pre-
treated with the drug. The H460 cells show a reduction in the levels of the p18 
caspase 8 fragment when pre-treated with MLN4924 followed by TRAIL, similar to 
the U2OS cells shown in panel B. HeLa cells and DU-145 cells however, show an 
increase in the amount of p18 following pre-treatment with MLN4924 which is not 
what we expected to see. At the very least it can be said that in these 4 cell lines 
the neddylation of cullin 3 (or any other cullin is not essential for the processing 
of caspase 8, with 2 cell lines indicating that this may even enhance the 
processing.  
197 
 
 
 
 
Figure 5-7 MLN4924 Treatment is Insufficient to Inhibit Caspase 8 Cleavage and May Even 
Increase Cleavage in Some Cell Lines.  
(A) MLN4924 was used for 1 hour prior to stimulation with TRAIL. Successful inhibition of neddylation 
is confirmed by the loss of the upper, neddylated band of cullin 3 shown here by representative 
western blot. In H460 cells MLN treatment reduces p18 caspase 8 levels following TRAIL stimulation. 
In both HeLa and DU-145 cells MLN treatment actually appears to increase caspase 8 cleavage; a 
slight increase in p18 protein levels can be observed in both levels with MLN pre-treatment compared 
to without pre-treatment. (B) This representative western blot showing the effect of MLN treatment 
on WT and DCNL5 KO U2OS shows that in WT cells MLN treatment causes a reduction in p18 
caspase 8, similar to the H460 cells. 
  
A 
B 
198 
 
 
 
5.2.7 Cullin 3 siRNA-Mediated Knockdown Has Less of an Effect 
than DCNL5 Knockdown 
In addition to investigating the requirement of cullin 3 to be neddylated to 
mediate its function in caspase 8 processing, we wanted to establish whether 
knockdown of the protein had a significant effect on caspase 8 cleavage. Existing 
data suggests that cullin 3 is absolutely required for the ubiquitination of caspase 
8. As with DCNL5, we used siRNA targeting the cullin 3 gene and used RNAiMAX to 
transfect for 48 to 72 hours prior to TRAIL stimulation. Success of the knockdown 
was confirmed by western blot for each experiment and in general cullin 3 
expression was able to be depleted in most cell lines. H460 cells and A375 cells 
show strong cullin 3 expression according to our data.  
The results of cullin 3 knockdown followed by TRAIL stimulation are shown in 
Figure 5-8. U2OS cells (Figure 5-8A) show a reduction in p43/41 levels when cullin 
3 expression is depleted compared to un-transfected cells following TRAIL 
treatment. H460 cells show a small reduction in both p43/41 and p18 fragments 
of caspase 8 following cullin 3 knockdown, as can be seen in the western blot in 
Figure 5-8B. This result is in line with the data found by Jin and colleagues, the 
reduction in caspase 8 cleavage does not need to be substantial for it to be 
indicative of a reduction in ubiquitination (Jin et al., 2009). Figure 5-8C shows 
that A375 cells also show a reduction in caspase 8 cleavage in the absence of cullin 
3 expression (although siRNA was not quite as successful in these cells), it is worth 
noting that DCNL5 knockdown, shown on the same Western Blot, appears to have 
a more significant effect than cullin 3 knockdown. As can be seen from the western 
blots, cullin 3 knockdown was not always completely successful (in the case of 
H460 cells and A375 cells in particular) therefore the small reduction in caspase 8 
cleavage may be due to enough cullin 3 being expressed to mediate processing of 
the protease. When we performed cullin knockdown using HeLa cells, we 
unexpectedly found that this actually increased the amount of caspase 8 being 
cleaved compared to cells expressing cullin 3 normally (see Figure 5-8D).  
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Figure 5-8 Cullin 3 Knockdown Reduces Caspase 8 Cleavage in U2OS, H460 and A375 Cells, 
but Increases Caspase 8 Cleavage in HeLa Cells.  
Representative western blot confirming knockdown of cullin 3 expression shown by the reduction in 
cullin 3 protein levels in (A) U2OS cells and (B) H460 cells, which in turn caused a reduction in p43/41 
caspase 8 cleavage. (C) Representative western blot showing that cullin 3 knockdown (as well as 
DCNL5 knockdown) in A375 cells caused a reduction in caspase 8 cleavage compared to un-
transfected cells  as a result of TRAIL treatment (D) Representative western blot showing that siRNA-
mediated knockdown of cullin 3 in HeLa cells caused in increase in p18 protein levels following TRAIL 
stimulation compared to un-transfected cells. 
In order to ensure that DCNL5 and cullin 3 expression levels have no effect in other 
pathways that affect caspase 8 cleavage, we used MCF-7 cells which are a breast 
cancer cell line and are known to be resistant to TRAIL treatment as a negative 
control. siRNA-mediated knockdown of both proteins, as shown in Figure 5-9, had 
A B 
C D 
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no effect on the caspase 8 cleavage following TRAIL treatment. In un-transfected 
cells we observe no caspase 8 cleavage following induction of apoptosis with 
TRAIL, which was expected given their insensitivity to the treatment. Knockdown 
of DCNL5 and cullin 3 expression has no effect. This may seem obvious, but this 
confirms that the roles for these proteins are specific to mediating caspase 8 
cleavage directly and have no off-target effects that may independently 
contribute to caspase 8 processing. An additional experiment for future work 
which would better probe the importance of DCNL5 and cullin 3 in this cell line 
would be to overexpress these proteins and determine if caspase 8 cleavage occurs 
with excess amounts of these proteins. 
 
Figure 5-9 TRAIL Resistant MCF-7 Cells Are Unaffected by Cullin 3 and DCNL5 Knockdown. 
Representative western blot showing that caspase 8 cleavage does not occur in MCF-7 cells 
following TRAIL treatment. Knockdown of DCNl5 or cullin 3 does not change this and these proteins 
likely act specifically to mediate caspase 8 cleavage directly rather than through another mechanism. 
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5.3 Discussion 
5.3.1 Summary 
We have built upon our finding that DCNL5 is required for caspase cleavage and 
demonstrated that it likely interacts with cullin 3 to mediate the ubiquitination 
of the caspase 8. In this chapter we have expanded our analysis to several cancer 
cell lines, and probed the role of not only DCNL5 in TRAIL-mediated apoptosis, but 
the role of neddylation in the pathway as well as the role of cullin 3 specifically 
in caspase 8 ubiquitination. We have shown that the role of DCNL5 is required in 
multiple cancer cell lines, and that DCNL5 appears to be more important in 
caspase 8 cleavage than cullin 3. We used MLN4924 to determine the effect of 
inhibiting cullin neddylation on caspase 8 cleavage. MLN4924 treatment caused 
slight reductions in the amounts of p18 caspase 8 being formed in U2OS and H460 
cells, however it was insufficient to inhibit caspase 8 cleavage completely. 
Interestingly, DU-145 cells and HeLa cells exhibited a slight increase in p18 
caspase 8 levels when pre-treated with the NEDD8 inhibitor compared to without. 
This result may arise from the role of MLN4924 in enhancing caspase 8 cleavage 
following TRAIL stimulation, however the treatment time used here was much 
shorter than in other research. Overall, this data supports the role for DCNL5 in 
caspase 8 cleavage in numerous cell lines and raises the issue of cullin 3 
involvement in these cell lines and the possible function of cullin 3 in the absence 
of its neddylation as a scaffold protein. 
5.3.2 DCNL5 is Required for Caspase 8 Cleavage in Multiple Cell 
Lines 
The results in this chapter point to a clear role for DCNL5 in caspase 8 cleavage in 
not only U2OS cells as used throughout this research, but also in other cancer cell 
lines. We successfully generated DCNL5 CRISPR/Cas9 KO cells using H460 cells to 
aid in our investigation of the role of DCNL5. These cells were selected based on 
their sensitivity to TRAIL and their extensive use in caspase 8 research, including 
the seminal work by Jin and colleagues in 2009. The KO clones both showed 
reduced p18 caspase cleavage in response to TRAIL compared to WT cells, and this 
result was mirrored by siRNA-mediated knockdown of DCNL5 in WT H460 cells 
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which also exhibited a reduction in caspase 8 cleavage. This provides an indication 
that the amount of DCNL5 being expressed in cells may relate directly to the 
amount of caspase 8 which is able to be cleaved. This data supported the findings 
in U2OS cells and suggested that the role of DCNL5 may be conserved in multiple 
different cell lines.  
In order to determine if our findings are more generally applicable with regards 
to the role of DCNL5 in cancer signalling, we wanted to test more cell lines for 
the importance of DCNL5 by using siRNA to ablate the levels of the protein and 
compare transfected to un-transfected cells in response to TRAIL. We were able 
to use cell lines from different cancers including A375 cells (skin melanoma), DU-
145 cells (prostate cancer), HeLa cells (cervical cancer) and MCF7 cells (breast 
cancer). MCF7 cells are known to be unresponsive to TRAIL stimulation due to a 
combination of high ratio of decoy TRAIL receptors to functional TRAIL receptors 
(Sanlioglu et al., 2005) which may in in part due to the constitutive endocytosis 
of death receptors 4 and 5 (Zhang and Zhang, 2008). In all the other cell lines we 
tested except for DU-145 cells, we found that DCNL5 knockdown resulted in a 
decrease in caspase 8 cleavage. The extent to which caspase 8 cleavage was 
impaired varied from one cell line to the next, with HeLa cells showing the most 
significant reduction in cleavage.  
The lack of role for DCNL5 in DU-145 prostate cancer cells may arise from the 
reduced sensitivity of this cell line to TRAIL stimulation. General consensus on 
these cells seems to be that they are not particularly sensitive to apoptosis 
induction using recombinant TRAIL, which we have employed in the present 
report. Research has shown that DU-145 cells (as well as other prostate cancer 
cell lines) are resistant to 100ng/ml to recombinant TRAIL and require co-
stimulation with doxorubicin in order to induce cytotoxicity (Voelkel-Johnson, 
King and Norris, 2002). It was also shown that adenoviral delivery of full-length 
TRAIL was able to induce cell death in DU-145 cells as well. Insensitivity of DU-
145 cells has also been shown by other researchers (ref Wei et al, 2018) and other 
work has shown DU-145 cells’ resistance to adenoviral delivery of full length 
TRAIL, which was linked to elevated expression of decoy TRAIL receptor (DcR2). 
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siRNA-mediated knockdown of DcR2 was able to sensitise the cells to TRAIL 
(Sanlioglu et al., 2007).  
In contrast to other research, DU-145 cells have also been shown to be sensitive 
to recombinant TRAIL and this was shown to be associated with the expression of 
a protein called hPEBP4 which is involved in phosphatidylethanolamine binding 
and is preferentially expressed in breast and ovarian cancer cells. DU-145 cells 
were shown to express low levels of hPEBP4 which rendered them sensitive to 
TRAIL while other prostate cancer cells (LNCaP) were found to highly express the 
protein which conferred the reduced sensitivity to TRAIL (Li et al., 2007). The 
conflicting data regarding the sensitivity of DU-145 cells to TRAIL makes it difficult 
to fully interpret our data showing that DCNL5 knockdown made no significant 
impact on caspase 8 cleavage. The fact that we see cleavage at all suggests that 
the cells are indeed sensitive to TRAIL on its own and require no additional 
stimulation or co-treatments, and therefore in this particular cell line DCNL5 may 
not play a crucial role in caspase 8 cleavage. 
As a follow up to the results seen in HeLa cells, which showed the most dramatic 
reduction in caspase 8 cleavage following siRNA-mediated knockdown of DCNL5 
expression, we wanted to determine the effect of overexpressing DCNL5. When 
compared to un-transfected cells, DCNL5 overexpressing HeLa cells showed a 
noticeable increase in caspase 8 cleavage when stimulated with. This contrasted 
neatly with the siRNA data, clearly linking DCNL5 protein levels to caspase 8 
cleavage. HeLa cells have been shown to be TRAIL sensitive and have been used 
extensively for studying TRAIL signalling and caspase 8 activity (Seol et al., 2001; 
Mohr, Yu and Zwacka, 2015) and thus represent a useful cell line to include in the 
present research. HeLa cell sensitivity to TRAIL has been shown to depend on a 
number of factors, including death receptor expression with DR4 expression 
conveying TRAIL sensitivity in these cells (Mohr, Yu and Zwacka, 2015). 
Interestingly, some research has shown that HeLa cells contain large amounts of 
DR5 within the nucleus which has been shown to confer resistance to TRAIL 
(Kojima et al., 2011), seemingly at odds with the finding that DR4 is the essential 
mediator of TRAIL signalling in this cell line. The inconsistency in response of HeLa 
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and other cell lines to TRAIL further highlights the difficulty in studying caspase 8 
signalling given the complexity of the pathways.  
The consistency in being able to reduce caspase 8 cleavage by inhibiting DCNL5 
expression suggests that the role of the protein is critical in many cancer cell lines. 
DCNL5 may in fact be a general regulator of apoptosis signalling in many cancer 
cell lines, and based on our results, DCNL5 not playing a role may be an exception 
rather than the rule. We have previously shown that DCNL5 KO cells are still able 
to recruit caspase 8 to the DISC in our cullin 3 co-IP experiment which indicates 
that the role of DCNL5 is likely not in the coordination of caspase 8 binding to the 
DISC. The deficiency in caspase 8 cleavage has been shown to be DAD-patch 
dependent by viability assays as well as by western blotting, strongly indicating 
that cullin proteins may in some way involved in the interaction of DCNL5 in this 
pathway. Technically, it is possible that DCNL5 interacts with another protein via 
the DAD patch region in its C-terminal PONY domain.  
We have however shown that DCNL5 interacts with cullin 3 in vivo for the first 
time and this lends support to the hypothesis that DCNL5 is interacting with cullin 
3 to mediate its neddylation and thus activity. MLN4924 treatment was not as 
severe in inhibiting caspase 8 cleavage as the lack of DCNL5 expression, which 
indicates that the function of DCNL5 may occur independently of its neddylation 
activity. This may suggest that cullin 3 may function as a scaffold protein and 
given that it is known to interact with caspase 8 in vivo, perhaps DCNL5 plays a 
role in coordinating this interaction. To date, no published data supports a role 
for DCNL proteins outside of their interactions with cullins, therefore further work 
is required to establish the binding partner(s) for DCNL5 in this pathway and 
whether the DAD-patch is an important region for binding to other proteins. We 
have shown in Chapter 3 that DCNL1 KO cells are sensitive to TRAIL and CHX/TNFα 
combination treatments but have looked at the role of DCNL3 which is known to 
neddylate cullin 3 at the plasma membrane (Meyer-Schaller et al., 2009). DCNL1 
is the best studied and most ubiquitously expressed DCNL protein and is also known 
to promote cullin 3 neddylation albeit in a different physiological context (Huang 
et al., 2017) so it seems likely that some specific characteristic of DCNL5 enables 
it to localise and interact with the DISC and caspase 8 to promote neddylation of 
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a cullin protein, possibly a non-cullin protein or simply interact with a protein via 
its DAD-patch. The likely region of DCNL5 that may mediate this specific 
interaction in the apoptosis response is the N-terminus which is the least 
conserved region between the DCNL proteins and is predicted to be unstructured 
(Keuss et al., 2016). It is possible that despite the similarity between the C-
terminal domain of DCNL proteins, only DCNL5 is capable of associating with cullin 
3 in this context, and our data suggests that this role may not even involve the 
transfer of NEDD8 and that DCNL5 may play a key structural role in DISC assembly 
or caspase 8 activation unable to be performed by other DCNL family members. 
Our data could therefore indicate a new function for DCNL5 and may be the first 
evidence for new binding partners for this family of proteins.  
5.3.3 Neddylation is not Essential for Caspase 8 Cleavage 
Cullin proteins are known regulators of caspase 8 ubiquitination in both pro and 
anti-apoptotic roles. Neddylation is an essential step in the activation of CRL 
complexes and un-neddylated cullins are thought to be non-functional however 
still important in forming complexes with CAND1 for efficient substrate exchange 
and rapid CRL assembly with different substrate adaptors (Wu et al., 2013). We 
wanted to investigate the effect of inhibiting neddylation prior to and during TRAIL 
stimulation to determine whether the lack of cullin neddylation would have an 
impact on caspase 8 ubiquitination. We were specifically wanting to determine 
whether inhibition of cullin 3 neddylation, which is the only known positive 
regulator of caspase 8 ubiquitination in extrinsic apoptosis (Jin et al., 2009), 
would reduce or totally inhibit caspase 8 processing in cells. 
Inhibiting neddylation had differing effects on different cell lines. U2OS as well as 
H460 cells displayed a reduction in caspase 8 cleavage but the formation of 
catalytically active p18 form was not entirely inhibited. This suggests that caspase 
8 processing is able to occur in the absence of the cullin 3-RBX1-based E3 ligase 
activity (or any active CRL E3 ligase for that matter) which to our knowledge is a 
novel finding in the context of the role of cullin 3 in this pathway. Another 
potential explanation for this result is that cullin 3 may play a role which is 
independent of its activity as the core of a CRL complex, perhaps as a scaffold 
protein, it would be interesting to determine whether CAND1 interacts with the 
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DISC since cullin 3 is likely in complex with this protein during MLN4924 treatment. 
In DU-145 and HeLa cells, MLN4924 treatment actually increased the levels of 
catalytically active caspase 8 compared to un-treated cells. Interpreting this 
result is difficult since as described in section 5.1.3, MLN4924 treatment has been 
shown to promote caspase 8 activation following both TNFα and TRAIL-mediated 
apoptosis induction.  
The research into the role of MLN4924 in extrinsic apoptosis has generally involved 
exposing cells to longer treatments with the drug, from 6 hours up to 72 hours 
(Wolenski et al., 2015; Zhao et al., 2011; Chen et al., 2016). Over longer 
treatment times, MLN will cause accumulation of CRL substrates which are no 
longer ubiquitinated and degraded including cell cycle regulators which can lead 
to cell cycle arrest and cell death by other pathways, which may result in cleavage 
of caspase 8 indirectly. In our research MLN4924 is only used for 2 hours, which is 
still sufficient to completely inhibit neddylation of all cullins, and this treatment 
is a significantly shorter time period and less likely to result in off-target effects 
due to reduction in degradation of CRL substrates. As a result, it is likely that any 
alterations in caspase 8 cleavage we detect are likely due to the specific inhibition 
of cullin neddylation. This presents an important issue with regards to the 
established mechanism involving cullin 3-mediated polyubiquitination of caspase 
8: why is caspase 8 cleavage enhanced in the absence of CRL activity? It is possible 
that the lack of cullin neddylation and thus CRL E3 ligase activity may have an 
effect on anti-apoptotic modifications of caspase 8 as well as the pro-apoptotic 
regulation by cullin 3 (see Figure 5-1 for a summary of caspase 8 regulation).  
If cullin-based E3 ligases which normally function to inhibit caspase 8 cleavage 
and activation (e.g. cullin 7) are inactivated by MLN4924, would this account for 
the increase we see in caspase 8 processing in some cell lines? This may be the 
case despite the lack of cullin 3 activity in activating caspase 8. It is perhaps a 
question of the balance of pro and anti-apoptotic ubiquitination modifications that 
are occurring at the level of caspase 8 which control the degree of caspase 8 
cleavage. As mentioned in section 5.1.2, TRAF2 mediates the polyubiquitination 
of caspase 8 in its p18 catalytic subunit after cullin 3 mediates the 
polyubiquitination of caspase 8 at its p10 catalytic subunit (Jin et al., 2009; 
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Gonzalvez et al., 2012). This modification by TRAF2 serves to trigger degradation 
of catalytically active caspase 8 upon release into the cytosol, thereby setting s 
shutoff timer for caspase 8 activity. In the context of neddylation, research has 
shown that another TRAF family member, TRAF6, undergoes neddylation at lysine 
124 which is required for it ability to mediate NF-κB activity (Liu et al., 2019). It 
is therefore possible that NEDD8 also plays a role in TRAF2 activity and MLN4924 
treatment may inhibit this negative regulation of caspase 8 and result in less 
caspase 8 being degraded in the cytosol and therefore more caspase 8 cleavage 
and activity. It is therefore possible that the negative regulation by some E3 
ligases is stronger than the positive regulation by cullin 3. 
As far as we are aware, this is the first time MLN4924 has been studied in the 
context of caspase 8 cleavage via cullin 3-mediated ubiquitination events. Future 
work in this area could focus on looking at the role of other cullin proteins in 
caspase 8 activations via siRNA as well as investigating peptides to block different 
DCNL proteins following the work by Monda and colleagues in determining the 
structure of DCNL proteins in complex with NEDD8 E2 enzymes (Monda et al., 
2013). More recently, inhibitors have been designed which specifically block 
neddylation of cullin 3 in cells, the first of which was called DI-591. This cell-
permeable compound was shown to bind to DCNL1 and DCNL2 with KD values of 
21.9nM and 11.2nM respectively (Zhou et al., 2017). Unexpectedly, this compound 
was shown to specifically reduce the neddylation of cullin 3 only while having 
minimal effect on the neddylation of other cullin proteins (Zhou et al., 2017). This 
inhibitor would be useful in the context of hour work, to specifically target cullin 
3 neddylation rather than having to inhibit the neddylation of all cullin proteins 
will MLN4924. This would more accurately tell us the importance of cullin 3 
neddylation. 
In the work by Jin and colleagues (Jin et al., 2009) they showed that cullin 3 
knockdown resulted in a significant reduction in caspase ubiquitination however 
they did not detect such a dramatic change at the level of caspase 8 cleavage. 
This suggests that a small reduction in caspase 8 cleavage can represent much 
more significant reductions in caspase 8 polyubiquitination. In our work we have 
been able to detect more significant reductions in caspase 8 cleavage than they 
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showed, suggesting that the impairment in caspase 8 ubiquitination might be even 
more severe. The fact that DCNL5 knockdown appears to have more of an effect 
on caspase 8 cleavage than the loss of E3 ligase activity (via neddylation inhibition) 
may provide insight into the role DCNL5 plays. We have shown that DCNL5 
involvement is dependent on DAD-patch interaction, however it may be that cullin 
neddylation is not an essential step and we may therefore be looking at a 
neddylation-independent role for cullin 3 as well as DCNL5, as mentioned above. 
5.3.4 Role of Cullin 3 in Apoptosis is Ambiguous 
To further probe the role of cullin 3 in caspase 8 activation in multiple cancer cell 
lines, we used siRNA to mediate the knockdown of cullin 3 expression prior to 
stimulation with TRAIL. The importance of neddylation has been questioned by 
our use of MLN4924 and appears largely to be cell line dependent. We suspected 
therefore that the role of cullin 3 may follow a similar trend. TRAIL stimulation 
resulted in less caspase 8 cleavage when cells were treated for cullin 3 siRNA in 
U2OS, H460 and A375 cell lines. U2OS and H460 cells also showed slight reductions 
in caspase 8 cleavage following MLN4924 pre-treatment (as discussed in 5.3.3) 
which mirrors the results seen here. HeLa cells, unexpectedly, showed an increase 
in caspase 8 cleavage following knockdown of cullin 3 expression. This result also 
mirrored the MLN4924 data which also showed an increase in caspase 8 processing 
when neddylation was inhibited. Taken together, this data brings into question 
the importance of cullin 3 in caspase 8 cleavage. We weren’t able to successfully 
analyse caspase 8 ubiquitination (since we did not perform treatments at 4°C as 
has been shown to increase signal) so cannot definitively conclude that the lack 
of caspase cleavage is as a direct result of a lack of ubiquitination, however it has 
been shown, as mentioned previously, that even a slight reduction in caspase 8 
cleavage can be indicative of a dramatic reduction in caspase 8 ubiquitination (Jin 
et al., 2009). When analysing our cullin 3 knockdown data, it is important to note 
that incomplete cullin 3 knockdown we saw for some of the cell lines may explain 
why we see only small reductions in caspase 8 cleavage. Optimisation of this 
process would clarify the importance of cullin 3 in these cell lines. 
Given the well-established role of cullin 3 and its unique function in regulating 
caspase 8 activity in a positive manner, the finding that HeLa cells appear to 
209 
 
 
 
undergo more caspase 8 cleavage in the absence of cullin 3 expression is puzzling. 
In the case of MLN4924 treatment it can be interpreted that the neddylation 
inhibitor prevents activation of CRLs and therefore CRL-mediated negative 
regulation of caspase 8, which may explain the reduction rather than total loss of 
caspase 8 cleavage, or the increase in caspase 8 cleavage depending upon cell line 
in question. For cullin 3 knockdown, the increased caspase 8 processing may also 
occur as a result of a loss of downstream ubiquitination events mediated by cullin 
3-based CRLs which may play a feedback role in caspase 8 activation. The other 
possibility is that in the absence of cullin 3 expression, another cullin protein is 
able to mediate the ubiquitination of caspase 8 in a pro-apoptotic manner, 
however to date no other cullins have been known to play such role but this would 
be an interesting hypothesis to analyse further. 
Our data supports previous findings (Jin et al., 2009) that cullin 3 knockdown 
results in a reduction in caspase 8 cleavage as detectable by western blot in H460 
cells. In our hands, U2OS and A375 cells show a similar dependence on cullin 3 for 
caspase 8 processing. The fact that we only see reductions in cleavage and not a 
total loss appears to indicate that there are other factors controlling caspase 8 
processing beyond cullin 3 which is an interesting finding and one which requires 
further investigation. The current picture of cullin 3 as being essential and unique 
in promoting caspase 8 cleavage may not be fully correct. The established 
mechanism for cullin 3 in mediating caspase 8 may therefore require some revision 
to account of cell-line specific differences or at the very least, further 
investigation into other pro-apoptotic regulators. Our use of MLN4924, and thus 
the investigation into the importance of neddylation, indicates that there may be 
non-cullin E3 ligases that play a role in activating caspase 8 and our data looking 
at cullin knockdown highlights the potential role of another cullin protein in 
regulating caspase 8 ubiquitination in a pro-apoptotic manner. It is also possible 
that there are other processes governing caspase 8 activity in a positive manner 
that are ubiquitin dependent but do not involve cullins or the direct ubiquitination 
of caspase 8. The balance of caspase 8 regulators may dictate the degree of 
caspase 8 cleavage and activity in cells and this may be regulated by both 
ubiquitination as well as by neddylation. 
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6 General Discussion 
6.1 Overview of Findings 
The NEDD8 E3 ligase family of proteins known as DCNL proteins, have well 
established roles in promoting cullin neddylation and thus regulating 
ubiquitination activity of CRL complexes. There are some limited unique roles for 
individual DCNL proteins that have been described, however little work has been 
undertaken into studying the physiological role of DCNL5. In the present work, we 
have uncovered a novel role for DCNL5 in the apoptosis response. We have shown 
that in the absence of DCNL5, U2OS cells exhibit a significantly reduced the ability 
to undergo apoptosis and this stems from a lack of caspase cleavage activity. We 
demonstrated that DCNL5 KO cells lack caspase 8 cleavage which is the crucial 
initiator caspase protein involved in mediating extrinsic apoptosis.  
We have shown for the first time that DCNL5 is able to interact with cullin 3 in 
cells at endogenous expression levels, and this is important because cullin 3 is 
well established as the key positive regulator of caspase 8 activity via 
polyubiquitination. Our findings support a model whereby DCNL5 may regulate 
cullin 3 neddylation (or at least interact with cullin 3) to promote its activity as 
the core of as an as yet uncharacterised CRL complex, perhaps independently of 
its neddylation, that promotes the polyubiquitination of caspase 8 which is 
required for its dimerization and cleavage. Using a variety of different cancer cell 
lines, we have provided compelling evidence that the role of DCNL5 is conserved 
across different tissue culture cells by manipulating DCNL5 expression using siRNA.  
In addition, we have also discovered that while the importance of DCNL5 is 
conserved across the cancer cell lines we tested, the importance of neddylation 
is less clear. Using the neddylation inhibitor MLN4924, we showed that while 
caspase 8 cleavage is reduced by the drug, some cleavage still occurs in the 
absence of neddylation. This is significant because the established mechanism 
governing caspase 8 cleavage involves the interaction of neddylated cullin 3 with 
caspase 8 to promote its polyubiquitination. What was unusual was that in some 
cell lines, including HeLa cells, MLN4924 actually increased caspase 8 cleavage 
which seems to be in direct contradiction of the established literature. 
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Interpretation of our results is difficult because multiple NEDD8-dependent E3 
ligases regulate caspase 8 activity in a negative manner, raising the possibility 
that MLN4924 inhibits this negative regulation as well as the positive regulation 
by cullin 3. We also queried the role of cullin 3 in caspase 8 cleavage by inhibiting 
expression of the protein by siRNA. We found that in U2OS and H460 cells, that 
this resulted in a reduction in caspase 8 processing, but in HeLa cells, we found 
that the lack of cullin 3 protein levels actually increased caspase 8 cleavage. 
Overall, our work presents evidence for a key role of DCNL5 in caspase 8 cleavage, 
and provides initial evidence for the role of cullin 3 as a scaffold-type protein 
which occurs independently of its neddylation, but also raises the possibility of 
other cullin proteins playing a role in promoting caspase 8 cleavage in the absence 
of cullin 3. Our results support the notion that the apoptosis signalling pathway is 
different in different cell types and thus further research is required to determine 
a unified model for caspase 8 cleavage and activation. 
6.2 A New Role for DCNL5 
A key finding in this study is the discovery of a  new physiological role of DCNL5. 
Our work is the first time any of the DCNL family members have been investigated 
for their role in the apoptosis response, and given that ubiquitination is a key 
regulator of various facets of apoptosis, it is perhaps unsurprising that there may 
be roles for these proteins in this pathway. We have robustly demonstrated that 
DCNL5 plays a part in caspase cleavage, having shown that the key initiator 
caspase, caspase 8, fails to undergo cleavage in the absence of DCNL5. We showed 
that the role of DCNL5 is contingent on its ability to interact via its DAD-patch, 
which is responsible for cullin-binding (Kurz et al., 2008) but may theoretically 
mediate interactions with other proteins. Given that there is significant 
promiscuity in function of the DCNL proteins in cells (Keuss et al., 2016; Monda et 
al., 2013) we anticipated that the role we had discovered for DCNL5 was unique 
and this assertion was supported by the finding that DCNL1 is not essential in this 
pathway and absence of DCNL1 did not confer resistance to death. We did not 
interrogate the role of any other of the DCNL proteins, but given that only DCNL1, 
DCNL3 and DCNL5 have had unique roles described in the literature (Meyer-
Schaller et al., 2009; Keuss et al., 2016; Thomas et al., 2018; Wu et al., 2011; 
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Bommeljé et al., 2014; Broderick et al., 2010), future work could probe the role 
of DCNL3 in this pathway in addition to DCNL1.  
The N-terminus of DCNL5 contains a nuclear localisation sequence which has 
shown to be essential for its neddylation activity in vivo (Bommeljé et al., 2014) 
however the rest of the N-terminus is uncharacterised. It therefore remains a 
possibility that DCNL5 is uniquely able to play a role in the apoptosis response due 
to its N-terminus interacting with one or more proteins. Paradoxically, we show 
that DCNL5 translocates out of the nucleus into the cytosol following TRAIL 
stimulation. Does DCNL5 retain its neddylation activity outside the nucleus? And 
how is DCNL5 shuttled out of the nucleus in response to the stimulus? The in vitro 
data suggests that all DCNL proteins can neddylate all cullins so it is widely 
accepted that the limitation for DCNL-cullin interaction and neddylation is 
subcellular localisation in cells, therefore if DCNL5 is able to localise to another 
subcellular compartment, it should presumably be able to neddylate the available 
cullin proteins. DCNL1 has been shown to undergo monoubiquitination mediated 
by the E3 ligase NEDD4-1 and subsequent export out of the nucleus (Wu et al., 
2011). It was suggested that the N-terminal UBA domain mediates interaction with 
ubiquitin or ubiquitin-linked NEDD4-1 to promote the monoubiquitination of 
DCNL1 at lysine residues within its PONY domain (Wu et al., 2011). It is therefore 
a possibility that DCNL5 undergoes monoubiquitination in its PONY domain which 
is the driving mechanism behind its nuclear export in the context of TRAIL 
signalling. DCNL5 lacks the UBA domain which is required to promote this 
monoubiquitination, so this hypothesis requires further investigation – mono-
ubiquitination of DCNL5 has not been seen experimentally before. 
In addition to showing that DCNL5 translocates out of the nucleus in response to 
TRAIL, we also demonstrated that DCNL5 interacts with cullin 3 in U2OS cells at 
endogenous expression levels for the first time. This represents the first 
interaction of DCNL5 with any specific cullin in cells, and provides evidence for 
the potential role of DCNL5 in promoting the neddylation of cullin 3 which is 
required for its ability to polyubiquitinate caspase 8, in coordination with RBX1 
(Jin et al., 2009). As mentioned previously, DCNL3 has been shown to neddylate 
cullin 3 (Meyer-Schaller et al., 2009) although there is evidence that it doesn’t 
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actually possess E3 ligase activity and serves to inhibit DCNL1-mediated 
neddylation of cullins (Huang et al., 2014). This finding is at odds with the 
convincing evidence that showed that ectopic expression of human DCNL3 (as well 
as DCNL5) in yeast Dcn1Δ cells restored Cdc53 (yeast cullin homologue) 
neddylation (Meyer-Schaller et al., 2009), and can therefore be disregarded. 
DCNL1 has also been shown to neddylate cullin 3 to promote midbody localization 
and activity of Cul3KLHL21 during abscission (Huang et al., 2017). The literature 
suggests that cullin 3 neddylation is regulated by 2 of the DCNL family members, 
so while we have shown that DNCL5 interacts with cullin 3, we cannot definitively 
say that DCNL5 promotes its neddylation in response to TRAL stimulation, however 
this is one hypothesis for its role in this pathway.  
Our data using the cullin non-binding DAD-patch mutant form of DCNL5 has 
consistently indicated that DCNL5’s role in promoting caspase 8 cleavage requires 
cullin binding, which supports the model in which DCNL5 neddylates cullin 3 to 
increase caspase 8 polyubiquitination. It is possible that DCNL5 interacts with 
another protein via its DAD patch; this highly charged (acidic) region which 
normally interacts with a positively charged region in cullin proteins (Kurz et al., 
2008) may also play roles in binding of other proteins via charged interactions and 
further experiments are required to probe this hypothesis further. Our data using 
the neddylation inhibitor MLN4924 indicates that neddylation may not be essential 
in all cancer cell lines which may support a non-cullin interaction mediated by 
DCNL5 to promote caspase 8 cleavage. If this were to be the case, this would 
indicate a novel, cullin-independent role for DCNL5 and perhaps all DCNL proteins. 
It would have been interesting to use some of the recently described DCNL 
inhibitors which tend to specifically inhibit cullin 3 neddylation. Multiple of these 
inhibitors have been synthesized and characterised which specifically inhibit the 
interaction between DCNL1 (and to a lesser extent DCNL2) and the acetylated N-
terminus of UBC12 which tend to preferentially reduce cullin 3 neddylation in cells 
(Zhou et al., 2017; Scott et al., 2017) as well as cullin 1 neddylation (Kim et al., 
2019). It has been shown that despite the conserved interaction between DCNL 
PONY domains and the acetylated N-termini of NEDD8 E2 enzymes, the affinities 
of these interactions vary greatly, with DCNL4 and DCNL5 exhibiting less 
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interaction with either E2 enzyme than DCNL1 and DCNL2 (Monda et al., 2013). 
This suggests that while the PONY domains are well conserved between then DCNL 
proteins, some of their in vivo functions may differ due to the different affinities 
towards E2 enzymes and possibly other binding partners. It is difficult to know 
whether the cullin 3 specificity exhibited by these DCNL inhibitors is common to 
all cullin 3-based CRLs or simply a subset which are neddylated by DCNL1 and 
DCNL2 which as mentioned above, tend to be targeted by this class of inhibitors. 
In terms of DCNL5, it is possible that in conjunction with its distinct N-terminal 
region, the C-terminal region of the protein may confer specific binding properties 
which allows it to play a unique role in caspase 8 cleavage.  
One of the most intriguing results we obtained, was the finding that DCNL5 KO 
cells lack a ubiquitination event that may or may not be caspase 8 
polyubiquitination. We used TUBEs to bind polyubiquitinated proteins in TRAIL-
treated lysates and found that in WT cells but not KO cells, un-modified full length 
and p43/41 caspase 8 co-precipitated with a polyubiquitinated protein. We cannot 
say what protein is failing to undergo polyubiquitination in the KO cells however 
it is highly likely that this event is required for caspase 8 cleavage and involves 
DCNL5 and this may represent the critical event which DCNL5 regulates. It is 
possible that another DISC-associating protein fails to become ubiquitinated and 
this results in less caspase 8 being processed in the absence of DCNL5. 
A non-catalytic role for caspase 8 has recently been described in which caspase 8 
acts as a scaffold for assembly of a structure which has been termed the 
FADDosome which consists of caspase 8 FADD and RIP1 and this complex leads to 
NF-κB-dependent inflammation (Henry and Martin, 2017). This complex was shown 
to form following TRAIL induction and caspase 8 (crucially including catalytically 
inactive caspase 8) was shown to be required for this complex formation and 
specifically recruits RIP1 to promote inflammation (Henry and Martin, 2017). In 
this role caspase 8 acts as a scaffold for complex assembly, and this complex 
involves downstream polyubiquitination of RIP1 which may therefore be what is 
being pulled on in our TUBE experiment, since we detect unmodified caspase 8. 
The role of this complex in the context of cell death and the role of DCNL5 in this 
complex is unclear, especially since we have comprehensively shown that caspase 
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8 fails to undergo cleavage in the absence of DCNL5. If anything, we would perhaps 
expect that this complex forms more readily in the DCNL5 KO cells since caspase 
8 processing is lacking and thus may more readily function as a scaffold for 
complex assembly. 
There exists another complex containing caspase 8 and is involved in apoptosis, 
called the Ripoptosome (Tenev et al., 2011). The complex contains RIP1, FADD 
and caspase 8 (similar to the FADDosome) and it has been established to assemble 
in response to genetic stress-induced depletion of IPAs including XIAP, cIAP1 and 
cIAP2 (Tenev et al., 2011). The complex is also negatively regulated by cFLIP and 
has been shown to assemble independently of death receptor mediated signalling 
(Tenev et al., 2011; Feoktistova et al., 2011). The Ripoptosome can promote both 
caspase-dependent cell death or caspase-independent cell death (Tenev et al., 
2011) but given that it forms as a result of inhibition of IAP expression, it is unclear 
if we are detecting formation of this complex in our TUBE experiment. IAPs have 
ubiquitin E3 ligase activity and regulate the apoptosis response (Ni, Li and Zou, 
2005) and they have been tentatively described as possessing NEDD8 E3 ligase 
activity (Broemer et al., 2010). This complex is inactivated by polyubiquitination 
of RIP1 and possibly caspase 8 by IAPs and it is likely this modification that we 
would be detecting in the WT cells if this is the complex that we are precipitating 
with the TUBEs. Much more work is required to elucidate which polyubiquitinated 
protein we precipitated in WT cells and too understand how DCNL5 coordinates 
this modification. 
6.3 A Potential Neddylation Independent Function for 
Cullin 3 
As mentioned throughout this thesis, the established mechanism for cullin 3-
mediated ubiquitination of caspase 8 involves RBX1 but this protein was not shown 
to associate with the DISC (Jin et al., 2009). It is possible that this is due to the 
transient nature of this interaction or perhaps due to the reduced stability of RBX1 
in its interaction with the DISC. This may perhaps indicate that cullin 3 plays a 
structural role in caspase 8 regulation, independently of its interaction with the 
RING protein. This would be a totally novel finding, however it is probably unlikely 
since RBX1 is absolutely required for cullin neddylation and the cullin 3 that 
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associates with the DISC has been shown to be neddylated (Jin et al., 2009). It is 
therefore more likely that RBX1 was not detected because the protein is small and 
may have migrated through the membrane.  Our data supports a potential NEDD8-
independent role for cullin 3 in promoting caspase 8 cleavage. In HeLa cells and 
DU-145 cells, MLN4924 treatment appeared to increase caspase 8 cleavage, likely 
corresponding to an increase in ubiquitination of caspase 8. In these cell lines, 
cullin 3 may be playing a role independent of its ubiquitination activity as the 
active core of a CRL E3 ligase complex since it fails to become neddylated. As 
discussed previously, the inhibition of neddylation may inactivate CRL complexes 
responsible for negatively regulating caspase 8 cleavage such as cullin 7 (Kong et 
al., 2019), and in the case of cullin 7 its role as a negative regulator of caspase 8 
was described and characterised in HeLa cells. It is therefore possible that the 
reason we see an increase in caspase 8 cleavage when neddylation is inhibited is 
because cullin 7-mediated negative regulation of caspase 8 is abolished and this 
may have more of an effect on caspase 8 cleavage than the lack of cullin 3-
mediated positive regulation. 
MLN4924 reduced caspase 8 processing in U2OS and H460 cells in our work, 
however it did not totally abolish caspase 8 cleavage. It has been shown that only 
a small reduction in caspase 8 cleavage as detected by western blotting can 
correlate with a significant reduction in caspase 8 ubiquitination (Jin et al., 2009), 
therefore our data for U2OS and H460 cells may represent significant reductions 
in caspase 8 polyubiquitination in the absence of neddylation. This largely 
supports the established role for neddylated cullin 3 in promoting caspase 
ubiquitination.  
In U2OS cells and H460 cells, some caspase 8 is still cleaved in the absence of 
neddylation which may also be explained by cullin 3 and DCNL5 playing scaffold 
roles in DISC assembly. It remains possible that this interaction is critical for 
caspase 8 activation even in the absence of NEDD8. To date, no NEDD8-
independent roles for cullin proteins have been described. Un-neddylated cullin 
proteins are known to exist in complex with CAND1 and DCNL proteins (Keuss et 
al., 2016) so it would be worth investigating if there is any interaction between 
CAND1 and caspase 8. This interaction would presumably not be direct and be 
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bridged by cullin 3. Another issue that has yet to be resolved regarding cullin 3-
mediated ubiquitination of caspase 8 is what the substrate adaptor is for this 
interaction. As mentioned previously, RBX1 was not found to associate with the 
DISC by both co-IP and mass spectrometry (Jin et al., 2009), which does support 
a potential scaffold role for cullin 3 in DISC association, however the same 
researchers comprehensively showed that it is neddylated cullin 3 that interacts 
with the DISC, and that RBX1 is required for caspase 8 polyubiquitination. This 
further supports the likelihood that RBX1 was simply not detected at the DISC, 
raising the question of whether other components were also undetected.  
6.4 Is Caspase 8 Regulated by Neddylation? 
There is some evidence that caspase proteins are regulated by neddylation, both 
in drosophila and in humans. A systematic in vivo RNAi screen identified DEN1, 
CSN5 and a predicted de-neddylase enzyme called CG1503 as being involved in 
apoptosis (Broemer et al., 2010). The drosophila effector caspase drICE (human 
caspase 3 homologue) was then identified as being neddylated in vivo under 
endogenous conditions, however this was expanded upon using His-tagged (and 
therefore overexpressed) NEDD8 to be mediated by a drosophila inhibitor of 
apoptosis called DIAP1 and reversed by the deneddylase enzyme DEN1 (Broemer 
et al., 2010). Human caspase 7 was identified as a target for neddylation and 
concluded to be mediated by X-linked inhibitor of apoptosis (XIAP) (Broemer et 
al., 2010) however this was done using NEDD8 overexpression which has been 
shown to result in the UBE1 (Ub E1 enzyme)-mediated activation and transfer of 
NEDD8 to targets  via ubiquitin machinery (Hjerpe et al., 2012). Other researchers 
concluded that while XIAP is able to function as a NEDD8 E3 ligase, it does not 
promote the neddylation of caspase 7 under endogenous conditions (Nagano et 
al., 2012). 
There is also literature indicating that caspase 1 is regulated by neddylation. 
Caspase 1 plays an inflammatory role and is unrelated in function to caspase 8, 
however it Is structurally and mechanistically similar and conserved. Caspase 1 
was shown to undergo neddylation under endogenous as well as overexpressed 
conditions, and this neddylation was required to promote its autocatalytic 
cleavage and processing (Segovia et al., 2015). NEDD8 interacted with the CARD 
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domain of caspase 1 to promote its autocatalytic processing and cleavage and this 
was inhibited by MLN4924 (Segovia et al., 2015). While caspase 8 does not possess 
a CARD domain, it remains a possibility that NEDD8 may directly regulate caspase 
8 processing. We were unable to detect interaction between DCNL5 and caspase 
8 however we were also unable to optimise that particular co-IP reaction, so 
cannot definitively conclude that there is no interaction in vivo. It is likely that 
DCNL5 interaction may not be detected by co-IP given that a) a very small amount 
of DCNL5 and caspase 8 will be involved and b) the interaction may be short-lived 
and occur at a very specific timepoint post-treatment and would therefore require 
significant investigation to accurately interrogate this.  
Neddylated cullin 3 interacts with caspase 8 (Jin et al., 2009), but it remains to 
be seen whether any other neddylation machinery associates with caspase 8 or 
the DISC. As mentioned previously, CAND1 exists in complex with un-neddylated 
cullins as well as DCNL proteins and since it is neddylated cullin 3 that interacts 
at the DISC, CAND1 by definition will not be present. The NEDD8 E2 enzymes 
interact directly with DCNL proteins which themselves bind to cullins (which bind 
RBX1) so it is possible that the E2 as well as DCNL5 (and the undetectable RBX1) 
may also be present at the DISC. Our data using MLN4924 supports the role for 
NEDD8 in TRAIL-mediated caspase 8 cleavage in U2OS and H460 cells in particular, 
and CHX/TNFα treatment was shown to require neddylation for full processing of 
caspase 8 to form the catalytically active p18 fragment. The MLN4924 treatment 
inhibited p18 caspase cleavage to the same extent that the pan-caspase inhibitor 
QVD-OPh did. The fact that MLN4924 inhibits the full cleavage of caspase 8 in 
response to TNFα-mediated apoptosis strongly supports a direct role for NEDD8 in 
regulating caspase 8 processing. DCNL5 would therefore likely play a role in this 
neddylation event in this scenario, however this is all largely hypothetical and 
there is little convincing data to support a role for caspases as NEDD8 targets. 
They key issue with performing these sorts of interactions by overexpressing the 
components including NEDD8 is that ubiquitin machinery is capable of mediating 
the addition of NEDD8 to a target substrate that was never a true substrate in the 
first place (Hjerpe et al., 2012), so great care needs to be taken to ensure that 
sufficient criteria is met to ensure a target is a bona fide NEDD8 target (Enchev, 
Schulman and Peter, 2015). 
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6.5 Is a New Model Required for Caspase 8 Cleavage? 
Our data indicates that neddylation as well as cullin 3 appear to be less essential 
for caspase 8 cleavage than the role of DCNL5. Whether DCNL5 functions as a 
NEDD8 E3 ligase or whether it acts as a scaffold protein or in some other protein-
protein interactions remains unclear. The present work questions the requirement 
for cullin 3 as well as neddylated cullin 3 in caspase 8 activity. siRNA-mediated 
knockdown of cullin 3 did reduce caspase cleavage in U2OS and H460 cells, 
consistent with its role in promoting cleavage, however in HeLa cells it had the 
opposite effect. Is the role of cullin 3 therefore cell line specific? Or are there 
additional roles for cullin 3 which serve to negatively regulate caspase 8 activity? 
It is widely accepted that TRAIL-mediated apoptotic signalling and thus TRAIL 
sensitivity varies significantly in different cell lines. This is thought to arise in part 
due to the variation in expression of endogenous inhibitors of apoptosis (ref Huang 
et al, 2016), the variation in expression of death receptors (Twomey et al., 2015), 
the diversity in cellular signalling responses (Baskar et al., 2019) and even cell-to-
cell variability in TRAIL-induced apoptosis (Spencer et al., 2009). Attempts have 
been made to establish models of cell-to-cell variability in apoptosis which was 
shown to explain fractional killing and predicts reversible resistance (Bertaux et 
al., 2014) and mechanisms underlying TRAIL resistance have been extensively 
studies for over a decade (Zhang and Fang, 2005; Trivedi and Mishra, 2015). Thus, 
the study of apoptosis is complicated and the level of variation from once cell line 
to the next or even from one cell within a population to the next cell, underlies 
just how complex developing treatments to overcome TRAIL resistance or to 
target specific interactions can be. 
A summary of some of the known regulators of caspase 8 activity as well as 
potential new roles for DCNL5 are shown in Figure 6-1. A fundamental axiom of 
extrinsic apoptosis involves the polyubiquitination of caspase 8 by neddylated 
cullin 3 in an RBX1-dependent process. This ubiquitination event promotes the 
dimerization and cleavage of caspase 8 and its subsequence association with p62 
in cytosolic ubiquitin-rich foci containing caspase 8 aggregates (Jin et al., 2009). 
The present study provides substantial evidence for the role of the NEDD8 E3 ligase 
DCNL5 in caspase 8 activation, in a DAD-patch dependent process. We have 
220 
 
 
 
queried the role of neddylation through the use of MLN4924 and the finding that 
different cell lines respond differently to the inhibition of cullin 3 neddylation 
which is thought to be essential for this process. We take this further by showing 
that cullin knockdown results in an increase in caspase 8 processing in HeLa cells 
which raises the possibility that there are other cullins which mediate 
ubiquitination of caspase 8 in a pro-apoptotic manner.  
In the absence of cullin 3, HeLa cells may undergo processing by another 
cullin/CRL complex which may be unique to these cells or common to a variety of 
other tissue culture cell lines. To date, cullin 3 is the only known positive regulator 
of caspase 8 activity in response to apoptosis induction. We consistently found 
that DCNL5 knockdown resulted in a more significant reduction in caspase 8 
cleavage than neddylation inhibition or cullin 3 knockdown, and the role of DCNL5 
appeared to be conserved in almost all the cell lines we tested. Further work is 
required to uncover the mechanism underlying DCNL5 involvement, and to 
establish whether it acts in coordination with cullin 3 or another cullin, or if DCNL5 
can interact with another protein to promote caspase 8 cleavage.  
Since DCNL5 has been implicated as an oncogene and is found to be overexpressed 
in oral and lung squamous cell carcinomas (Bommeljé et al., 2014), it is worth 
further investigation to determine whether DCNL5 expression correlates with 
resistance to apoptosis in all cancers and if this is the case, whether mutant DCNL5 
is responsible for this. siRNA-mediated knockdown of DCNL5 in cancer cell lines 
resulted in a decrease in viability of cancer cells with high endogenous DCNL5 
expression (Bommeljé et al., 2014) which on the surface seems paradoxical with 
respect to the data presented in this thesis. We have comprehensively shown that 
DCNL5 is required for extrinsic apoptosis, but cell viability and disease 
pathogenesis can be affected by many pathways beyond extrinsic apoptosis and 
DCNL5 may therefore play roles elsewhere in cellular processes. Our data using 
the cullin non-binding DAD-patch mutant suggests that expression of this version 
of DCNL5 conveys significant resistance to TRAIL-mediated apoptosis and extrinsic 
apoptosis in general, so if similar mutations occur in cancers, this may explain why 
DCNL5 expression correlates with poor disease survival. The role of DCNL5 in 
apoptosis represents an interesting field for further investigation. Our data 
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presents a significant and comprehensive phenotype in tissue culture cells of 
apoptosis resistance in the absence of DCNL5 expression which may make it a 
potential therapeutic target in the future. We provide initial evidence for 
additional regulators of caspase 8 cleavage which may also represent additional 
targets in cancer therapy and drug development. 
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Figure 6-1 Potential Interactions Involved in Caspase 8 Activation 
This schematic overview summarises potential regulators of caspase 8 activity based on the findings 
from the present study. (A) It is possible that DCNL5 interacts with FADD, caspase 8 or another 
protein via its DAD-patch since we have shown that DCNL5 involvement requires these residues and 
that neddylation may not be essential. (B) Our cullin knockdown data suggests that there may be 
other cullin proteins that can act as positive regulators of caspase 8 activity. (C) DCNL3 is known to 
neddylate cullin 3 at the plasma membrane (Meyer-Schaller et al, 2009) but it is currently unknown 
whether it is DCNL3 which mediate cullin 3 neddylation in the context of caspase 8 activation. (D) 
There is precedent for the neddylation of TRAF6 (Liu et al, 2019) therefore it is possible that TRAF2 
also requires neddylation which may explain why. MLN4924 enhances caspase 8 activity in some 
cell lines since this may inhibit the degradation of caspase 8 by TRAF2 (Gonzalvez et al, 2012). (E) 
Our data supports a potential role for DCNL5 in promoting the neddylation of cullin 3, since we have 
shown that they interact in vivo under endogenous conditions and that the role of DCNL5 is 
dependent on DAD-interaction and therefore cullin binding. Cullin knockdown and MLN4924 
supports this hypothesis in U2OS and H460 cells. (F) It is possible that DCNL1 regulates cullin 3 
neddylation since this interaction has been shown in vivo (ref Huang et al, 2017) and inhibition of 
DCNL1 has been shown to specifically reduce cullin 3 neddylation (ref Zhou et al, 2017). We found 
that DCNL1 KO cells were as sensitive if not more so than WT cells to apoptosis, which suggests 
that while DCNL1 may be responsible for some cullin 3 neddylation, it is not essential in this cellular 
context. Red boxes with question marks represent possible interactions not yet demonstrated 
experimentally and thus potential future avenues of investigation.
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